



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : <b>A61K 39/395, 43/00, C12N 15/02 C12P 21/08</b>		A2	(11) International Publication Number: <b>WO 94/11026</b> (43) International Publication Date: <b>26 May 1994 (26.05.94)</b>		
(21) International Application Number: <b>PCT/US93/10953</b>		(74) Agents: WEISS, Steven, M. et al.; Lyon & Lyon, 611 West Sixth Street, 34th Floor, Los Angeles, CA 90017 (US).			
(22) International Filing Date: <b>12 November 1993 (12.11.93)</b>		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).			
(30) Priority data: <b>07/978,891 13 November 1992 (13.11.92) US</b>		<b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>			
(71) Applicant: IDEC PHARMACEUTICALS CORPORATION [US/US]; 11011 Torreyana Road, San Diego, CA 92121-1104 (US).					
(72) Inventors: ANDERSON, Darrell, R. ; 1851 Navato Place, Escondido, CA 92029 (US). RASTETTER, William, H. ; 16067 Puerta Del Sol, Rancho Santa Fe, CA 92067 (US). HANNA, Nabil ; 3255 Fortuna Ranch Road, Olivenhain, CA 92024 (US). LEONARD, John, E. ; 1960 Avenida Joaquin, Encinitas, CA 92024 (US). NEWMAN, Roland, A. ; 43111 Robbins Street, San Diego, CA 92122 (US). REFF, Mitchell, E. ; 4166 Combe Way, San Diego, CA 92122 (US).					
(54) Title: <b>THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELED ANTIBODIES TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR TREATMENT OF B CELL LYMPHO-MA</b>					
(57) Abstract					
<p>Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.</p>					

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CC	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELED  
ANTIBODIES TO HUMAN B LYMPHOCYTE RESTRICTED  
DIFFERENTIATION ANTIGEN FOR TREATMENT OF B CELL  
LYMPHOMA**

5

**37 C.F.R. §1.74(d)/(e) Copyright Notice**

- 10 A portion of the disclosure of this patent document contains material which is subject to copyright protection. The copyright owner does not object to the reproduction by anyone of the patent document or the patent disclosure, as it appears in the Patent and Trademark Office patent files or records, but otherwise reserves all copyright rights whatsoever.

15

**RELATED APPLICATIONS**

- This is a Continuation-in-Part of United States Serial No. 07/978,891, filed November 13, 1992, pending. This patent document is related to United States 20 Serial No. 07/977,691, entitled "IMPAIRED DOMINANT SELECTABLE MARKER SEQUENCE FOR ENHANCEMENT OF EXPRESSION OF CO-LINKED GENE PRODUCT AND EXPRESSION VECTOR SYSTEMS COMPRISING SAME" having U.S. Serial No. 07/977,691 (pending; filed November 13, 1992) and "IMPAIRED DOMINANT SELECTABLE MARKER 25 SEQUENCE AND INTRONIC INSERTION STRATEGIES FOR ENHANCEMENT OF EXPRESSION OF GENE PRODUCT AND EXPRESSION VECTOR SYSTEMS COMPRISING SAME," U.S. Serial No. \_\_\_\_\_ (filed simultaneously herewith). The related patent documents are incorporated herein by reference.

30

**TABLE OF CONTENTS**

- A. FIELD OF THE INVENTION
- B. BACKGROUND OF THE INVENTION
- 5 C. SUMMARY OF THE INVENTION
- D. BRIEF DESCRIPTION OF THE DRAWINGS
- E. DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
- F. EXAMPLES
- I. RADIOLABELED ANTI-CD20 ANTIBODY 2B8
  - 10 A. Anti-CD20 Monoclonal Antibody (Murine) Production ("2B8")
    - B. Preparation of 2B8-MX-DTPA Conjugate
      - i. MX-DTPA
      - ii. Preparation of 2B8
      - iii. Conjugation of 2B8 with MX-DTPA
    - iv. Determination of MX-DTPA Incorporation
    - v. Immunoreactivity of 2B8-MX-DTPA
    - vi. Preparation of Indium-[111]-labeled 2B8-MX-DTPA ("I2B8")
    - vii. Preparation of Yttrium-[90]-labeled 2B8-MX-DTPA ("Y2B8")
  - 20 C. Non-Human Animal Studies
    - i. Distribution of Radiolabeled 2B8-MX-DTPA
    - ii. Tumor Localization of I2B8
    - iii. Biodistribution and Tumor Localization Studies with Radiolabeled 2B8-MX-DTPA
  - D. Human Studies
    - i. 2B8 and 2B8-MX-DTPA: Immunohistology Studies with Human Tissues
    - ii. Clinical Analysis of I2B8 (Imaging) and Y2B8 (Therapy)
      - a. Phase I/II Clinical Trial: Single Dose Therapy Study
      - b. Phase I/II Clinical Trial: Multiple Dose Therapy Study
- 35

- 5
- II. CHIMERIC ANTI-CD20 PRODUCTION
- A. Construction of Chimeric Anti-CD20 Immunoglobulin DNA Expression Vectors
- B. Creation of Chimeric Anti-CD20 Producing CHO and SP2/0 Transfectomas
- C. Determination of Immunological Activity of Chimeric Anti-CD20 Antibodies
- 10 i. Human Clq Analysis
- ii. Complement Dependent Cell Lyses
- iii. Antibody Dependent Cellular Cytotoxicity Effector Assay
- III. DEPLETION OF B CELLS IN VIVO USING CHIMERIC ANTI-CD20
- A. Non-Human Primate Study
- 15 B. Clinical Analysis of C2B8
- i. Phase I/II Clinical Trial of C2B8: Single Dose Therapy Study
- ii. Phase I/II Clinical Trial of C2B8: Multiple Dose Therapy Study
- IV. COMBINATION THERAPY: C2B8 AND Y2B8
- 20 A. Preparation of Y2B8
- B. Preparation of C2B8
- C. Results
- V. ALTERNATIVE THERAPY STRATEGIES
- VI. DEPOSIT INFORMATION
- 25 G. SEQUENCE LISTING
- H. CLAIMS

A. FIELD OF THE INVENTION

- The references to be discussed throughout this document are set forth merely for the information described therein prior to the filing dates of this document, and
- 5 nothing herein is to be construed as an admission, either express or implied, that the references are "prior art" or that the inventors are not entitled to antedate such descriptions by virtue of prior inventions or priority based on earlier filed applications.
- 10 The present invention is directed to the treatment of B cell lymphoma using chimeric and radiolabeled antibodies to the B cell surface antigen Bp35 ("CD20").

B. BACKGROUND OF THE INVENTION

- 15 The immune system of vertebrates (for example, primates, which include humans, apes, monkeys, etc.) consists of a number of organs and cell types which have evolved to: accurately and specifically recognize foreign microorganisms ("antigen") which invade the vertebrate-host; specifically bind to such foreign microorganisms; and, eliminate/destroy such foreign microorganisms.
- 20 Lymphocytes, amongst others, are critical to the immune system. Lymphocytes are produced in the thymus, spleen and bone marrow (adult) and represent about 30% of the total white blood cells present in the circulatory system of humans (adult). There are two major sub-populations of lymphocytes: T cells and B cells. T cells are responsible for cell mediated immunity, while B cells are responsible
- 25 for antibody production (humoral immunity). However, T cells and B cells can be considered as interdependent--in a typical immune response, T cells are activated when the T cell receptor binds to fragments of an antigen that are bound to major histocompatibility complex ("MHC") glycoproteins on the surface of an antigen presenting cell; such activation causes release of biological

mediators ("interleukins") which, in essence, stimulate B cells to differentiate and produce antibody ("immunoglobulins") against the antigen.

Each B cell within the host expresses a different antibody on its surface - thus,  
5 one B cell will express antibody specific for one antigen, while another B cell will  
express antibody specific for a different antigen. Accordingly, B cells are quite  
diverse, and this diversity is critical to the immune system. In humans, each B  
cell can produce an enormous number of antibody molecules (*ie* about 10<sup>7</sup> to 10<sup>8</sup>).  
Such antibody production most typically ceases (or substantially decreases) when  
10 the foreign antigen has been neutralized. Occasionally, however, proliferation of  
a particular B cell will continue unabated; such proliferation can result in a  
cancer referred to as "B cell lymphoma."

T cells and B cells both comprise cell surface proteins which can be utilized as  
15 "markers" for differentiation and identification. One such human B cell marker  
is the human B lymphocyte-restricted differentiation antigen Bp35, referred to  
as "CD20." CD20 is expressed during early pre-B cell development and remains  
until plasma cell differentiation. Specifically, the CD20 molecule may regulate a  
step in the activation process which is required for cell cycle initiation and  
20 differentiation and is usually expressed at very high levels on neoplastic  
("tumor") B cells. CD20, by definition, is present on both "normal" B cells as well  
as "malignant" B cells, *ie* those B cells whose unabated proliferation can lead to  
B cell lymphoma. Thus, the CD20 surface antigen has the potential of serving as  
a candidate for "targeting" of B cell lymphomas.

25

In essence, such targeting can be generalized as follows: antibodies specific to  
the CD20 surface antigen of B cells are, *eg* injected into a patient. These anti-  
CD20 antibodies specifically bind to the CD20 cell surface antigen of (ostensibly)  
both normal and malignant B cells; the anti-CD20 antibody bound to the CD20

surface antigen may lead to the destruction and depletion of neoplastic B cells. Additionally, chemical agents or radioactive labels having the potential to destroy the tumor can be conjugated to the anti-CD20 antibody such that the agent is specifically "delivered" to, e.g. the neoplastic B cells. Irrespective of the approach, a primary goal is to destroy the tumor: the specific approach can be determined by the particular anti-CD20 antibody which is utilized and, thus, the available approaches to targeting the CD20 antigen can vary considerably.

For example, attempts at such targeting of CD20 surface antigen have been reported. Murine (mouse) monoclonal antibody 1F5 (an anti-CD20 antibody) was reportedly administered by continuous intravenous infusion to B cell lymphoma patients. Extremely high levels (>2 grams) of 1F5 were reportedly required to deplete circulating tumor cells, and the results were described as being "transient." Press *et al.*, "Monoclonal Antibody 1F5 (Anti-CD20) Serotherapy of Human B-Cell Lymphomas." *Blood* 69/2:584-591 (1987). A potential problem with this approach is that non-human monoclonal antibodies (eg, murine monoclonal antibodies) typically lack human effector functionality, *i.e.* they are unable to, *inter alia*, mediate complement dependent lysis or lyse human target cells through antibody dependent cellular toxicity or Fc-receptor mediated phagocytosis. Furthermore, non-human monoclonal antibodies can be recognized by the human host as a foreign protein; therefore, repeated injections of such foreign antibodies can lead to the induction of immune responses leading to harmful hypersensitivity reactions. For murine-based monoclonal antibodies, this is often referred to as a Human Anti-Mouse Antibody response, or "HAMA" response. Additionally, these "foreign" antibodies can be attacked by the immune system of the host such that they are, in effect, neutralized before they reach their target site.

Lymphocytes and lymphoma cells are inherently sensitive to radiotherapy for several reasons: the local emission of ionizing radiation of radiolabeled antibodies may kill cells with or without the target antigen (eg, CD20) in close proximity to antibody bound to the antigen; penetrating radiation may obviate  
5 the problem of limited access to the antibody in bulky or poorly vascularized tumors; and, the total amount of antibody required may be reduced. The radionuclide emits radioactive particles which can damage cellular DNA to the point where the cellular repair mechanisms are unable to allow the cell to continue living; therefore, if the target cells are tumors, the radioactive label  
10 beneficially kills the tumor cells. Radiolabeled antibodies, by definition, include the use of a radioactive substance which may require the need for precautions for both the patient (*ie* possible bone marrow transplantation) as well as the health care provider (*ie* the need to exercise a high degree of caution when working with the radioactivity).

15

Therefore, an approach at improving the ability of murine monoclonal antibodies to be effective in the treatment of B-cell disorders has been to conjugate a radioactive label or toxin to the antibody such that the label or toxin is localized at the tumor site. For example, the above-referenced IF5 antibody has been  
20 "labeled" with iodine-131 (" $^{131}\text{I}$ ") and was reportedly evaluated for biodistribution in two patients. See Eary, J.F. *et al.*, "Imaging and Treatment of B-Cell Lymphoma" *J. Nuc. Med.* 31/8:1257-1268 (1990); see also, Press, O.W. *et al.*, "Treatment of Refractory Non-Hodgkin's Lymphoma with Radiolabeled MB-1 (Anti-CD37) Antibody" *J. Clin. Onc.* 7/8:1027-1038 (1989) (indication that one  
25 patient treated with  $^{131}\text{I}$ -labeled IF-5 achieved a "partial response"); Goldenberg, D.M. *et al.*, "Targeting, Dosimetry and Radioimmunotherapy of B-Cell Lymphomas with Iodine-131-Labeled LL2 Monoclonal Antibody" *J. Clin. Onc.* 9/4:548-564 (1991) (three of eight patients receiving multiple injections reported to have developed a HAMA response); Appelbaum, F.R. "Radiolabeled

- Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma"  
*Hem./Onc. Clinics of N.A.* 5/5:1013-1025 (1991) (review article); Press, O.W. *et al* "Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support." *New England Journal of Medicine* 329/17: 1219-12223  
5 (1993) (iodine-131 labeled anti-CD20 antibody IF5 and B1); and Kaminski, M.G. *et al* "Radioimmunotherapy of B-Cell Lymphoma with [<sup>131</sup>I] Anti-B1 (Anti-CD20) Antibody". *NEJM* 329/7 (1993) (iodine-131 labeled anti-CD20 antibody B1; hereinafter "Kaminski").
- 10 Toxins (*ie* chemotherapeutic agents such as doxorubicin or mitomycin C) have also been conjugated to antibodies. *See, for example*, PCT published application WO 92/07466 (published May 14, 1992).
- "Chimeric" antibodies, *ie* antibodies which comprise portions from two or more  
15 different species (*eg*, mouse and human) have been developed as an alternative to "conjugated" antibodies. For example, Liu, A.Y. *et al.*, "Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 with Potent Fc-Dependent Biologic Activity" *J. Immun.* 139/10:3521-3526 (1987), describes a mouse/human chimeric antibody directed against the CD20 antigen. *See also*, PCT Publication  
20 No. WO 88/04936. However, no information is provided as to the ability, efficacy or practicality of using such chimeric antibodies for the treatment of B cell disorders in the reference. It is noted that *in vitro* functional assays (*eg* complement dependent lysis ("CDC"); antibody dependent cellular cytotoxicity ("ADCC"), etc.) cannot inherently predict the *in vivo* capability of a chimeric  
25 antibody to destroy or deplete target cells expressing the specific antigen. *See*, for example, Robinson, R.D. *et al.*, "Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities," *Hum. Antibod. Hybridomas* 2:84-93 (1991) (chimeric mouse-human antibody having

undetectable ADCC activity). Therefore, the potential therapeutic efficacy of chimeric antibody can only truly be assessed by *in vivo* experimentation.

- What is needed, and what would be a great advance in the art, are therapeutic  
5 approaches targeting the CD20 antigen for the treatment of B cell lymphomas in primates, including, but not limited to, humans.

#### C. SUMMARY OF THE INVENTION

- 10 Disclosed herein are therapeutic methods designed for the treatment of B cell disorders, and in particular, B cell lymphomas. These protocols are based upon the administration of immunologically active chimeric anti-CD20 antibodies for the depletion of peripheral blood B cells, including B cells associated with lymphoma; administration of radiolabeled anti-CD20 antibodies for targeting  
15 localized and peripheral B cell associated tumors; and administration of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies in a cooperative therapeutic strategy.

#### D. BRIEF DESCRIPTION OF THE DRAWINGS

20

Figure 1 is a diagrammatic representation of a tandem chimeric antibody expression vector useful in the production of immunologically active chimeric anti-CD20 antibodies ("TCAE 8");

- 25 Figures 2A through 2E are the nucleic acid sequence of the vector of Figure 1;

Figures 3A through 3F are the nucleic acid sequence of the vector of Figure 1 further comprising murine light and heavy chain variable regions ("anti-CD20 in TCAE 8");

Figure 4 is the nucleic acid and amino acid sequences (including CDR and framework regions) of murine variable region light chain derived from murine anti-CD20 monoclonal antibody 2B8;

5

Figure 5 is the nucleic acid and amino acid sequences (including CDR and framework regions) of murine variable region heavy chain derived from murine anti-CD20 monoclonal antibody 2B8;

10 Figure 6 are flow cytometry results evidencing binding of fluorescent-labeled human C1q to chimeric anti-CD20 antibody, including, as controls labeled C1q; labeled C1q and murine anti-CD20 monoclonal antibody 2B8; and labeled C1q and human IgG1,k;

15 Figure 7 represents the results of complement related lysis comparing chimeric anti-CD20 antibody and murine anti-CD20 monoclonal antibody 2B8;

Figure 8 represents the results of antibody mediated cellular cytotoxicity with *in vivo* human effector cells comparing chimeric anti-CD20 antibody and 2B8;

20

Figure 9A, 9B and 9C provide the results of non-human primate peripheral blood B lymphocyte depletion after infusion of 0.4 mg/kg (A); 1.6 mg/kg (B); and 6.4 mg/kg (C) of immunologically active chimeric anti-CD20 antibody;

25 Figure 10 provides the results of, *inter alia*, non-human primate peripheral blood B lymphocyte depletion after infusion of 0.01 mg/kg of immunologically active chimeric anti-CD20 antibody;

Figure 11 provides results of the tumoricidal impact of Y2B8 in a mouse xenographic model utilizing a B cell lymphoblastic tumor;

5      **Figure 12 provides results of the tumoricidal impact of C2B8 in a mouse xenographic model utilizing a B cell lymphoblastic tumor;**

Figure 13 provides results of the tumoricidal impact of a combination of Y2B8 and C2B8 in a mouse xenographic model utilizing a B cell lymphoblastic tumor; and

10     Figures 14A and 14B provide results from a Phase I/II clinical analysis of C2B8 evidencing B-cell population depletion over time for patients evidencing a partial remission of the disease (14A) and a minor remission of the disease (14B).

**E. DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS**

15

Generally, antibodies are composed of two light chains and two heavy chain molecules; these chains form a general "Y" shape, with both light and heavy chains forming the arms of the Y and the heavy chains forming the base of the Y.

20     Light and heavy chains are divided into domains of structural and functional homology. The variable domains of both the light ("V<sub>L</sub>") and the heavy ("V<sub>H</sub>") chains determine recognition and specificity. The constant region domains of light ("C<sub>L</sub>") and heavy ("C<sub>H</sub>") chains confer important biological properties, *eg* antibody chain association, secretion, transplacental mobility, Fc receptor binding complement binding, etc. The series of events leading to

25     immunoglobulin gene expression in the antibody producing cells are complex. The variable domain region gene sequences are located in separate germ line gene segments referred to as "V<sub>H</sub>," "D," and "J<sub>H</sub>," or "V<sub>L</sub>" and "J<sub>L</sub>." These gene segments are joined by DNA rearrangements to form the complete V regions expressed in heavy and light chains, respectively. The rearranged, joined V

segments ( $V_L$ - $J_L$  and  $V_H$ - $D$ - $J_H$ ) then encode the complete variable regions or antigen binding domains of light and heavy chains, respectively.

Serotherapy of human B cell lymphomas using an anti-CD20 murine monoclonal antibody (1F5) has been described by Press *et al.*, (69 *Blood* 584, 1987, *supra*); the reported therapeutic responses, unfortunately, were transient. Additionally, 25% of the tested patients reportedly developed a human anti-mouse antibody (HAMA) response to the serotherapy. Press *et al.*, suggest that these antibodies, conjugated to toxins or radioisotopes, might afford a more lasting clinical benefit than the unconjugated antibody.

Owing to the debilitating effects of B cell lymphoma and the very real need to provide viable treatment approaches to this disease, we have embarked upon different approaches having a particular antibody, 2B8, as the common link between the approaches. One such approach advantageously exploits the ability of mammalian systems to readily and efficiently recover peripheral blood B cells; using this approach, we seek to, in essence, purge or deplete B cells in peripheral blood and lymphatic tissue as a means of also removing B cell lymphomas. We accomplish this by utilization of, *inter alia*, immunologically active, chimeric anti-CD20 antibodies. In another approach, we seek to target tumor cells for destruction with radioactive labels.

As used herein, the term "anti-CD20 antibody" is an antibody which specifically recognizes a cell surface non-glycosylated phosphoprotein of 35,000 Daltons, typically designated as the human B lymphocyte restricted differentiation antigen Bp35, commonly referred to as CD20. As used herein, the term "chimeric" when used in reference to anti-CD20 antibodies, encompasses antibodies which are most preferably derived using recombinant deoxyribonucleic acid techniques and which comprise both human (including

immunologically "related" species, *eg*, chimpanzee) and non-human components: the constant region of the chimeric antibody is most preferably substantially identical to the constant region of a natural human antibody; the variable region of the chimeric antibody is most preferably derived from a non-human source  
5 and has the desired antigenic and specificity to the CD20 cell surface antigen. The non-human source can be any vertebrate source which can be used to generate antibodies to a human CD20 cell surface antigen or material comprising a human CD20 cell surface antigen. Such non-human source includes, but is not limited to, rodents (*eg*, rabbit, rat, mouse, etc.) and non-  
10 human primates (*eg*, Old World Monkey, Ape, etc.). Most preferably, the non-human component (variable region) is derived from a murine source. As used herein, the phrase "immunologically active" when used in reference to chimeric anti-CD20 antibodies, means a chimeric antibody which binds human C1q, mediates complement dependent lysis ("CDC") of human B lymphoid cell lines,  
15 and lyses human target cells through antibody dependent cellular cytotoxicity ("ADCC"). As used herein, the phrases "indirect labeling" and "indirect labeling approach" both mean that a chelating agent is covalently attached to an antibody and at least one radionuclide is inserted into the chelating agent. Preferred chelating agents and radionuclides are set forth in Srivagtava, S.C. and Mease,  
20 R.C., "Progress in Research on Ligands, Nuclides and Techniques for Labeling Monoclonal Antibodies," *Nucl. Med. Bio.* 18/6: 589-603 (1991) ("Srivagtava") which is incorporated herein by reference. A particularly preferred chelating agent is 1-isothiocyanatobenzyl-3-methyldiothelene triaminepent acetic acid ("MX-DTPA"); particularly preferred radionuclides for indirect labeling include  
25 indium [111] and yttrium [90]. As used herein, the phrases "direct labeling" and "direct labeling approach" both mean that a radionuclide is covalently attached directly to an antibody (typically via an amino acid residue). Preferred radionuclides are provided in Srivagtava; a particularly preferred radionuclide

for direct labeling is iodine [131] covalently attached via tyrosine residues. The indirect labeling approach is particularly preferred.

The therapeutic approaches disclosed herein are based upon the ability of the  
5 immune system of primates to rapidly recover, or rejuvenate, peripheral blood B  
cells. Additionally, because the principal immune response of primates is  
occasioned by T cells, when the immune system has a peripheral blood B cell  
deficiency, the need for "extraordinary" precautions (*ie* patient isolation, etc.) is  
not necessary. As a result of these and other nuances of the immune systems of  
10 primates, our therapeutic approach to B cell disorders allows for the purging of  
peripheral blood B cells using immunologically active chimeric anti-CD20  
antibodies.

Because peripheral blood B cell disorders, by definition, can indicate a necessity  
15 for access to the blood for treatment, the route of administration of the  
immunologically active chimeric anti-CD20 antibodies and radioalabeled anti-  
CD20 antibodies is preferably parenteral; as used herein, the term "parenteral"  
includes intravenous, intramuscular, subcutaneous, rectal, vaginal or  
intraperitoneal administration. Of these, intravenous administration is most  
20 preferred.

The immunologically active chimeric anti-CD20 antibodies and radiolabeled anti-  
CD20 antibodies will typically be provided by standard technique within a  
pharmaceutically acceptable buffer, for example, sterile saline, sterile buffered  
25 water, propylene glycol, combinations of the foregoing, etc. Methods for  
preparing parenterally administerable agents are described in *Pharmaceutical  
Carriers & Formulations*, Martin, Remington's Pharmaceutical Sciences, 15th  
Ed. (Mack Pub. Co., Easton, PA 1975), which is incorporated herein by reference.

The specific, therapeutically effective amount of immunologically active chimeric anti-CD20 antibodies useful to produce a unique therapeutic effect in any given patient can be determined by standard techniques well known to those of ordinary skill in the art.

5

Effective dosages (*ie* therapeutically effective amounts) of the immunologically active chimeric anti-CD20 antibodies range from about 0.001 to about 30 mg/kg body weight, more preferably from about 0.01 to about 25 mg/kg body weight, and most preferably from about 0.4 to about 20.0 mg/kg body weight. Other 10 dosages are viable; factors influencing dosage include, but are not limited to, the severity of the disease; previous treatment approaches; overall health of the patient; other diseases present, etc. The skilled artisan is readily credited with assessing a particular patient and determining a suitable dosage that falls within the ranges, or if necessary, outside of the ranges.

15

Introduction of the immunologically active chimeric anti-CD20 antibodies in these dose ranges can be carried out as a single treatment or over a series of treatments. With respect to chimeric antibodies, it is preferred that such introduction be carried out over a series of treatments; this preferred approach is 20 predicated upon the treatment methodology associated with this disease. While not wishing to be bound by any particular theory, because the immunologically active chimeric anti-CD20 antibodies are both immunologically active and bind to CD20, upon initial introduction of the immunologically active chimeric anti-CD20 antibodies to the individual, peripheral blood B cell depletion will begin; 25 we have observed a nearly complete depletion within about 24 hours post treatment infusion. Because of this, subsequent introduction(s) of the immunologically active chimeric anti-CD20 antibodies (or radiolabeled anti-CD20 antibodies) to the patient is presumed to: a) clear remaining peripheral blood B cells; b) begin B cell depletion from lymph nodes; c) begin B cell depletion

- from other tissue sources, *eg*, bone marrow, tumor, etc. Stated again, by using repeated introductions of the immunologically active chimeric anti-CD20 antibodies, a series of events take place, each event being viewed by us as important to effective treatment of the disease. The first "event" then, can be
- 5 viewed as principally directed to substantially depleting the patient's peripheral blood B cells; the subsequent "events" can be viewed as either principally directed to simultaneously or serially clearing remaining B cells from the system clearing lymph node B cells, or clearing other tissue B cells.
- 10 In effect, while a single dosage provides benefits and can be effectively utilized for disease treatment/management, a preferred treatment course can occur over several stages; most preferably, between about 0.4 and about 20 mg/kg body weight of the immunologically active chimeric anti-CD20 antibodies is introduced to the patient once a week for between about 2 to 10 weeks, most
- 15 preferably for about 4 weeks.

With reference to the use of radiolabeled anti-CD20 antibodies, a preference is that the antibody is non-chimeric; this preference is predicted upon the significantly longer circulating half-life of chimeric antibodies vis-a-vis murine

20 antibodies (*ie* with a longer circulating half-life, the radionuclide is present in the patient for extended periods). However, radiolabeled chimeric antibodies can be beneficially utilized with lower milli-Curies ("mCi") dosages used in conjunction with the chimeric antibody relative to the murine antibody. This scenario allows for a decrease in bone marrow toxicity to an acceptable level, while maintaining

25 therapeutic utility.

A variety of radionuclides are applicable to the present invention and those skilled in the art are credited with the ability to readily determine which radionuclide is most appropriate under a variety of circumstances. For example,

iodine [131] is a well known radionuclide used for targeted immunotherapy.

However, the clinical usefulness of iodine [131] can be limited by several factors including: eight-day physical half-life; dehalogenation of iodinated antibody both in the blood and at tumor sites; and emission characteristics (e.g. large gamma

5 component) which can be suboptimal for localized dose deposition in tumor.

With the advent of superior chelating agents, the opportunity for attaching metal chelating groups to proteins has increased the opportunities to utilize other radionuclides such as indium [131] and yttrium [90]. Yttrium [90] provides several benefits for utilization in radioimmunotherapeutic applications: the 64

10 hour half-life of yttrium [90] is long enough to allow antibody accumulation by tumor and, unlike e.g. iodine [131], yttrium [90] is a pure beta emitter of high energy with no accompanying gamma irradiation in its decay, with a range in tissue of 100 to 1000 cell diameters. Furthermore, the minimal amount of penetrating radiation allows for outpatient administration of yttrium [90]-

15 labeled antibodies. Furthermore, internalization of labeled antibody is not required for cell killing, and the local emission of ionizing radiation should be lethal for adjacent tumor cells lacking the target antigen.

One non-therapeutic limitation to yttrium [90] is based upon the absence of

20 significant gamma radiation making imaging therewith difficult. To avoid this problem, a diagnostic "imaging" radionuclide, such as indium [111], can be utilized for determining the location and relative size of a tumor prior to the administration of therapeutic doses of yttrium [90]-labeled anti-CD20. Indium

[111] is particularly preferred as the diagnostic radionuclide because: between

25 about 1 to about 10mCi can be safely administered without detectable toxicity; and the imaging data is generally predictive of subsequent yttrium [90]-labeled antibody distribution. Most imaging studies utilize 5mCi indium [111]-labeled antibody because this dose is both safe and has increased imaging efficiency compared with lower doses, with optimal imaging occurring at three to six days

after antibody administration. *See, for example, Murray J.L. , 26 J. Nuc. Med. 3328 (1985) and Carraguillo, J.A. et al , 26 J. Nuc. Med. 67 (1985).*

Effective single treatment dosages (*i.e* therapeutically effective amounts) of  
5 yttrium [90] labeled anti-CD20 antibodies range from between about 5 and about  
75mCi, more preferably between about 10 and about 40mCi. Effective single  
treatment non-marrow ablative dosages of iodine [131] labeled anti-CD20  
antibodies range from between about 5 and about 70mCi, more preferably  
between about 5 and about 40mCi. Effective single treatment ablative dosages  
10 (*i.e* may require autologous bone marrow transplantation) of iodine [131] labeled  
anti-CD20 antibodies range from between about 30 and about 600mCi, more  
preferably between about 50 and less than about 500mCi. In conjunction with a  
chimeric anti-CD20 antibody, owing to the longer circulating half life vis-a-vis  
murine antibodies, an effective single treatment non-marrow ablative dosages of  
15 iodine [131] labeled chimeric anti-CD20 antibodies range from between about 5  
and about 40mCi, more preferably less than about 30mCi. Imaging criteria for,  
*e.g* the indium [111] label, are typically less than about 5mCi.

With respect to radiolabeled anti-CD20 antibodies, therapy therewith can also  
20 occur using a single therapy treatment or using multiple treatments. Because of  
the radionuclide component, it is preferred that prior to treatment, peripheral  
stem cells ("PSC") or bone marrow ("BM") be "harvested" for patients  
experiencing potentially fatal bone marrow toxicity resulting from radiation. BM  
and/or PSC are harvested using standard techniques, and then purged and  
25 frozen for possible reinfusion. Additionally, it is most preferred that prior to  
treatment a diagnostic dosimetry study using a diagnostic labeled antibody (*e.g*  
using indium [111]) be conducted on the patient, a purpose of which is to ensure  
that the therapeutically labeled antibody (*e.g* using yttrium [90]) will not become  
unnecessarily "concentrated" in any normal organ or tissue.

Chimeric mouse/human antibodies have been described. See, for example, Morrison, S.L. et al., *PNAS* 81:6851-6854 (November 1984); European Patent Publication No. 172494; Bouljenne, G.L. et al., *Nature* 312:642 (December 1984); 5 Neubeiger, M.S. et al., *Nature* 314:268 (March 1985); European Patent Publication No. 125023; Tan et al., *J. Immunol.* 135:8564 (November 1985); Sun, L.K. et al., *Hybridoma* 5/1:517 (1986); Sahagan et al., *J. Immunol.* 137:1066-1074 (1986). See generally, Muron, *Nature* 312:597 (December 1984); Dickson, *Genetic Engineering News* 5/3 (March 1985); Marx, *Science* 229:455 (August 10 1985); and Morrison *Science* 229:1202-1207 (September 1985). Robinson et al., in PCT Publication Number WO 88/04936 describe a chimeric antibody with human constant region and murine variable region, having specificity to an epitope of CD20; the murine portion of the chimeric antibody of the Robinson references is derived from the 2H7 mouse monoclonal antibody (gamma 2b, kappa). While the 15 reference notes that the described chimeric antibody is a "prime candidate" for the treatment of B cell disorders, this statement can be viewed as no more than a suggestion to those in the art to determine whether or not this suggestion is accurate for this particular antibody, particularly because the reference lacks any data to support an assertion of therapeutic effectiveness, and importantly, 20 data using higher order mammals such as primates or humans.

Methodologies for generating chimeric antibodies are available to those in the art. For example, the light and heavy chains can be expressed separately, using, for example, immunoglobulin light chain and immunoglobulin heavy chains in 25 separate plasmids. These can then be purified and assembled *in vitro* into complete antibodies; methodologies for accomplishing such assembly have been described. See, for example, Scharff, M., *Harvey Lectures* 69:125 (1974). *In vitro* reaction parameters for the formation of IgG antibodies from reduced isolated light and heavy chains have also been described. See, for example, Beychok, S.,

*Cells of Immunoglobulin Synthesis*, Academic Press, New York, p. 69, 1979. Co-expression of light and heavy chains in the same cells to achieve intracellular association and linkage of heavy and light chains into complete H<sub>2</sub>L<sub>2</sub> IgG antibodies is also possible. Such co-expression can be accomplished using either 5 the same or different plasmids in the same host cell.

Another approach, and one which is our most preferred approach for developing a chimeric non-human/human anti-CD20 antibody, is based upon utilization of an expression vector which includes, *ab initio*, DNA encoding heavy and light 10 chain constant regions from a human source. Such a vector allows for inserting DNA encoding non-human variable region such that a variety of non-human anti-CD20 antibodies can be generated, screened and analyzed for various characteristics (eg type of binding specificity, epitope binding regions, etc.); thereafter, cDNA encoding the light and heavy chain variable regions from a 15 preferred or desired anti-CD20 antibody can be incorporated into the vector. We refer to these types of vectors as Tandem Chimeric Antibody Expression ("TCAE") vectors. A most preferred TCAE vector which was used to generate immunologically active chimeric anti-CD20 antibodies for therapeutic treatment of lymphomas is TCAE 8. TCAE 8 is a derivative of a vector owned by the 20 assignee of this patent document, referred to as TCAE 5.2 the difference being that in TCAE 5.2, the translation initiation start site of the dominant selectable marker (neomycin phosphotransferase, "NEO") is a consensus Kozak sequence, while for TCAE 8, this region is a partially impaired consensus Kozak sequence. Details regarding the impact of the initiation start site of the dominant 25 selectable marker of the TCAE vectors (also referred to as "ANEX vector") vis-a-vis protein expression are disclosed in detail in the co-pending application filed herewith.

TCAE 8 comprises four (4) transcriptional cassettes, and these are in tandem order, *ie* a human immunoglobulin light chain absent a variable region; a human immunoglobulin heavy chain absent a variable region; DHFR; and NEO. Each transcriptional cassette contains its own eukaryotic promotor and 5 polyadenylation region (reference is made to Figure 1 which is a diagrammatic representation of the TCAE 8 vector). Specifically:

- 1) the CMV promoter/enhancer in front of the immunoglobulin heavy chain is a truncated version of the promoter/enhancer in front of the light chain, from the 10 Nhe I site at -350 to the Sst I site at -16 (*see*, 41 *Cell* 521, 1985).
- 2) a human immunoglobulin light chain constant region was derived via amplification of cDNA by a PCR reaction. In TCAE 8, this was the human immunoglobulin light chain kappa constant region (Kabat numbering, amino acids 108-214, allotype Km 3, (*see*, Kabat, E.A. "Sequences of proteins of immunological interest," NIH Publication, Fifth Ed. No. 91-3242, 1991)), and the human immunoglobulin heavy chain gamma 1 constant region (Kabat numbering amino acids 114-478, allotype Gmla, Gmlz). The light chain was isolated from normal human blood (IDEC Pharmaceuticals Corporation, La Jolla, CA); RNA therefrom was used to synthesize cDNA which was then amplified using PCR techniques (primers were derived vis-a-vis the consensus from Kabat). The heavy chain was isolated (using PCR techniques) from cDNA prepared from RNA which was in turn derived from cells transfected with a human IgG1 vector (*see*, 3 *Prot. Eng.* 531, 1990; vector pN<sub>γ1</sub>62). Two amino acids 20 were changed in the isolated human IgG1 to match the consensus amino acid sequence from Kabat, to wit: amino acid 225 was changed from valine to alanine (GTT to GCA), and amino acid 287 was changed from methionine to lysine (ATG to AAG);

- 3) The human immunoglobulin light and heavy chain cassettes contain synthetic signal sequences for secretion of the immunoglobulin chains;
- 4) The human immunoglobulin light and heavy chain cassettes contain specific DNA restriction sites which allow for insertion of light and heavy immunoglobulin variable regions which maintain the transitional reading frame and do not alter the amino acids normally found in immunoglobulin chains;
- 5) The DHFR cassette contained its own eukaryotic promoter (mouse beta globin major promoter, "BETA") and polyadenylation region (bovine growth hormone polyadenylation, "BGH"); and
- 6) The NEO cassette contained its own eukaryotic promoter (BETA) and polyadenylation region (SV40 early polyadenylation, "SV").

15

With respect to the TCAE 8 vector and the NEO cassette, the Kozak region was a partially impaired consensus Kozak sequence (which included an upstream Cla I site):

20

ClaI -3 +1

GGGAGCTTGG ATCGAT ccTct ATG Gtt

(In the TCAE 5.2 vector, the change is between the ClaI and ATG regions, to wit: ccAcc.)

25

The complete sequence listing of TCAE 8 (including the specific components of the four transcriptional cassettes) is set forth in Figure 2 (SEQ. ID. NO. 1).

As will be appreciated by those in the art, the TCAE vectors beneficially allow for substantially reducing the time in generating the immunologically active chimeric anti-CD20 antibodies. Generation and isolation of non-human light and heavy chain variable regions, followed by incorporation thereof within the 5 human light chain constant transcriptional cassette and human heavy chain constant transcriptional cassette, allows for production of immunologically active chimeric anti-CD20 antibodies.

We have derived a most preferred non-human variable region with specificity to 10 the CD20 antigen using a murine source and hybridoma technology. Using polymerase chain reaction ("PCR") techniques, the murine light and heavy variable regions were cloned directly into the TCAE 8 vector--this is the most preferred route for incorporation of the non-human variable region into the TCAE vector. This preference is principally predicated upon the efficiency of the 15 PCR reaction and the accuracy of insertion. However, other equivalent procedures for accomplishing this task are available. For example, using TCAE 8 (or an equivalent vector), the sequence of the variable region of a non-human anti-CD20 antibody can be obtained, followed by oligonucleotide synthesis of portions of the sequence or, if appropriate, the entire sequence; thereafter, the 20 portions or the entire synthetic sequence can be inserted into the appropriate locations within the vector. Those skilled in the art are credited with the ability to accomplish this task.

Our most preferred immunologically active chimeric anti-CD20 antibodies were 25 derived from utilization of TCAE 8 vector which included murine variable regions derived from monoclonal antibody to CD20; this antibody (to be discussed in detail, *infra*), is referred to as "2B8." The complete sequence of the variable regions obtained from 2B8 in TCAE 8 ("anti-CD20 in TCAE 8") is set forth in Figure 3 (SEQ. ID. NO. 2).

- The host cell line utilized for protein expression is most preferably of mammalian origin; those skilled in the art are credited with ability to preferentially determine particular host cell lines which are best suited for the desired gene product to be expressed therein. Exemplary host cell lines include, but are not limited to, DG44 and DUXBII (Chinese Hamster Ovary lines, DHFR minus), HELA (human cervical carcinoma), CVI (monkey kidney line), COS (a derivative of CVI with SV40 T antigen), R1610 (Chinese hamster fibroblast) BALBC/3T3 (mouse fibroblast), HAK (hamster kidney line), SP2/O (mouse myeloma), P3x63-Ag3.653 (mouse myeloma), BFA-lclBPT (bovine endothelial cells), RAJI (human lymphocyte) and 293 (human kidney). Host cell lines are typically available from commercial services, the American Tissue Culture Collection or from published literature.
15. Preferably the host cell line is either DG44 ("CHO") or SP2/O. See Urland, G. et al., "Effect of gamma rays and the dihydrofolate reductase locus: deletions and inversions." *Som. Cell & Mol. Gen.* 12/6:555-566 (1986), and Shulman, M. et al., "A better cell line for making hybridomas secreting specific antibodies." *Nature* 276:269 (1978), respectively. Most preferably, the host cell line is DG44.
20. Transfection of the plasmid into the host cell can be accomplished by any technique available to those in the art. These include, but are not limited to, transfection (including electrophoresis and electroporation), cell fusion with enveloped DNA, microinjection, and infection with intact virus. See, Ridgway, A.A.G. "Mammalian Expression Vectors." Chapter 24.2, pp. 470-472 *Vectors*,
25. Rodriguez and Denhardt, Eds. (Butterworths, Boston, MA 1988). Most preferably, plasmid introduction into the host is via electroporation.

**F. EXAMPLES**

The following examples are not intended, nor are they to be construed, as limiting the invention. The examples are intended to evidence: dose-imaging 5 using a radiolabeled anti-CD20 antibody ("I2B8"); radiolabeled anti-CD20 antibody ("Y2B8"); and immunologically active, chimeric anti-CD20 antibody ("C2B8") derived utilizing a specific vector ("TCAE 8") and variable regions derived from murine anti-CD20 monoclonal antibody ("2B8").

**10 I. RADIOLABELED ANTI-CD20 ANTIBODY 2B8****A. Anti-CD20 Monoclonal Antibody (Murine) Production ("2B8")**

BALB/C mice were repeatedly immunized with the human lymphoblastoid cell line SB (*see*, Adams, R.A. *et al.*, "Direct implantation and serial 15 transplantation of human acute lymphoblastic leukemia in hamsters, SB-2." *Can Res* 28:1121-1125 (1968); this cell line is available from the American Tissue Culture Collection, Rockville, MD., under ATCC accession number ATCC CCL 120), with weekly injections over a period of 3-4 months. Mice evidencing high serum titers of anti-CD20 antibodies, as determined by inhibition of known 20 CD20-specific antibodies (anti-CD20 antibodies utilized were Leu 16, Beckton Dickinson, San Jose, CA, Cat. No. 7670; and Bl, Coulter Corp., Hialeah, FL, Cat. No. 6602201) were identified; the spleens of such mice were then removed. Spleen cells were fused with the mouse myeloma SP2/0 in accordance with the protocol described in Einfeld, D.A. *et al.*, (1988) *EMBO* 7:711 (SP2/0 has ATCC 25 accession no. ATCC CRL 8006).

Assays for CD20 specificity were accomplished by radioimmunoassay. Briefly, purified anti-CD20 Bl was radiolabeled with  $I^{125}$  by the iodobead method as described in Valentine, M.A. *et al.*, (1989) *J. Biol. Chem.* 264:11282. ( $I^{125}$

Sodium Iodide, ICN, Irvine, CA, Cat. No. 28665H). Hybridomas were screened by co-incubation of 0.05 ml of media from each of the fusion wells together with 0.05 ml of  $I^{125}$  labeled anti-CD20 Bl (10 ng) in 1% BSA, PBS (pH 7.4), and 0.5 ml of the same buffer containing 100,000 SB cells. After incubation for 1 hr at room temperature, the cells were harvested by transferring to 96 well titer plates (V&P Scientific, San Diego, CA), and washed thoroughly. Duplicate wells containing unlabeled anti-CD20 Bl and wells containing no inhibiting antibody were used as positive and negative controls, respectively. Wells containing greater than 50% inhibition were expanded and cloned. The antibody 10 demonstrating the highest inhibition was derived from the cloned cell line designated herein as "2B8."

B. Preparation of 2B8-MX-DTPA Conjugate

i. MX-DTPA

15 Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid ("carbon-14 labeled MX-DTPA") was used as a chelating agent for conjugation of radiolabel to 2B8. Manipulations of MX-DTPA were conducted to maintain metal-free conditions, *ie* metal-free reagents were utilized and, when possible, polypropylene plastic containers (flasks, beakers, graduated 20 cylinders, pipette tips) washed with Alconox and rinsed with Milli-Q water, were similarly utilized. MX-DTPA was obtained as a dry solid from Dr. Otto Gansow (National Institute of Health, Bethesda, MD) and stored desiccated at 4°C (protected from light), with stock solutions being prepared in Milli-Q water at a concentration of 2-5mM, with storage at -70°C. MX-DTPA was also obtained 25 from Coulter Immunology (Hialeah, Florida) as the disodium salt in water and stored at -70°C.

ii. Preparation of 2B8

Purified 2B8 was prepared for conjugation with MX-DTPA by transferring the antibody into metal-free 50mM bicine-NaOff, pH 8.6, containing 150 mM NaCl, using repetitive buffer exchange with CENTRICON 30<sup>TM</sup> spin filters (30,000D, MWCO; Amicon). Generally, 50-200 µL of protein (10 mg/ml) was added to the filter unit, followed by 2 mL of bicine buffer. The filter was centrifuged at 4°C in a Sorval SS-34 rotor (6,000 rpm, 45 min.). Retentate volume was approximately 50-100 µL; this process was repeated twice using the same filter. Retentate was transferred to a polypropylene 1.5 mL screw cap tube, assayed for protein, diluted to 10.0 mg/mL and stored at 4°C until utilized; protein was similarly transferred into 50 mM sodium citrate, pH 5.5, containing 150 mM NaCl and 0.05% sodium azide, using the foregoing protocol.

iii. Conjugation of 2B8 with MX-DTPA

Conjugation of 2B8 with MX-DTPA was performed in polypropylene tubes at ambient temperature. Frozen MX-DTPA stock solutions were thawed immediately prior to use. 50-200 mL of protein at 10 mg/mL were reacted with MX-DTPA at a molar ratio of MX-DTPA-to-2B8 of 4:1. Reactions were initiated by adding the MX-DTPA stock solution and gently mixing; the conjugation was allowed to proceed overnight (14 to 20 hr), at ambient temperature. Unreacted MX-DTPA was removed from the conjugate by dialysis or repetitive ultrafiltration, as described above in Example I.B.ii, into metal-free normal saline (0.9% w/v) containing 0.05% sodium azide. The protein concentration was adjusted to 10 mg/mL and stored at 4°C in a polypropylene tube until radiolabeled.

iv. Determination of MX-DTPA Incorporation

MX-DTPA incorporation was determined by scintillation counting and comparing the value obtained with the purified conjugate to the specific

activity of the carbon-[14]-labeled MX-DTPA. For certain studies, in which non-radioactive MX-DTPA (Coulter Immunology) was utilized, MX-DTPA incorporation was assessed by incubating the conjugate with an excess of a radioactive carrier solution of yttrium-[90] of known concentration and specific activity.

A stock solution of yttrium chloride of known concentration was prepared in metal-free 0.05 N HCl to which carrier-free yttrium-[90] (chloride salt) was added. An aliquot of this solution was analyzed by liquid scintillation counting to determine an accurate specific activity for this reagent. A volume of the yttrium chloride reagent equal to 3-times the number of mols of chelate expected to be attached to the antibody, (typically 2 mol/mol antibody), was added to a polypropylene tube, and the pH adjusted to 4.0-4.5 with 2 M sodium acetate. Conjugated antibody was subsequently added and the mixture incubated 15-30 min. at ambient temperature. The reaction was quenched by adding 20 mM EDTA to a final concentration of 1 mM and the pH of the solution adjusted to approximately pH 6 with 2M sodium acetate.

After a 5 min. incubation, the entire volume was purified by high-performance, size-exclusion chromatography (described *infra*). The eluted protein-containing fractions were combined, the protein concentration determined, and an aliquot assayed for radioactivity. The chelate incorporation was calculated using the specific activity of the yttrium-[90] chloride preparation and the protein concentration.

25

v. Immunoreactivity of 2B8-MX-DTPA

The immunoreactivity of conjugated 2B8 was assessed using whole-cell ELISA. Mid-log phase SB cells were harvested from culture by centrifugation and washed two times with 1X HBSS. Cells were diluted to 1-2 X

10<sup>6</sup> cells/mL in HBSS and aliquoted into 96-well polystyrene microtiter plates at 50,000-100,000 cells/well. The plates were dried under vacuum for 2 h. at 40-45°C to fix the cells to the plastic; plates were stored dry at -20°C until utilized. For assay, the plates were warmed to ambient temperature immediately before 5 use, then blocked with 1X PBS, pH 7.2-7.4 containing 1% BSA (2 h). Samples for assay were diluted in 1X PBS/1% BSA, applied to plates and serially diluted (1:2) into the same buffer. After incubating plates for 1 h. at ambient temperature, the plates were washed three times with 1X PBS. Secondary antibody (goat anti-mouse IgG1-specific HRP conjugate 50 µL) was added to wells (1:1500 dilution in 10 1X PBS/1% BSA) and incubated 1 h. at ambient temperature. Plates were washed four times with 1X PBS followed by the addition of ABTS substrate solution (50 mM sodium citrate, pH 4.5 containing 0.01% ATBS and 0.001% H<sub>2</sub>O<sub>2</sub>). Plates were read at 405 nm after 15-30 min. incubation. Antigen-negative HSB cells were included in assays to monitor non-specific binding.

15 Immunoreactivity of the conjugate was calculated by plotting the absorbance values vs. the respective dilution factor and comparing these to values obtained using native antibody (representing 100% immunoreactivity) tested on the same plate; several values on the linear portion of the titration profile were compared and a mean value determined (data not shown).

20

vi. Preparation of Indium-[111]-Labeled 2B8-MX-DTPA ("I2B8")

Conjugates were radiolabeled with carrier-free indium-[111]. An aliquot of isotope (0.1-2 mCi/mg antibody) in 0.05 M HCl was transferred to a polypropylene tube and approximately one-tenth volume of metal-free 2 M HCl 25 added. After incubation for 5 min., metal-free 2 M sodium acetate was added to adjust the solution to pH 4.0-4.4. Approximately 0.5 mg of 2B8-MX-DTPA was added from a stock solution of 10.0 mg/mL DTPA in normal saline, or 50 mM sodium citrate/150 mM NaCl containing 0.05% sodium azide, and the solution gently mixed immediately. The pH solution was checked with pH paper to verify

a value of 4.0-4.5 and the mixture incubated at ambient temperature for 15-30 min. Subsequently, the reaction was quenched by adding 20 mM EDTA to a final concentration of 1 mM and the reaction mixture was adjusted to approximately pH 6.0 using 2 M sodium acetate.

5

After a 5-10 min. incubation, uncomplexed radioisotope was removed by size-exclusion chromatography. The HPLC unit consisted of Waters Model 6000 or TosoHaas Model TSK-6110 solvent delivery system fitted, respectively, with a Waters U6K or Rheodyne 700 injection valve. Chromatographic separations 10 were performed using a gel permeation column (BioRad SEC-250; 7.5 x 300 mm or comparable TosoHaas column) and a SEC-250 guard column (7.5 x 100 mm). The system was equipped with a fraction collector (Pharmacia Frac200) and a UV monitor fitted with a 280 nm filter (Pharmacia model UV-1). Samples were applied and eluted isocratically using 1X PBS, pH 7.4, at 1.0 mL/min flow rate. 15 One-half milliliter fractions were collected in glass tubes and aliquots of these counted in a gamma counter. The lower and upper windows were set to 100 and 500 KeV respectively.

The radioincorporation was calculated by summing the radioactivity associated 20 with the eluted protein peak and dividing this number by the total radioactivity eluted from the column; this value was then expressed as a percentage (data not shown). In some cases, the radioincorporation was determined using instant thin-layer chromatography ("ITLC"). Radiolabeled conjugate was diluted 1:10 or 1:20 in 1X PBS containing or 1X PBS/1 mM DTPA, then 1  $\mu$ L was spotted 1.5 cm 25 from one end of a 1 x 5 cm strip of ITLC SG paper. The paper was developed by ascending chromatography using 10% ammonium acetate in methanol:water (1:1;v/v). The strip was dried, cut in half crosswise, and the radioactivity associated with each section determined by gamma counting. The radioactivity associated with the bottom half of the strip (protein-associated radioactivity) was

expressed as a percentage of the total radioactivity, determined by summing the values for both top and bottom halves (data not shown).

Specific activities were determined by measuring the radioactivity of an 5 appropriate aliquot of the radiolabeled conjugate. This value was corrected for the counter efficiency (typically 75%) and related to the protein concentration of the conjugate, previously determined by absorbance at 280 nm, and the resulting value expressed as mCi/mg protein.

10 For some experiments, 2B8-MX-DTPA was radiolabeled with indium [111] following a protocol similar to the one described above but without purification by HPLC; this was referred to as the "mix-and-shoot" protocol.

vii. Preparation of Yttrium-[90]-Labeled 2B8-MX-DTPA ("Y2B8")

15 The same protocol described for the preparation of I2B8 was followed for the preparation of the yttrium-[90]-labeled 2B8-MX-DTPA ("Y2B8") conjugate except that 2 ng HCl was not utilized; all preparations of yttrium-labeled conjugates were purified by size-exclusion chromatography as described above.

20

C. Non-Human Animal Studies.

i. Biodistribution of Radiolabeled 2B8-MX-DTPA

I2B8 was evaluated for tissue biodistribution in six-to-eight week old BALB/c mice. The radiolabeled conjugate was prepared using clinical-grade 25 2B8-MX-DTPA following the "mix and shoot" protocol described above. The specific activity of the conjugate was 2.3 mCi/mg and the conjugate was formulated in PBS, pH 7.4 containing 50mg/mL HSA. Mice were injected intravenously with 100 µL of I2B8 (approximately 21 µCi) and groups of three mice were sacrificed by cervical dislocation at 0, 24, 48, and 72 hours. After

sacrifice, the tail, heart, lungs, liver, kidney, spleen, muscle, and femur were removed, washed and weighed; a sample of blood was also removed for analysis. Radioactivity associated with each specimen was determined by gamma counting and the percent injected dose per gram tissue subsequently determined. No 5 attempt was made to discount the activity contribution represented by the blood associated with individual organs.

In a separate protocol, aliquots of 2B8-MX-DTPA incubated at 4°C and 30°C for 10 weeks were radiolabeled with indium-[111] to a specific activity of 2.1 mCi/mg 10 for both preparations. These conjugates were then used in biodistribution studies in mice as described above.

For dosimetry determinations, 2B8-MX-DTPA was radiolabeled with indium-[111] to a specific activity of 2.3 mCi/mg and approximately 1.1  $\mu$ Ci was injected 15 into each of 20 BALB/c mice. Subsequently, groups of five mice each were sacrificed at 1, 24, 48 and 72 hours and their organs removed and prepared for analysis. In addition, portions of the skin, muscle and bone were removed and processed for analysis; the urine and feces were also collected and analyzed for the 24-72 hour time points.

20 Using a similar approach, 2B8-MX-DTPA was also radiolabeled with yttrium-[90] and its biological distribution evaluated in BALB/c mice over a 72-hour time period. Following purification by HPLC size exclusion chromatography, four groups of five mice each were injected intravenously with approximately 1  $\mu$ Ci of 25 clinically-formulated conjugate (specific activity:12.2 mCi/mg); groups were subsequently sacrificed at 1, 24, 48 and 72 hours and their organs and tissues analyzed as described above. Radioactivity associated with each tissue specimen was determined by measuring bremstrahlung energy with a gamma scintillation counter. Activity values were subsequently expressed as percent injected dose

per gram tissue or percent injected dose per organ. While organs and other tissues were rinsed repeatedly to remove superficial blood, the organs were not perfused. Thus, organ activity values were not discounted for the activity contribution represented by internally associated blood.

5

ii. Tumor Localization of I2B8

The localization of radiolabeled 2B8-MX-DTPA was determined in athymic mice bearing Ramos B cell tumors. Six-to-eight week old athymic mice were injected subcutaneously (left-rear flank) with 0.1 mL of RPMI-1640 containing  $1.2 \times 10^7$  Ramos tumor cells which had been previously adapted for growth in athymic mice. Tumors arose within two weeks and ranged in weight from 0.07 to 1.1 grams. Mice were injected intravenously with 100  $\mu$ L of indium-[111]-labeled 2B8-MX-DTPA (16.7  $\mu$ Ci) and groups of three mice were sacrificed by cervical dislocation at 0, 24, 48, and 72 hours. After sacrifice the tail, heart, lungs, liver, kidney, spleen, muscle, femur, and tumor were removed, washed, weighed; a sample of blood was also removed for analysis. Radioactivity associated with each specimen was determined by gamma counting and the percent injected dose per gram tissue determined.

20

iii. Biodistribution and Tumor Localization Studies with Radiolabeled 2B8-MX-DTPA

Following the preliminary biodistribution experiment described above (Example I.B.viii.a.), conjugated 2B8 was radiolabeled with indium-[111] to a specific activity of 2.3 mCi/mg and roughly 1.1  $\mu$ Ci was injected into each of twenty BALB/c mice to determine biodistribution of the radiolabeled material. Subsequently, groups of five mice each were sacrificed at 1, 24, 48 and 72 hours and their organs and a portion of the skin, muscle and bone were removed and processed for analysis. In addition, the urine and feces were collected and analyzed for the 24-72 hour time-points. The level of radioactivity in the blood dropped from 40.3% of the injected dose per gram at 1 hour to 18.9% at 72 hours

(data not shown). Values for the heart, kidney, muscle and spleen remained in the range of 0.7-9.8% throughout the experiment. Levels of radioactivity found in the lungs decreased from 14.2% at 1 hour to 7.6% at 72 hours; similarly the respective liver injected-dose per gram values were 10.3% and 9.9%. These data 5 were used in determining radiation absorbed dose estimates I2B8 described below.

The biodistribution of yttrium-[90]-labeled conjugate, having a specific activity of 12.2 mCi/mg antibody, was evaluated in BALB/c mice. Radioincorporations of 10 >90% were obtained and the radiolabeled antibody was purified by HPLC. Tissue deposition of radioactivity was evaluated in the major organs, and the skin, muscle, bone, and urine and feces over 72 hours and expressed as percent injected dose/g tissue. Results (not shown) evidenced that while the levels of radioactivity associated with the blood dropped from approximately 39.2% 15 injected dose per gram at 1 hour to roughly 15.4% after 72 hours the levels of radioactivity associated with tail, heart, kidney, muscle and spleen remained fairly constant at 10.2% or less throughout the course of the experiment. Importantly, the radioactivity associated with the bone ranged from 4.4% of the injected dose per gram bone at 1 hour to 3.2% at 72 hours. Taken together, these 20 results suggest that little free yttrium was associated with the conjugate and that little free radiometal was released during the course of the study. These data were used in determining radiation absorbed dose estimates for Y2B8 described below.

25 For tumor localization studies, 2B8-MX-DTPA was prepared and radiolabeled with <sup>111</sup>Indium to a specific activity of 2.7 mCi/mg. One hundred microliters of labeled conjugate (approximately 24 µCi) were subsequently injected into each of 12 athymic mice bearing Ramos B cell tumors. Tumors ranged in weight from 0.1 to 1.0 grams. At time points of 0, 24, 48, and 72 hours following injection, 50

μL of blood was removed by retro-orbital puncture, the mice sacrificed by cervical dislocation, and the tail, heart, lungs, liver, kidney, spleen, muscle, femur, and tumor removed. After processing and weighing the tissues, the radioactivity associated with each tissue specimen was determined using a gamma counter  
5 and the values expressed as percent injected dose per gram.

The results (not shown) evidenced that the tumor concentrations of the <sup>111</sup>In-  
2B8-MX-DTPA increased steadily throughout the course of the experiment.  
Thirteen percent of the injected dose was accumulated in the tumor after 72  
10 hours. The blood levels, by contrast, dropped during the experiment from over  
30% at time zero to 13% at 72 hours. All other tissues (except muscle) contained  
between 1.3 and 6.0% of the injected dose per gram tissue by the end of the  
experiment; muscle tissue contained approximately 13% of the injected dose per  
gram.

15

D. Human Studies

i. 2B8 and 2B8-MX-DTPA: Immunohistology Studies with Human Tissues

20 The tissue reactivity of murine monoclonal antibody 2B8 was evaluated using a panel of 32 different human tissues fixed with acetone. Antibody 2B8 reacts with the anti-CD20 antigen which had a very restricted pattern of tissue distribution, being observed only in a subset of cells in lymphoid tissues including those of hematopoietic origin.

25

In the lymph node, immunoreactivity was observed in a population of mature cortical B-lymphocytes as well as proliferating cells in the germinal centers. Positive reactivity was also observed in the peripheral blood, B-cell areas of the tonsils, white pulp of the spleen, and with 40-70% of the medullary lymphocytes  
30 found in the thymus. Positive reactivity was also seen in the follicles of the

lamina propria (Peyer's Patches) of the large intestines. Finally, aggregates or scattered lymphoid cells in the stroma of various organs, including the bladder, breast, cervix, esophagus, lung, parotid, prostate, small intestine, and stomach, were also positive with antibody 2B8 (data not shown).

5

All simple epithelial cells, as well as the stratified epithelia and epithelia of different organs, were found to be unreactive. Similarly, no reactivity was seen with neuroectodermal cells, including those in the brain, spinal cord and peripheral nerves. Mesenchymal elements, such as skeletal and smooth muscle 10 cells, fibroblasts, endothelial cells, and polymorphonuclear inflammatory cells were also found to be negative (data not shown).

The tissue reactivity of the 2B8-MX-DTPA conjugate was evaluated using a panel of sixteen human tissues which had been fixed with acetone. As previously 15 demonstrated with the native antibody (data not shown), the 2B8-MX-DTPA conjugate recognized the CD20 antigen which exhibited a highly restricted pattern of distribution, being found only on a subset of cells of lymphoid origin. In the lymph node, immunoreactivity was observed in the B cell population. Strong reactivity was seen in the white pulp of the spleen and in the medullary 20 lymphocytes of the thymus. Immunoreactivity was also observed in scattered lymphocytes in the bladder, heart, large intestines, liver, lung, and uterus, and was attributed to the presence of inflammatory cells present in these tissues. As with the native antibody, no reactivity was observed with neuroectodermal cells or with mesenchymal elements (data not shown).

25

ii. Clinical Analysis of I2B8 (Imaging) and Y2B8 (Therapy)

a. Phase I/II Clinical Trial Single Dose Therapy Study

A Phase I/II clinical analysis of I2B8 (imaging) followed by treatment with a single therapeutic dose of Y2B8 is currently being conducted.

5 For the single-dose study, the following schema is being followed:

1. Peripheral Stem Cell (PSC) or Bone Marrow (BM) Harvest with Purging;
2. I2B8 Imaging;
3. Y2B8 Therapy (three Dose Levels); and
- 10 4. PSC or Autologous BM Transplantation (if necessary based upon absolute neutrophil count below 500/mm<sup>3</sup> for three consecutive days or platelets below 20,000/mm<sup>3</sup> with no evidence of marrow recovery on bone marrow examination).

15 The Dose Levels of Y2B8 are as follows:

<u>Dose Level</u>	<u>Dose (mCi)</u>
1.	20
2.	30
3.	40

20 Three patients are to be treated at each of the dose levels for determination of a Maximum Tolerated Dose ("MTD").

Imaging (Dosimetry) Studies are conducted as follows: each patient is involved in two *in vivo* biodistribution studies using I2B8. In the first study, 2mg of I2B8 (5mCi), is administered as an intravenous (i.v.) infusion over one hour; one week later 2B8 (*i.e.* unconjugated antibody) is administered by i.v. at a rate not to exceed 250mg/hr followed immediately by 2mg of I2B8 (5mCi) administered by i.v. over one hour. In both studies, immediately following the I2B8 infusion, each patient is imaged and imaging is repeated at time  $t = 14\text{-}18$  hr (if indicated),  $t = 30$  24 hr;  $t = 72$  hr; and  $t = 96$  hr (if indicated). Whole body average retention times for the indium [111] label are determined; such determinations are also made for recognizable organs or tumor lesions ("regions of interest").

The regions of interest are compared to the whole body concentrations of the label; based upon this comparison, an estimate of the localization and concentration of Y2B8 can be determined using standard protocols. If the 5 estimated cumulative dose of Y2B8 is greater than eight (8) times the estimated whole body dose, or if the estimated cumulative dose for the liver exceeds 1500 cGy, no treatment with Y2B8 should occur.

If the imaging studies are acceptable, either 0.0 or 1.0mg/kg patient body weight 10 of 2B8 is administered by i.v. infusion at a rate not to exceed 250mg/h. This is followed by administration of Y2B8 (10,20 or 40mCi) at an i.v. infusion rate of 20mCi/hr.

b. Phase I/II Clinical Trial: Multiple Dose Therapy Study

15 A Phase I/II clinical analysis of of Y2B8 is currently being conducted. For the multiple-dose study, the following schema is being followed:

1. PSC or BM Harvest;
2. I2B8 Imaging;
- 20 3. Y2B8 Therapy (three Dose Levels) for four doses or a total cumulative dose of 80mCi; and
4. PSC or Autologous BM Transplantation (based upon decision of medical practitioner).

25 The Dose Levels of Y2B8 are as follows:

<u>Dose Level</u>	<u>Dose (mCi)</u>
1.	10
2.	15
3.	20

30 Three patients are to be treated at each of the dose levels for determination of an MTD.

- Imaging (Dosimetry) Studies are conducted as follows: A preferred imaging dose for the unlabeled antibody (*ie* 2B8) will be determined with the first two patients. The first two patients will receive 100mg of unlabeled 2B8 in 250cc of normal saline over 4 hrs followed by 0.5mCi of I2B8 -- blood will be sampled for
- 5 biodistribution data at times  $t = 0$ ,  $t = 10\text{min.}$ ,  $t = 120\text{ min.}$ ,  $t = 24\text{ hr}$ , and  $t = 48\text{ hr}$ . Patients will be scanned with multiple regional gamma camera images at times  $t = 2\text{ hr}$ ,  $t = 24\text{ hr}$  and  $t = 48\text{ hr}$ . After scanning at  $t = 48\text{ hr}$ , the patients will receive 250mg of 2B8 as described, followed by 4.5mCi of I2B8 -- blood and scanning will then follow as described. If 100mg of 2B8 produces superior
- 10 imaging, then the next two patients will receive 50mg of 2B8 as described, followed by 0.5mCi of I2B8 followed 48 hrs later by 100mg 2B8 and then with 4.5mCi of I2B8. If 250mg of 2B8 produces superior imaging, then the next two patients will receive 250mg of 2B8 as described, followed by 0.5mCi of I2B8 followed 48 hrs later with 500mg 2B8 and then with 4.5mCi of I2B8. Subsequent
- 15 patients will be treated with the lowest amount of 2B8 that provides optimal imaging. Optimal imaging will be defined by: (1) best effective imaging with the slowest disappearance of antibody; (2) best distribution minimizing compartmentalization in a single organ; and (3) best subjective resolution of the lesion (tumor/background comparison).
- 20
- For the first four patients, the first therapeutic dose of Y2B8 will begin 14 days after the last dose of I2B8; for subsequent patients, the first therapeutic dose of Y2B8 will begin between two to seven days after the I2B8.
- 25 Prior to treatment with Y2B8, for the patients other than the first four, 2B8 will be administered as described, followed by i.v. infusion of Y2B8 over 5-10 min. Blood will be sampled for biodistribution at times  $t = 0$ ,  $t = 10\text{min.}$ ,  $t = 120\text{ min.}$ ,  $t = 24\text{ hr}$  and  $t = 48\text{ hr}$ . Patients will receive repetitive doses of Y2B8 (the same dose administered as with the first dose) approximately every six to eight weeks

for a maximum of four doses, or total cumulative dose of 80mCi. It is most preferred that patients not receive a subsequent dose of Y2B8 until the patients' WBC is greater than/equal to 3,000 and AGC is greater than/equal to 100,000.

- 5 Following completion of the three-dose level study, an MTD will be defined. Additional patients will then be enrolled in the study and these will receive the MTD.

10 **II. CHIMERIC ANTI-CD20 ANTIBODY PRODUCTION ("C2B8")**

A. Construction of Chimeric Anti-CD20 Immunoglobulin DNA Expression Vector

15 RNA was isolated from the 2B8 mouse hybridoma cell (as described in Chomczynki, P. et al., "Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction." *Anal. Biochem.* 162:156-159 (1987)). and cDNA was prepared therefrom. The mouse immunoglobulin light chain variable region DNA was isolated from the cDNA by polymerase chain reaction  
20 using a set of DNA primers with homology to mouse light chain signal sequences at the 5' end and mouse light chain J region at the 3' end. Primer sequences were as follows:

1. V<sub>L</sub> Sense (SEQ. ID. NO. 3)

25

5' ATC AC AGATCT CTC ACC ATG GAT TTT CAG GTG CAG

ATT ATC AGC TTC 3'

30 (The underlined portion is a Bgl II site; the above-lined portion is the start codon.)

2. V<sub>L</sub> Antisense (SEQ. ID. NO. 4)

5' TGC AGC ATC CGTACG TTT GAT TTC CAG CTT 3'

(The underlined portion is a Bsi WI site.)

5

See, Figures 1 and 2 for the corresponding Bgl II and Bsi WI sites in TCAE 8, and Figure 3 for the corresponding sites in anti-CD20 in TCAE 8.

These resulting DNA fragment was cloned directly into the TCAE 8 vector in  
10 front of the human kappa light chain constant domain and sequenced. The  
determined DNA sequence for the murine variable region light chain is set forth  
in Figure 4 (SEQ. ID. NO. 5); *see also* Figure 3, nucleotides 978 through 1362.  
Figure 4 further provides the amino acid sequence from this murine variable  
region, and the CDR and framework regions. The mouse light chain variable  
15 region from 2B8 is in the mouse kappa VI family. *See, Kabat, supra.*

The mouse heavy chain variable region was similarly isolated and cloned in front  
of the human IgGl constant domains. Primers were as follows:

20 1.  $V_H$  Sense (SEQ. ID. NO. 6)

5' GCG GCT CCC ACGCGT GTC CTG TCC CAG 3'

(The underlined portion is an Mlu I site.)

25

2.  $V_H$  Antisense (SEQ. ID. NO. 7)

5' GG(G/C) TGT TGT GCTAGC TG(A/C) (A/G)GA GAC  
(G/A)GT GA 3'

(The underlined portion is an Nhe I site.)

- See, Figures 1 and 2 for corresponding Mlu I and Nhe I sites in TCAE 8, and  
5 Figure 3 for corresponding sites in anti-CD20 in TCAE 8.

The sequence for this mouse heavy chain is set forth in Figure 5 (SEQ. ID. NO. 8); see also Figure 3, nucleotide 2401 through 2820. Figure 5 also provides the amino acid sequence from this murine variable region, and the CDR and  
10 framework regions. The mouse heavy chain variable region from 2B8 is in the mouse VH 2B family. See, Kabat, *supra*.

B. Creation of Chimeric Anti-CD20 Producing CHO and SP2/0 Transfectomas

15 Chinese hamster ovary ("CHO") cells DG44 were grown in SSFM II minus hypoxanthine and thymidine media (Gibco, Grand Island, NY, Form No. 91-0456PK); SP2/0 mouse myeloma cells were grown in Dulbecco's Modified Eagles Medium media ("DMEM") (Irvine Scientific, Santa Ana, Ca., Cat. No. 9024) with 5% fetal bovine serum and 20 ml/L glutamine added. Four million cells were  
20 electroporated with either 25 µg CHO or 50 µg SP2/0 plasmid DNA that had been restricted with Not I using a BTX 600 electroporation system (BTX, San Diego, CA) in 0.4 ml disposable cuvettes. Conditions were either 210 volts for CHO or 180 volts for SP2/0, 400 microfaradays, 13 ohms. Each electroporation was plated into six 96 well dishes (about 7,000 cells/well). Dishes were fed with  
25 media containing G418 (GENETICIN, Gibco, Cat. No. 860-1811) at 400 µg/ml active compound for CHO (media further included 50 µM hypoxanthine and 8 µM thymidine) or 800 µg/ml for SP2/0, two days following electroporation and thereafter 2 or 3 days until colonies arose. Supernatant from colonies was assayed for the presence of chimeric immunoglobulin via an ELISA specific for  
30 human antibody. Colonies producing the highest amount of immunoglobulin

were expanded and plated into 96 well plates containing media plus methotrexate (25 nM for SP2/0 and 5nM for CHO) and fed every two or three days. Supernatants were assayed as above and colonies producing the highest amount of immunoglobulin were examined. Chimeric anti-CD20 antibody was 5 purified from supernatant using protein A affinity chromatography.

Purified chimeric anti-CD20 was analyzed by electrophoresis in polyacrylamide gels and estimated to be greater than about 95% pure. Affinity and specificity of the chimeric antibody was determined based upon 2B8. Chimeric anti-CD20 10 antibody tested in direct and competitive binding assays, when compared to murine anti-CD20 monoclonal antibody 2B8, evidenced comparable affinity and specificity on a number of CD20 positive B cells lines (data not presented). The apparent affinity constant ("Kap") of the chimeric antibody was determined by direct binding of  $I^{125}$  radiolabeled chimeric anti-CD20 and compared to 15 radiolabeled 2B8 by Scatchard plot; estimated Kap for CHO produced chimeric anti-CD20 was  $5.2 \times 10^{-9}$  M and for SP2/0 produced antibody,  $7.4 \times 10^{-9}$  M. The estimated Kap for 2B8 was  $3.5 \times 10^{-9}$  M. Direct competition by radioimmunoassay was utilized to confirm both the specificity and retention of 20 immunoreactivity of the chimeric antibody by comparing its ability to effectively compete with 2B8. Substantially equivalent amounts of chimeric anti-CD20 and 2B8 antibodies were required to produce 50% inhibition of binding to CD20 antigens on B cells (data not presented), ie there was a minimal loss of inhibiting activity of the anti-CD20 antibodies, presumably due to chimerization.

25 The results of Example II.B indicate, *inter alia*, that chimeric anti-CD20 antibodies were generated from CHO and SP2/0 transfectomas using the TCAE 8 vectors, and these chimeric antibodies had substantially the same specificity and binding capability as murine anti-CD20 monoclonal antibody 2B8.

C. Determination of Immunological Activity of Chimeric Anti-CD20 Antibodies

i. Human C1q Analysis

Chimeric anti-CD20 antibodies produced by both CHO and SP2/0 cell lines were evaluated for human C1q binding in a flow cytometry assay using fluorescein labeled C1q (C1q was obtained from Quidel, Mira Mesa, CA, Prod. No. A400 and FITC label from Sigma, St. Louis MO, Prod. No. F-7250; FITC. Labeling of C1q was accomplished in accordance with the protocol described in *Selected Methods In Cellular Immunology*, Michell & Shiigi, Ed. (W.H. Freeman & Co., San Francisco, CA, 1980, p. 292). Analytical results were derived using a Becton Dickinson FACScan™ flow cytometer (fluorescein measured over a range of 515-545 nm). Equivalent amounts of chimeric anti-CD20 antibody, human IgG1,K myeloma protein (Binding Site, San Diego, Ca, Prod. No. BP078), and 2B8 were incubated with an equivalent number of CD20-positive SB cells, followed by a wash step with FACS buffer (.2% BSA in PBS, pH 7.4, .02% sodium azide) to remove unattached antibody, followed by incubation with FITC labeled C1q. Following a 30-60 min. incubation, cells were again washed. The three conditions, including FITC-labeled C1q as a control, were analyzed on the FACScan™ following manufacturing instructions. Results are presented in Figure 6.

As the results of Figure 6 evidence, a significant increase in fluorescence was observed only for the chimeric anti-CD20 antibody condition; ie only SB cells with adherent chimeric anti-CD20 antibody were C1q positive, while the other conditions produced the same pattern as the control.

ii. Complement Dependent Cell Lyses

Chimeric anti-CD20 antibodies were analyzed for their ability to lyse lymphoma cell lines in the presence of human serum (complement source). CD20 positive SB cells were labeled with  $^{51}\text{Cr}$  by admixing 100 $\mu\text{Ci}$  of  $^{51}\text{Cr}$  with

1x10<sup>6</sup> SB cells for 1 hr at 37°C; labeled SB cells were then incubated in the presence of equivalent amounts of human complement and equivalent amounts (0-50 µg/ml) of either chimeric anti-CD20 antibodies or 2B8 for 4 hrsat 37°C (see, Brunner, K.T. et al., "Quantitative assay of the lytic action of immune lymphoid 5 cells on <sup>51</sup>Cr-labeled allogeneic target cells *in vitro*." *Immunology* 14:181-189 (1968). Results are presented in Figure 7.

The results of Figure 7 indicate, *inter alia*, that chimeric anti-CD20 antibodies produced significant lysis (49%) under these conditions.

10

iii. Antibody Dependent Cellular Cytotoxicity Effector Assay

For this study, CD20 positive cells (SB) and CD20 negative cells (T cell leukemia line HSB; see, Adams, Richard, "Formal Discussion," *Can. Res.* 27:2479-2482 (1967); ATCC deposit no. ATCC CCL 120.1) were utilized; both 15 were labeled with <sup>51</sup>Cr. Analysis was conducted following the protocol described in Brunner, K.T. et al., "Quantitative assay of the lytic action of immune lymphoid cells on <sup>51</sup>Cr-labeled allogeneic target cells *in vitro*; inhibition by isoantibody and drugs." *Immunology* 14:181-189 (1968); a substantial chimeric anti-CD20 antibody dependent cell mediated lysis of CD20 positive SB target 20 cells (<sup>51</sup>Cr-labeled) at the end of a 4 hr, 37°C incubation, was observed and this effect was observed for both CHO and SP2/0 produced antibody (effector cells were human peripheral lymphocytes; ratio of effector cells:target was 100:1). Efficient lysis of target cells was obtained at 3.9 µg/ml. In contrast, under the same conditions, the murine anti-CD20 monoclonal antibody 2B8 had a 25 statistically insignificant effect, and CD20 negative HSB cells were not lysed. Results are presented in Figure 8.

The results of Example II indicate, *inter alia*, that the chimeric anti-CD20 antibodies of Example I were immunologically active.

**III. DEPLETION OF B CELLS *IN VIVO* USING CHIMERIC ANTI-CD20****A *Non-Human Primate Study***

- 5 Three separate non-human primate studies were conducted. For convenience, these are referred to herein as "Chimeric Anti-CD20: CHO & SP2/0;" "Chimeric Anti-CD20: CHO;" and "High Dosage Chimeric Anti-CD20." Conditions were as follows:
- 10 Chimeric Anti-CD20: CHO & SP2/0  
Six cynomolgus monkeys ranging in weight from 4.5 to 7 kilograms (White Sands Research Center, Alamogordo, NM) were divided into three groups of two monkeys each. Both animals of each group received the same dose of immunologically active chimeric anti-CD20 antibody. One animal in each group  
15 received purified antibody produced by the CHO transfectoma; the other received antibody produced by the SP2/0 transfectoma. The three groups received antibody dosages corresponding to 0.1 mg/kg, 0.4 mg/kg, and 1.6 mg/kg each day for four (4) consecutive days. The chimeric immunologically active anti-CD20 antibody, which was admixed with sterile saline, was administered by  
20 intravenous infusion; blood samples were drawn prior to each infusion. Additional blood samples were drawn beginning 24 hrs after the last injection (T=0) and thereafter on days 1, 3, 7, 14 and 28; blood samples were also taken thereafter at biweekly intervals until completion of the study at day 90.
- 25 Approximately 5 ml of whole blood from each animal was centrifuged at 2000 RPM for 5 min. Plasma was removed for assay of soluble chimeric anti-CD20 antibody levels. The pellet (containing peripheral blood leukocytes and red blood cells) was resuspended in fetal calf serum for fluorescent-labeled antibody

analysis (see, "Fluorescent Antibody Labeling of Lymphoid Cell Population," *infra*.).

#### Chimeric Anti-CD20: CHO

5 Six cynomolgus monkeys ranging in weight from 4 to 6 kilograms (White Sands) were divided into three groups of two monkeys each. All animals were injected with immunologically active chimeric anti-CD20 antibodies produced from the CHO transfectoma (in sterile saline). The three groups were separated as follows: subgroup 1 received daily intravenous injections of 0.01 mg/kg of the antibody over a four (4) day period; subgroup 2 received daily intravenous injections of 0.4 mg/kg of the antibody over a four (4) day period; subgroup 3 received a single intravenous injection of 6.4 mg/kg of the antibody. For all three subgroups, a blood sample was obtained prior to initiation of treatment; additionally, blood samples were also drawn at T=0, 1, 3, 7, 14 and 28 days

10 following the last injection, as described above, and these samples were processed for fluorescent labeled antibody analysis (see, "Fluorescent Antibody Labeling," *infra*). In addition to peripheral blood B cell quantitation, lymph node biopsies were taken at days 7, 14 and 28 following the last injection, and a single cell preparation stained for quantitation of lymphocyte populations by flow

15 cytometry.

20

#### High Dosage Chimeric Anti-CD20

Two cynomolgus monkeys (White Sands) were infused with 16.8 mg/kg of the immunologically active chimeric anti-CD20 antibodies from the CHO transfectomas (in sterile saline) weekly over a period of four consecutive weeks. At the conclusion of the treatment, both animals were anesthetized for removal of bone marrow; lymph node biopsies were also taken. Both sets of tissue were stained for the presence of B lymphocytes using Leu 16 by flow cytometry following the protocol described in Ling, N.R. *et al.*, "B-cell and plasma cell

25

antigens." *Leucocyte Typing III White Cell Differentiations Antigens*, A.J. McMichael, Ed. (Oxford University Press, Oxford UK, 1987), p. 302.

Fluorescent Antibody Labeling of Lymphoid Cell Population

- 5 After removal of plasma, leukocytes were washed twice with Hanks Balanced Salt Solution ("HBSS") and resuspended in a plasma equivalent volume of fetal bovine serum (heat inactivated at 56°C for 30 min.). A 0.1 ml volume of the cell preparation was distributed to each of six (6), 15 ml conical centrifuge tubes
- 10 Fluorescein labeled monoclonal antibodies with specificity for the human lymphocyte surface markers CD2 (AMAC, Westbrook, ME), CD20 (Becton Dickinson) and human IgM (Binding Site, San Diego, CA) were added to 3 of the tubes for identifying T and B lymphocyte populations. All reagents had previously tested positive to the corresponding monkey lymphocyte antigens.
- 15 Chimeric anti-CD20 antibody bound to monkey B cell surface CD20 was measured in the fourth tube using polyclonal goat anti-human IgG coupled with phycoerythrin (AMAC). This reagent was pre-adsorbed on a monkey Ig-sepharose column to prevent cross-reactivity to monkey Ig, thus allowing specific detection and quantitation of chimeric anti-CD20 antibody bound to cells. A fifth tube included both anti-IgM and anti-human IgG reagents for double stained B
- 20 cell population. A sixth sample was included with no reagents for determination of autofluorescence. Cells were incubated with fluorescent antibodies for 30 min., washed and fixed with 0.5 ml of fixation buffer (0.15 M NaCl, 1% paraformaldehyde, pH7.4) and analyzed on a Becton Dickinson FACScan™ instrument. Lymphocyte populations were initially identified by forward versus
- 25 right angle light scatter in a dot-plot bitmap with unlabeled leucocytes. The total lymphocyte population was then isolated by gating out all other events. Subsequent fluorescence measurements reflected only gated lymphocyte specific events.

### Depletion of Peripheral Blood B Lymphocytes

No observable difference could be ascertained between the efficacy of CHO and SP2/0 produced antibodies in depleting B cells *in vivo*, although a slight increase in B cell recovery beginning after day 7 for monkeys injected with chimeric anti-  
5 CD20 antibodies derived from CHO transfectomas at dosage levels 1.6 mg/kg and 6.4 mg/kg was observed and for the monkey injected with SP2/0 producing antibody at the 0.4 mg/kg dose level. Figures 9A, B and C provide the results derived from the chimeric anti-CD20:CHO & SP2/0 study, with Figure 9A directed to the 0.4 mg/kg dose level; Figure 9B directed to the 1.6 mg/kg dose  
10 level; and Figure 9C directed to the 6.4 mg/kg dose level.

As is evident from Figure 9, there was a dramatic decrease (>95%) in peripheral B cell levels after the therapeutic treatment across all tested dose ranges, and these levels were maintained up to seven (7) days post infusion; after this period,  
15 B cell recovery began, and, the time of recovery initiation was independent of dosage levels.

In the Chimeric Anti-CD20:CHO study, a 10-fold lower antibody dosage concentration (0.01 mg/kg) over a period of four daily injections (0.04 mg/kg total)  
20 was utilized. Figure 10 provides the results of this study. This dosage depleted the peripheral blood B cell population to approximately 50% of normal levels estimated with either the anti-surface IgM or the Leu 16 antibody. The results also indicate that saturation of the CD20 antigen on the B lymphocyte population was not achieved with immunologically active chimeric anti-CD20  
25 antibody at this dose concentration over this period of time for non-human primates; B lymphocytes coated with the antibody were detected in the blood samples during the initial three days following therapeutic treatment. However, by day 7, antibody coated cells were undetectable.

Table I summarizes the results of single and multiple doses of immunologically active chimeric anti-CD20 antibody on the peripheral blood populations; single dose condition was 6.4 mg/kg; multiple dose condition was 0.4 mg/kg over four (4) consecutive days (these results were derived from the monkeys described above).

5 //

//

//

//

//

10 //

//

//

//

//

15 //

//

//

//

//

20 //

//

//

//

//

25 //

//

//

//

**TABLE I**  
**PERIPHERAL BLOOD POPULATION FROM C2B8 PRIMATE STUDY**

	<u>Monkey</u>	<u>Dose</u>	<u>Day</u>	<u>CD2</u>	<u>Anti-Hu IgG</u>
5	A	0.4 mg/kg (4 doses)	Prebleed	81.5	-
			0	86.5	0.2
			7	85.5	0.0
			21	93.3	-
	10		28	85.5	-
10	B	0.4 mg/kg (4 doses)	Prebleed	81.7	-
			0	94.6	0.1
			7	92.2	0.1
			21	84.9	-
	15		28	84.1	-
15	C	6.4 mg/kg (1 dose)	Prebleed	77.7	0.0
			7	85.7	0.1
			21	86.7	-
			28	76.7	-
	20				
20	D	6.4 mg/kg (1 dose)	Prebleed	85.7	0.1
			7	94.7	0.1
			21	85.2	-
			28	85.9	-
	25				
30	Monkey	<u>Anti-Hu IgG+</u> <u>Anti-Hu IgM*</u>		<u>Leu-16</u>	<u>% B Cell Depletion</u>
35	A				
40	B				
45	C				
50	D				

\*Double staining population which indicates extent of chimeric anti-CD20 coated B cells.

The data summarized in Table I indicates that depletion of B cells in peripheral blood under conditions of antibody excess occurred rapidly and effectively, regardless of single or multiple dosage levels. Additionally, depletion was  
5 observed for at least seven (7) days following the last injection, with partial B cell recovery observed by day 21.

Table II summarizes the effect of immunologically active, chimeric anti-CD20 antibodies on cell populations of lymph nodes using the treatment regimen of  
10 Table I (4 daily doses of 0.4 mg/kg; 1 dose of 6.4 mg/kg); comparative values for normal lymph nodes (control monkey, axillary and inguinal) and normal bone marrow (two monkeys) are also provided.

//  
//  
15 //  
//  
//  
//  
//  
20 //  
//  
//  
//  
//  
25 //  
//  
//  
//  
//  
30 //

TABLE II  
CELL POPULATIONS OF LYMPH NODES

	<u>Monkey</u>	<u>Dose</u>	<u>Day</u>	<u>CD2</u>	<u>Anti-Hu IgM</u>
5	A	0.4 mg/kg (4 doses)	7	66.9	-
			14	76.9	19.6
			28	61.6	19.7
10	B	0.4 mg/kg (4 doses)	7	59.4	-
			14	83.2	9.9
			28	84.1	15.7
15	C	6.4 mg/kg (1 dose)	7	75.5	-
			14	74.1	17.9
			28	66.9	23.1
20	D	6.4 mg/kg (1 dose)	7	83.8	-
			14	74.1	17.9
			28	84.1	12.8

TABLE II (continued)

	<u>Monkey</u>	<u>Anti-Hu IgG +</u> <u>Anti-Hu IgM</u>	<u>Leu-16</u>	<u>% B Lymphocyte Depletion</u>
25	A	7.4	40.1	1
		0.8	22.6	44
		-	26.0	36
30	B	29.9	52.2	0
		0.7	14.5	64
		-	14.6	64
35	C	22.3	35.2	13
		1.1	23.9	41
		-	21.4	47
40	D	12.5	19.7	51
		0.2	8.7	78
		-	12.9	68

TABLE II (continued)

		<u>CD2</u>	<u>Anti-Hu IgG+</u> <u>Anti-Hu IgM</u>	<u>Anti-Hu IgM</u>	<u>Leu-16</u>	<u>% B Lymphocyte Depletion</u>
	Normal Lymph Nodes					
45	Control 1					
	Axillary	55.4	25.0	-	41.4	NA
	Inguinal	52.1	31.2	-	39.5	NA
	Normal Bone Marrow					
50	Control 2	65.3	19.0	-	11.4	NA
	Control 3	29.8	28.0	-	16.6	NA

The results of Table II evidence effective depletion of B lymphocytes for both treatment regimens. Table II further indicates that for the non-human primates, complete saturation of the B cells in the lymphatic tissue with immunologically active, chimeric anti-CD20 antibody was not achieved; additionally, antibody 5 coated cells were observed seven (7) days after treatment, followed by a marked depletion of lymph node B cells, observed on day 14.

Based upon this data, the single High Dosage Chimeric Anti-CD20 study referenced above was conducted, principally with an eye toward 10 pharmacology/toxicology determination. *Ie* this study was conducted to evaluate any toxicity associated with the administration of the chimeric antibody, as well as the efficacy of B cell depletion from peripheral blood lymph nodes and bone marrow. Additionally, because the data of Table II indicates that for that study, the majority of lymph node B cells were depleted between 7 and 14 days 15 following treatment, a weekly dosing regimen might evidence more efficacious results. Table III summarizes the results of the High Dosage Chimeric Anti-CD20 study.

//  
//  
20 //  
//  
//  
//  
//  
25 //  
//  
//  
//  
//

TABLE III  
CELL POPULATIONS OF LYMPH NODES AND BONE MARROW

		Lymphocyte Populations (%)				
	Monkey	CD2	CD20 <sup>a</sup>	mIgM + anti-C2B8 <sup>b</sup>	C2B8 <sup>c</sup>	Day <sup>d</sup>
<i>Inguinal Lymph Node</i>						
10	E	90.0	5.3	4.8	6.5	22
	F	91.0	6.3	5.6	6.3	22
15	G	89.9	5.0	3.7	5.8	36
	H	85.4	12.3	1.7	1.8	36
20	<i>Bone Marrow</i>					
	E	46.7	4.3	2.6	2.8	22
25	F	41.8	3.0	2.1	2.2	22
	G	35.3	0.8	1.4	1.4	36
	H	25.6	4.4	4.3	4.4	36

30   <sup>a</sup>Indicates population stained with Leu 16.

35   <sup>b</sup>Indicates double staining population, positive for surface IgM cells and chimeric antibody coated cells.

40   <sup>c</sup>Indicates total population staining for chimeric antibody including double staining surface IgM positive cells and single staining (surface IgM negative) cells.

45   <sup>d</sup>Days after injection of final 16.8 mg/kg dose.

Both animals evaluated at 22 days post treatment cessation contained less than 5% B cells, as compared to 40% in control lymph nodes (see, Table II, *supra*).

Similarly, in the bone marrow of animals treated with chimeric anti-CD20 antibody, the levels of CD20 positive cells were less than 3% as compared to 11-15% in the normal animals (see, Table II, *supra*). In the animals evaluated at 36 days post treatment cessation, one of the animals (H) had approximately 12% B cells in the lymph node and 4.4% B cells in bone marrow, while the other (G) had

approximately 5% B cells in the lymph node and 0.8% in the bone marrow--the data is indicative of significant B cell depletion.

The results of Example III.A indicate, *inter alia*, that low doses of immunologically active, chimeric anti-CD20 leads to long-term peripheral blood B cell depletion in primates. The data also indicates that significant depletion of B cell populations was achieved in peripheral lymph nodes and bone marrow when repetitive high doses of the antibody were administered. Continued follow-up on the test animals has indicated that even with such severe depletion of peripheral B lymphocytes during the first week of treatment, no adverse health effects have been observed. Furthermore, as recovery of B cell population was observed, a conclusion to be drawn is that the pluripotent stem cells of these primates were not adversely affected by the treatment.

15 B. Clinical Analysis of C2B8

i. Phase I/II Clinical Trial of C2B8: Single Dose Therapy Study

Fifteen patients having histologically documented relapsed B cell lymphoma have been treated with C2B8 in a Phase I/II Clinical Trial. Each patient received a single dose of C2B8 in a dose-escalating study; there were three patients per dose: 10mg/m<sup>2</sup>; 50mg/m<sup>2</sup>; 100mg/m<sup>2</sup>; 250mg/m<sup>2</sup> and 500mg/m<sup>2</sup>. Treatment was by i.v. infusion through an 0.22 micron in-line filter with C2B8 being diluted in a final volume of 250cc or a maximal concentration of 1mg/ml of normal saline. Initial rate was 50cc/hr for the first hour; if no toxicity was seen, dose rate was able to be escalated to a maximum of 200cc/hr.

25

Toxicity (as indicated by the clinician) ranged from "none", to "fever" to "moderate" (two patients) to "severe" (one patient); all patients completed the therapy treatment. Peripheral Blood Lymphocytes were analyzed to determine, *inter alia*, the impact of C2B8 on T-cells and B-cells. Consistently for all

patients, Peripheral Blood B Lymphocytes were depleted after infusion with C2B8 and such depletion was maintained for in excess of two weeks.

One patient (receiving 100mg/m<sup>2</sup> of C2B8) evidenced a Partial Response to the  
5 C2B8 treatment (reduction of greater than 50% in the sum of the products of the perpendicular diameters of all measurable indicator lesions lasting greater than four weeks, during which no new lesions may appear and no existing lesions may enlarge); at least one other patient (receiving 500mg/m<sup>2</sup>) evidenced a Minor Response to the C2B8 treatment (reduction of less than 50% but at least 25% in  
10 the sum of the products of the two longest perpendicular diameters of all measurable indicator lesions). For presentational efficiency, results of the PBLs are set forth in Figure 14; data for the patient evidencing a PR is set forth in Figure 14A; for the patient evidencing an MR, data is set forth in Figure 14B. In Figure 14, the following are applicable: ■ = Lymphocytes; □ = CD3+ cells  
15 (T cells); ▲ = CD20<sup>+</sup> cells; ● = CD19<sup>+</sup> cells; ○ = Kappa; △ = lambda; and ◆ = C2B8. As evidenced, the B cell markers CD20 and CD19, Kappa and Lambda, were depleted for a period in excess of two weeks; while there was a slight, initial reduction in T-cell counts, these returned to an approximate base-line level in a relatively rapid time-frame.

20

ii. Phase I/II Clinical Trial of C2B8: Multiple Dose Therapy Study

Patients having histologically confirmed B cell lymphoma with measurable progressive disease are eligible for this study which is separated into two parts: in Phase I, consisting of a dose escalation to characterize dose  
25 limiting toxicities and determination of biologically active tolerated dose level, groups of three patients will receive weekly i.v. infusions of C2B8 for a total of four (4) separate infusions. Cumulative dose at each of the three levels will be as follows: 500mg/m<sup>2</sup> (125mg/m<sup>2</sup>/infusion); 1000mg/m<sup>2</sup> (250mg/m<sup>2</sup>/infusion);

1500mg/m<sup>2</sup> (375mg/m<sup>2</sup>/infusion. A biologically active tolerated dose is defined, and will be determined, as the lowest dose with both tolerable toxicity and adequate activity); in Phase II, additional patients will receive the biologically active tolerated dose with an emphasis on determining the activity of the four 5 doses of C2B8.

#### IV. COMBINATION THERAPY: C2B8 AND Y2B8

A combination therapeutic approach using C2B8 and Y2B8 was 10 investigated in a mouse xenographic model (nu/nu mice, female, approximately 10 weeks old) utilizing a B cell lymphoblastic tumor (Ramos tumor cells). For comparative purposes, additional mice were also treated with C2B8 and Y2B8.

Ramos tumor cells (ATCC, CRL 1596) were maintained in culture using RPMI- 15 1640 supplemented with 10% fetal calf serum and glutamine at 37°C and 5% CO<sub>2</sub>. Tumors were initiated in nine female nude mice approximately 7-10 weeks old by subcutaneous injection of 1.7 x 10<sup>6</sup> Ramos cells in a volume of 0.10ml (HBSS) using a 1cc syringe fitted with 25g needle. All animals were manipulated in a laminar flow hood and all cages, bedding, food and water were 20 autoclaved. Tumor cells were passaged by excising tumors and passing these through a 40 mesh screen; cells were washed twice with 1X HBSS (50ml) by centrifugation (1300RPM), resuspended in 1X HBSS to 10 x 10<sup>6</sup> cells/ml, and frozen at -70°C until used.

25 For the experimental conditions, cells from several frozen lots were thawed, pelleted by centrifugation (1300RPM) and washed twice with 1X HBSS. Cells were then resuspended to approximately 2.0 x 10<sup>6</sup> cells/ml. Approximately 9 to 12 mice were injected with 0.10ml of the cell suspension (s.c.) using a 1cc syringe fitted with a 25g needle; injections were made on the animal's left side,

approximately mid-region. Tumors developed in approximately two weeks.

Tumors were excised and processed as described above. Study mice were injected as described above with  $1.67 \times 10^6$  cells in 0.10ml HBSS.

- 5     Based on preliminary dosing experiments, it was determined that 200mg of C2B8 and 100 $\mu$ Ci of Y2B8 would be utilized for the study. Ninety female nu/nu mice (approximately 10 weeks old) were injected with the tumor cells.
- Approximately ten days later, 24 mice were assigned to four study groups (six mice/group) while attempting to maintain a comparable tumor size distribution
- 10    in each group (average tumor size, expressed as a product of length x width of the tumor, was approximately 80mm<sup>2</sup>). The following groups were treated as indicated via tail-vain injections using a 100 $\mu$ l Hamilton syringe fitted with a 25g needle:
- 15           A.    Normal Saline  
              B.    Y2B8 (100 $\mu$ Ci)  
              C.    C2B8 (200 $\mu$ g); and  
              D.    Y2B8 (100 $\mu$ Ci) + C2B8 (200 $\mu$ g)

- 20    Groups tested with C2B8 were given a second C2B8 injection (200 $\mu$ g/mouse) seven days after the initial injection. Tumor measurements were made every two or three days using a caliper.

- 25    Preparation of treatment materials were in accordance with the following protocols:

A.    Preparation of Y2B8

- Yttrium-[90] chloride (6mCi) was transformed to a polypropylene tube and adjusted to pH 4.1-4.4 using metal free 2M sodium acetate. 2B8-MX-DTPA
- 30    (0.3mg in normal saline; see above for preparation of 2B8-MX-DTPA) was added

and gently mixed by vortexing. After 15 min. incubation, the reaction was quenched by adding 0.05 x volume 20mM EDTA and 0.05X volume 2M sodium acetate. Radioactivity concentration was determined by diluting 5.0 $\mu$ l of the reaction mixture in 2.5ml 1 x PBS containing 75mg/ml HSA and 1mM DTPA 5 ("formulation buffer"); counting was accomplished by adding 10.0 $\mu$ l to 20ml of Ecolume<sup>TM</sup> scintillation cocktail. The remainder of the reactive mixture was added to 3.0ml formulation buffer, sterile filtered and stored at 2-8°C until used. Specific activity (14mCi/mg at time of injection) was calculated using the 10 radioactivity concentration and the calculated protein concentration based upon the amount of antibody added to the reaction mixture. Protein-associated radioactivity was determined using instant thin-layer chromatography. Radioincorporation was 95%. Y2B8 was diluted in formulation buffer immediately before use and sterile-filtered (final radioactivity concentration was 1.0mCi/ml).

15

B. Preparation of C2B8

C2B8 was prepared as described above. C2B8 was provided as a sterile reagent in normal saline at 5.0mg/ml. Prior to injection, the C2B8 was diluted in normal saline to 2.0mg/ml and sterile filtered.

20

C. Results

Following treatment, tumor size was expressed as a product of length and width, and measurements were taken on the days indicated in Figure 11 (Y2B8 vs. Saline); Figure 12 (C2B8 vs. Saline); and Figure 13 (Y2B8 + C2B8 vs. Saline).

25 Standard error was also determined.

As indicated in Figure 13, the combination of Y2B8 and C2B8 exhibited tumoricidal effects comparable to the effects evidenced by either Y2B8 or C2B8.

## V. ALTERNATIVE THERAPY STRATEGIES

Alternative therapeutic strategies recognized in view of the foregoing examples are evident. One such strategy employs the use of a therapeutic dose of C2B8 followed within about one week with a combination of either 2B8 and radioabeled 2B8 (*eg* Y2B8); or 2B8, C2B8 and, *eg* Y2B8; or C2B8 and, *eg* Y2B8.

An additional strategy is utilization of radiolabeled C2B8 -- such a strategy allows for utilization of the benefits of the immunologically active portion of C2B8 plus those benefits associated with a radiolabel. Preferred radiolabels include yttrium-90 given the larger circulating half-life of C2B8 versus the murine antibody 2B8. Because of the ability of C2B8 to deplete B-cells, and the benefits to be derived from the use of a radiolabel, a preferred alternative strategy is to treat the patient with C2B8 (either with a single dose or multiple doses) such that most, if not all, peripheral B cells have been depleted. This would then be followed with the use of radiolabeled 2B8; because of the depletion of peripheral B cells, the radiolabeled 2B8 stands an increased chance of targeting tumor cells. Iodine [131] labeled 2B8 is preferably utilized, given the types of results reported in the literature with this label (*see* Kaminski). An alternative preference involves the use of a radiolabeled 2B8 (or C2B8) first in an effort to increase the permeability of a tumor, followed by single or multiple treatments with C2B8; the intent of this strategy is to increase the chances of the C2B8 in getting both outside and inside the tumor mass. A further strategy involved the use of chemotherapeutic agent in combination with C2B8. These strategies include so-called "staggered" treatments, *ie*, treatment with a chemotherapeutic agent, followed by treatment with C2B8, followed by a repetition of this protocol. Alternatively, initial treatment with a single or multiple doses of C2B8, thereafter followed with chemotherapeutic treatment, is viable. Preferred chemotherapeutic agents include, but are not limited to:

cyclophosphamide; doxorubicin; vincristine; and prednisone, *See Armitage, J.O. et al., Cancer 50:1695 (1982)*, incorporated herein by reference.

The foregoing alternative therapy strategies are not intended to be limiting, but  
5 rather are presented as being representative.

## VI. DEPOSIT INFORMATION

Anti-CD20 in TCAE 8 (transformed in *E. coli* for purposes of deposit) was  
10 deposited with the American Type Culture Collection (ATCC), 12301 Parklawn  
Drive, Rockville, Maryland, 20852, under the provisions of the Budapest Treaty  
for the International Recognition of the Deposit of Microorganisms for the  
Purpose of Patent Procedure ("Budapest Treaty"). The microorganism was  
tested by the ATCC on November 9, 1992, and determined to be viable on that  
15 date. The ATCC has assigned this microorganism for the following ATCC deposit  
number: ATCC 69119 (anti-CD20 in TCAE 8). Hybridoma 2B8 was deposited  
with the ATCC on June 22, 1993 under the provisions of the Budapest Treaty.  
The viability of the culture was determined on June 25, 1993 and the ATCC has  
assigned this hybridoma the following ATCC deposit number: HB 11388.

20 //

//

//

//

//

25 //

//

//

//

//

## **G. SEQUENCE LISTING**

5 (1) GENERAL INFORMATION

(i) **APPLICANT:** Darrell Anderson, Nabil Hanna, John Leonard, Roland Newman and Mitchell Reff and William H. Rastetter

10 (ii) TITLE OF INVENTION: THERAPEUTIC APPLICATION OF  
CHIMERIC AND RADIOLABELED  
ANTIBODIES TO HUMAN B  
LYMPHOCYTE RESTRICTED  
DIFFERENTIATION ANTIGEN FOR  
TREATMENT OF B CELL LYMPHOMA

15

(iii) NUMBER OF SEQUENCES: 8

20 (iv) CORRESPONDING ADDRESS:

(v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Diskette, 3.5 inch, 1.44 Mb
- (B) COMPUTER: Macintosh
- (C) OPERATING SYSTEM: MS.DOS
- (D) SOFTWARE: Microsoft Word 5.0

(vi) CURRENT APPLICATION DATA

40 (A) APPLICATION NUMBER:  
(B) FILING DATE:  
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

45 (A) NAME: Burgoon, Richard P. Jr.  
(B) REGISTRATION NUMBER: 34,787  
(C) REFERENCE/DOCKET NUMBER:

(ix) TELECOMMUNICATION INFORMATION:

50 (A) TELEPHONE: (619) 550-8500  
(B) TELEFAX: (619) 550-8750

## (2) INFORMATION FOR SEQ ID NO: 1:

## 5 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8540 bases  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: circular

10 (ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: yes

15 (iv) ANTI-SENSE: no

(ix) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

20	GACGTCGCGG CCGCTCTAGG CCTCCAAAAA AGCCTCCTCA CTACTTCTGG AATAGCTCAG	60
	AGGCCGAGGC GGCCCTGGCC TCTGCATAAA TAAAAAAAAT TAGTCAGCCA TGCATGGGGC	120
	GGAGAATGGG CGGAACGTGGG CGGAGTTAGG GGCGGGATGG GCGGAGTTAG GGGCGGGACT	180
25	ATGGTTGCTG ACTAATTGAG ATGCATGCTT TGCACTACTTC TGCTGCTGG GGAGCCTGGG	240
	GACTTTCCAC ACCTGGTTGC TGACTAATTG AGATGCATGC TTTGCATACT TCTGCCTGCT	300
	GGGGAGCCTG GGGACTTTCC ACACCCCTAAC TGACACACAT TCCACAGAAAT TAATTCCCCT	360
30	AGTTATTAAT AGTAATCAAT TACGGGTCA TTAGTTCATATA CCCATATAT GGAGTTCCGC	420
	GTTACATAAAC TTACGGTAAA TGGCCCCCCT GGCTGACCGC CCAACGACCC CCCGCCATTG	480
35	ACGTCAATAA TGACGTATGT TCCCATAAGTA ACGCCAATAG GGACTTTCCA TTGACGTCAA	540
	TGGGTGGACT ATTTACGGTA AACTGCCAC TTGGCAGTAC ATCAAGTGTAA TCATATGCCA	600
40	AGTACGCCCT CTATTGACGT CAATGACGGT AAATGGCCCG CCTGGCATTAA TGCCCAAGTAC	660
	ATGACCTTAT GGGACTTTCC TACTTGGCAG TACATCTACG TATTAGTCAT CGCTATTACC	720
	ATGGTGATGC GGTTTTGGCA GTACATCAAT GGGCGTGGAT AGCGGTTTGA CTCACGGGA	780
45	TTTCCAAGTC TCCACCCCAT TGACGTCAAT GGGAGTTTGT TTTGGCACCA AAATCAACGG	840
	GACTTTCCAA AATGTCGTAA CAACTCCGCC CCATTGACGC AAATGGCGG TAGGCGTGTAA	900
50	CGGTGGGAGG TCTATATAAG CAGAGCTGGG TACGTGAACC GTCAGATCGC CTGGAGACGC	960
	CATCACAGAT CTCTCACCAT GAGGGTCCCC GCTCAGCTCC TGGGGCTCCT GCTGCTCTGG	1020
	CTCCCAGGTG CACGATGTGA TGGTACCAAG GTGCAAATCA AACGTACGGT GGCTGCACCA	1080
55	TCTGTCTTCA TCTTCCCGCC ATCTGATGAG CAGTTGAAAT CTGGAACCTGC CTCTGTTGTG	1140
	TGCCTGCTGA ATAACCTCTA TCCCAGAGAG GCCAAAGTAC AGTGGAAAGGT GGATAACGCC	1200
60	CTCCAATCGG GTAACTCCCA GGAGAGTGTC ACAGAGCAGG ACAGCAAGGA CAGCACCTAC	1260

	AGCCTCAGCA GCACCCGTGAC GCTGAGCAAA GCAGACTACG AGAACACAA AGTCTACGCC	1320
	TGCGAAGTCA CCCATCAGGG CCTGAGCTCG CCCGTCACAA AGAGCTTCAA CAGGGGAGAG	1380
5	TGTTGAATTG AGATCCGTTA ACGGTTACCA ACTACCTAGA CTGGATTCTG GACAACATGC	1440
	GGCCGTGATA TCTACGTATG ATCAGCCTCG ACTGTGCCTT CTAGTTGCCA GCCATCTGTT	1500
10	GTTTGCCCCCT CCCCCGTGCC TTCCTTGACC CTGGAAGGTG CCACCTCCAC TGTCCTTCC	1560
	TAATAAAATG AGGAAATTGC ATCGCATTGT CTGAGTAGGT GTCATTCTAT TCTGGGGGGT	1620
	GGGGTGGGGC AGGACAGCAA GGGGGAGGAT TGGGAAGACA ATAGCAGGCA TGCTGGGGAT	1680
15	GCGGTGGGCT CTATGGAACC AGCTGGGCT CGACAGCTAT GCCAAGTACG CCCCCTATTG	1740
	ACGTCAATGA CGGTAAATGG CCCGCCTGGC ATTATGCCA GTACATGACC TTATGGGACT	1800
20	TTCCTACTTG GCAGTACATC TACGTATTAG TCATCGCTAT TACCATGGTG ATGCGGTTTT	1860
	GGCAGTACAT CAATGGCGT GGATAGCGGT TTGACTCACG GGGATTTCCA AGTCTCCACC	1920
	CCATTGACGT CAATGGGAGT TTGTTTGGC ACCAAAATCA ACAGGACTTT CCAAAATGTC	1980
25	GTAACAACTC CGCCCCATTG ACGCAAATGG GCGGTAGGCG TGTACGGTGG GAGGTCTATA	2040
	TAAGCAGAGC TGGGTACGTC CTCACATTCA GTGATCAGCA CTGAACACAG ACCCGTCGAC	2100
30	ATGGGTTGGA GCCTCATCTT GCTCTTCCTT GTCGCTGTTG CTACGCGTGT CGCTAGCACC	2160
	AAGGGCCCAT CGGTCTTCCC CCTGGCACCC TCCTCCAAGA GCACCTCTGG GGGCACAGCG	2220
	GCCCTGGGCT GCCTGGTCAA GGACTACTTC CCCGAACCGG TGACGGTGTG GTGGAACTCA	2280
35	GGCGCCCTGA CCAGCGCGT GCACACCTTC CCGGCTGTCC TACAGTCCTC AGGACTCTAC	2340
	TCCCTCAGCA GCGTGGTGAC CGTGCCCTCC AGCAGCTTGG GCACCCAGAC CTACATCTGC	2400
40	AACGTGAATC ACAAGCCCAG CAACACCAAG GTGGACAAGA AAGCAGAGCC CAAATCTTGT	2460
	GACAAAACTC ACACATGCCA ACCGTGCCA GCACCTGAAC TCCTGGGGGG ACCGTCAGTC	2520
	TTCCCTTTCC CCCCCAAACCA CAAGGACACC CTCATGATCT CCCGGACCCC TGAGGTCACA	2580
45	TGCGTGGTGG TGGACGTGAG CCACGAAGAC CCTGAGGTCA AGTTCAACTG GTACGTGGAC	2640
	GGCGTGGAGG TGCATAATGC CAAGACAAAG CCGCGGGAGG AGCAGTACAA CAGCACGTAC	2700
50	CGTGTGGTCA GCGTCCTCAC CGTCCTGCAC CAGGACTGGC TGAATGGCAA GGAGTACAAG	2760
	TGCAAGGTCT CCAACAAAGC CCTCCCAGCC CCCATCGAGA AAACCATCTC CAAAGCCAAA	2820
	GGGCAGCCCC GAGAACACAA GGTGTACACC CTGCCCCCAT CCCGGGATGA GCTGACCAAG	2880
55	AACCAGGTCA GCCTGACCTG CCTGGTCAA GGCTTCTATC CCAGCGACAT CGCCGTGGAG	2940
	TGGGAGAGCA ATGGGCAGCC GGAGAACAAAC TACAAGACCA CGCCTCCCGT GCTGGACTCC	3000
60	GACGGCTCCT TCTTCCTCTA CAGCAAGCTC ACCGTGGACA AGAGCAGGTG GCAGCAGGG	3060
	AACGTCTTCT CATGCTCCGT GATGCATGAG GCTCTGCACA ACCACTACAC GCAGAACAGC	3120
	CTCTCCCTGT CTCCGGTAA ATGAGGATCC GTAACGGTT ACCAACTACC TAGACTGGAT	3180

	TCGTGACAAC ATGCGGCCGT GATATCTACG TATGATCAGC CTCGACTGTG CCTTCTAGTT	3240
5	GCCAGCCATC TGTTGTTGC CCCTCCCCG TGCCCTCCTT GACCCTGGAA GGTGCCACTC	3300
	CCACTGTCCT TTCTAATAA AATGAGGAAA TTGCATCGCA TTGTCTGAGT AGGTGTCATT	3360
	CTATTCTGGG GGGTGGGGTG GGGCAGGACA GCAAGGGGA GGATTGGAA GACAATACCA	3420
10	GGCATGCTGG GGATGCGGTG GGCTCTATGG AACCAAGCTGG GGCTCGACAG CGCTGGATCT	3480
	CCCGATCCCC AGCTTGCTT CTCAATTCT TATTCGCATA ATGAGAAAAA AAGGAAAATT	3540
15	AATTTAACCA CCAATTCACT AGTTGATTGA GCAAATGCGT TGCCAAAAG GATGCTTTAG	3600
	AGACAGTGTT CTCTGCACAG ATAAGGACAA ACATTATTCA GAGGGAGTAC CCAGAGCTGA	3660
	GACTCCTAACG CCAGTGAGTG GCACAGCATT CTAGGGAGAA ATATGCTTGT CATCACCGAA	3720
20	GCCTGATTCC GTAGAGCCAC ACCTTGGTAA GGGCCAATCT GCTCACACAG GATAGAGAGG	3780
	GCAGGAGCCA GGGCAGAGCA TATAAGGTGA GGTAGGATCA GTTGCTCCTC ACATTTGCTT	3840
25	CTGACATAGT TGTGTTGGG GCTTGGATAG CTTGGACAGC TCAGGGCTGC GATTTCGCGC	3900
	CAAACCTGAC GGCAATCCTA GCGTGAAGGC TGGTAGGATT TTATCCCCGC TGCCATCATG	3960
	GTTCGACCAT TGAACTCAT CGTCGCCGTG TCCCAAAATA TGGGGATTGG CAAGAACGGA	4020
30	GACCTACCCCT GCCCTCCGCT CAGGAACGAG TTCAAGTACT TCCAAAGAAT GACCACAACC	4080
	TCTTCAGTGG AAGGTAAACA GAATCTGGTG ATTATGGTA GGAAAACCTG GTTCTCCATT	4140
35	CCTGAGAAGA ATCGACCTTT AAAGGACAGA ATTAATATAG TTCTCAGTAG AGAACTCAAA	4200
	GAACCACCAAC GAGGAGCTCA TTTCTTGCC AAAAGTTGG ATGATGCCTT AAGACTTATT	4260
	GAACAACCGG AATTGGCAAG TAAAGTAGAC ATGGTTTGGG TAGTCGGAGG CAGTTCTGTT	4320
40	TACCAAGGAAG CCATGAATCA ACCAGGCCAC CTTAGACTCT TTGTGACAAG GATCATGCAG	4380
	GAATTTGAAA GTGACACGTT TTTCCCAGAA ATTGATTGG CGAAATATAA ACTTCTCCCA	4440
45	GAATACCCAG GCGTCCTCTC TGAGGTCCAG GAGGAAAAAG GCATCAAGTA TAAGTTGAA	4500
	GTCTACGAGA AGAAAGACTA ACAGGAAGAT GCTTCAAGT TCTCTGCTCC CCTCCTAAAG	4560
	CTATGCATTT TTATAAGACC ATGGGACTTT TGCTGGCTTT AGATCAGCCT CGACTGTGCC	4620
50	TTCTAGTTGC CAGCCATCTG TTGTTGCCCT CTCCTCCGTG CCTTCCTGAA CCCTGGAAGG	4680
	TGCCACTCCC ACTGTCCTTT CCTAATAAAA TGAGGAAATT GCATCGCATT GTCTGAGTAG	4740
55	GTGTCATTCT ATTCTGGGGG GTGGGGTGGG GCAGGACAGC AAGGGGGAGG ATTGGGAAGA	4800
	CAATAGCAGG CATGCTGGGG ATGCGGTGGG CTCTATGGAA CCAGCTGGGG CTCGAGCTAC	4860
	TAGCTTGCT TCTCAATTTC TTATTCGAT AATGAGAAAA AAAGGAAAAT TAATTTAAC	4920
60	ACCAATTCACT AGTTGATTG AGCAAATGCG TTGCCAAAAA GGATGCTTTA GAGACAGTGT	4980
	TCTCTGCACA GATAAGGACA AACATTATTC AGAGGGAGTA CCCAGAGCTG AGACTCCTAA	5040

	GCCAGTGAGT GGCACAGCAT TCTAGGGAGA AATATGCTTG TCATCACCGA AGCCTGATTC	5100
	CGTAGAGCCA CACCTTGGTA AGGGCCAATC TGCTCACACA GGATAGAGAG GGCAGGGAGCC	5160
5	AGGGCAGAGC ATATAAGGTG AGGTAGGATC AGTTGCTCCT CACATTTGCT TCTGACATAG	5220
	TTGTGTTGGG AGCTTGGATC GATCCTCTAT GGTTGAACAA GATGGATTGC ACGCAGGTTG	5280
10	TCCGGCCGCT TGGGTGGAGA GGCTATTGG CTATGACTGG GCACAAACAGA CAATCGGCTG	5340
	CTCTGATGCC GCCGTGTTCC GGCTGTCAAGC GCAGGGGGCGC CCGGTTCTTT TTGTCAGAAC	5400
	CGACCTGTCC GGTGCCCTGA ATGAACTGCA GGACGGAGCA GCGCGGCTAT CGTGGCTGGC	5460
15	CACGACGGGC GTTCCCTGCG CAGCTGTGCT CGACGTTGTC ACTGAAGCGG GAAGGGACTG	5520
	GCTGCTATTG GGCGAAGTGC CGGGGCAGGA TCTCCTGTCA TCTCACCTTG CTCCCTGCCGA	5580
20	GAAAGTATCC ATCATGGCTG ATGCAATGCG CGGGCTGCAT ACGCTTGATC CGGCTACCTG	5640
	CCCATTGAC CACCAAGCGA AACATCGCAT CGAGCGAGCA CGTACTCGGA TGGAAAGCCGG	5700
	TCTTGTGCGAT CAGGATGATC TGGACGAAGA GCATCAGGGG CTCGCGCCAG CGAACTGTT	5760
25	CGCCAGGCTC AAGGGCGCGA TGCCCGACGG CGAGGATCTC GTCGTGACCC ATGGCGATGC	5820
	CTGCTTGGCCG AATATCATGG TGGAAAATGG CCGCTTTCT GGATTCACTG ACTGTGGCCG	5880
30	GCTGGGTGTG CGGGACCGCT ATCAGGACAT AGCGTTGGCT ACCCGTGATA TTGCTGAAGA	5940
	GCTTGGCCCCG GAATGGGCTG ACCGCTTCCCT CGTGTCTTAC GGTATCGCCG CTCCCGATTC	6000
	GCAGCGCATC GCCTCTATC GCCTCTTGA CGAGTTCTTC TGAGCGGGAC TCTGGGGTTC	6060
35	GAAATGACCG ACCAAGCGAC GCCCAACCTG CCATCACGAG ATTCGATTC CACCGCCGCC	6120
	TTCTATGAAA GGTTGGGCTT CGGAATCGTT TTCCGGGACG CGGGCTGGAT GATCCTCCAG	6180
40	CGCGGGGATC TCATGCTGGA GTTCTTCGCC CACCCCAACT TGTATTGCT AGCTTATAAT	6240
	GGTTACAAAT AAACCAATAG CATCACAAAT TTCACAAATA AACCAATTTT TTCACCTGCAT	6300
	TCTAGTTGTG GTTGTCCAA ACTCATCAAT CTATCTTATC ATGCTGGAT CGCGGCCGCG	6360
45	ATCCCGTCGA GAGCTTGCGG TAATCATGGT CATAGCTGTT TCCTGTGTGA AATTGTTATC	6420
	CGCTCACAAAT TCCACACAAAC ATACGAGCCG GAAGCATAAA GTGTAAGCC TGGGGTGCCT	6480
50	AATGAGTGAG CTAACTCACA TTAATTGCGT TGCGCTCACT GCCCCGTTTC CAGTCGGGAA	6540
	ACCTGTGCGT CGAGCTGCAT TAATGAATCG GCCAACCGCGC GGGGAGAGGC GGTGGCGTA	6600
	TTGGGCGCTC TTCCGCTTCC TCGCTCACTG ACTCGCTGCG CTCGGTCGTT CGGCTGCCG	6660
55	GACCCGTATC AGCTCACTCA AAGGCGGTAA TACGGTTATC CACAGAAATCA GGGGATAACG	6720
	CAGGAAAGAA CATGTGAGCA AAAGGCCAGC AAAAGCCAG GAACCGTAAA AAGGCCGCGT	6780
60	TGCTGGCGTT TTTCCATAGG CTCCGCCCCC CTGACGAGCA TCACAAAAAT CGACGCTCAA	6840
	CTCAGAGGTG GCGAARCCCG ACAGGACTAT AAAGATACCA GGCGTTCCC CCTGGAAGCT	6900
	CCCTCGTGGC CTCTCCTGTT CCGACCCCTGCG CGCTTACCGG ATACCTGTCC GCCTTCTCC	6960

	CTTCGGGAAG CGTGGCGCTT TCTCAATGCT CACCGCTGTAG GTATCTCAGT TCGGTGTAGG	7020
5	TCGTTCGCTC CAAGCTGGGC TGTGTGCACG AACCCCCCGT TCAGCCCGAC CGCTGCGCCT	7080
	TATCCCGTAA CTATCGTCTT GAGTCCAACC CGGTAAGACA CGACTTATCG CCACTGGCAG	7140
	CAGCCACTGG TAACAGGATT AGCAGAGCGA GGTATGTAGG CGGTGCTACA GAGTTCTTGA	7200
10	AGTGGTGGCC TAACTACCGC TACACTAGAA GGACAGTATT TGGTATCTGC GCTCTGCTGA	7260
	AGCCAGTTAC CTTCGAAAA AGAGTTGGTA GCTCTTGATC CGGCAAACAA ACCACCGCTG	7320
15	GTAGCGGTGG TTTTTTGTG TGCAAGCAGC AGATTACGCG CAGAAAAAAA GGATCTCAAG	7380
	AAGATCCTTT GATCTTTCT ACGGGGTCTG ACGCTCAGTG GAACGAAAAC TCACGTTAAG	7440
	GGATTTGGT CATGAGATTA TCAAAAAGGA TCTTCACCTA GATCCTTTTA AATTAAAAAT	7500
20	GAAGTTTTAA ATCAATCTAA AGTATATATG AGTAAACTTG GTCTGACAGT TACCAATGCT	7560
	TAATCAGTGA GGCACCTATC TCAGCGATCT GTCTATTCG TTCATCCATA GTTGCCGTGAC	7620
25	TCCCCGTCGT GTAGATAACT ACGATAACGGG AGGGCTTACC ATCTGGCCCC AGTGCCTGCAA	7680
	TGATACCGCG AGACCCACGC TCACCGGCTC CAGATTATC AGCAATAAAC CAGCCAGCCG	7740
	GAAGGGCCGA GCGCAGAACT GGTCTTGCAA CTTTATCCGC CTCCATCCAG TCTATTAAATT	7800
30	GTTGCCGGGA AGCTAGAGTA AGTAGTTCGC CAGTTAATAG TTTGCGCAAC GTTGTGCCA	7860
	TTGCTACAGG CATCGTGGTG TCACGCTCGT CGTTGGTAT GGCTTCATTC AGCTCCGGTT	7920
35	CCCAACGATC AAGGCGAGTT ACATGATCCC CCATGTTGTG CAAAAAAAGCG GTTAGCTCCT	7980
	TGGTCTCC GATCGTTGTC AGAAGTAAGT TGGCCGCAGT GTTATCACTC ATGGTTATGG	8040
	CAGCACTGCA TAATTCTCTT ACTGTCATGC CATCCGTAAG ATGCTTTCT GTGACTGGTG	8100
40	AGTACTCAAC CAAGTCATTC TGAGAATAGT GTATGCGGCG ACCGAGTTGC TCTTGGCCGG	8160
	CGTCAATACG GGATAATACC GCGCCACATA GCAGAACTTT AAAAGTGCTC ATCATTGGAA	8220
	AACGTTCTTC GGGGCGAAAA CTCTCAAGGA TCTTACCGCT GTTGAGATCC AGTTCGATGT	8280
45	AACCCACTCG TGCACCCAAC TGATCTTCAG CATCTTTAC TTTCACCAGC GTTCTGGGT	8340
	GAGCAAAAAAC AGGAAGGCAA AATGCCGCAA AAAAGGGAAT AAGGGCGACA CGGAAATGTT	8400
50	GAATACTCAT ACTCTCCCTT TTTCATATT ATTGAAGCAT TTATCAGGGT TATTGTCTCA	8460
	TGAGCGGATA CATATTGAA TGTATTTAGA AAAATARACA AATAGGGGTT CCGCGCACAT	8520
	TTCCCCGAAA AGTGCCACCT	8540
55		

## (3) INFORMATION FOR SEQ ID NO: 2:

## 60 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 9209 bases

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: circular

5 (ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: yes

10 (iv) ANTI-SENSE: no

(ix) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

15	GACGTCGCGG CCGCTCTAGG CCTCCAAAAA AGCCTCCTCA CTACTTCTGG AATAGCTCAG	60
	AGGCCGAGGC GGCCTCGGCC TCTGCATAAA TAAAAAAAAT TAGTCAGCCA TGCATGGGGC	120
	GGAGAATGGG CGGAACGTGGG CGGAGTTAGG GGCGGGATGG GCGGAGTTAG GGGCGGGACT	180
20	ATGGTTGCTG ACTAATTGAG ATGCATGCTT TGCATACTTC TGCCCTGCTGG GGAGCCTGGG	240
	GACTTTCCAC ACCTGGTTGC TGACTAATTG AGATGCATGC TTTGCATACT TCTGCCTGCT	300
25	GGGGAGCCTG GGGACTTTCC ACACCCCTAAC TGACACACAT TCCACAGAAT TAATTCCCCT	360
	AGTTATTAAT AGTAATCAAT TACGGGGTCA TTAGTTCAT A GCCCATATAT GGAGTTCCGC	420
	GTTACATAAC TTACGGTAAA TGGCCCGCCT GGCTGACCGC CCAACGACCC CCGCCCATTG	480
30	ACGTCAATAA TGACGTATGT TCCCATAGTA ACGCCAATAG GGACTTTCCA TTGACGTCAA	540
	TGGGTGGACT ATTTACGGTA AACTGCCAC TTGGCAGTAC ATCAAGTGTA TCATATGCCA	600
35	AGTACGCCCT CTATTGACGT CAATGACGGT AAATGGCCCG CCTGGCATT A TGCCAGTAC	660
	ATGACCTTAT GGGACTTTCC TACTTGGCAG TACATCTACG TATTAGTCAT CGCTATTACC	720
	ATGGTGATGC GGTTTGCA GTACATCAAT GGGCGTGGAT AGCGGTTGA CTCACGGGA	780
40	TTTCCAAGTC TCCACCCCCAT TGACGTCAAT GGGAGTTGT TTTGGCACCA AAATCAACGG	840
	GACTTTCCAA AATGTCGTAA CAACTCCGCC CCATTGACGC AAATGGGCGG TAGGCAGTGA	900
45	CGGTGGGAGG TCTATATAAG CAGAGCTGGG TACGTGAACC GTCAGATCGC CTGGAGACGC	960
	CATCACAGAT CTCTCACTAT GGATTTCAAG GTGCAGATT TCAGCTTCCT GCTAATCAGT	1020
	GCTTCAGTCA TAATGTCCAG AGGACAAATT GTTCTCTCCC AGTCTCCAGC AACCTGTCT	1080
50	GCATCTCCAG GGGAGAAGGT CACAATGACT TGCAGGGCCA GCTCAAGTGT AAGTTACATC	1140
	CACTGGTTCC AGCAGAAGCC AGGATCCTCC CCCAAACCCCT GGATTTATGC CACATCCAAC	1200
55	CTGGCTTCTG GAGTCCCTGT TCGCTTCAGT GGCAGTGGGT CTGGGACTTC TTACTCTCTC	1260
	ACAATCAGCA GAGTGGAGGC TGAAGATGCT GCCACTTATT ACTGCCAGCA GTGGACTAGT	1320
	AACCCACCCA CGTTGGAGG GGGGACCAAG CTGAAATCA AACGTACGGT GGCTGCACCA	1380
60	TCTGTCTTCA TCTTCCCGCC ATCTGATGAG CAGTTGAAAT CTGGAACCTGC CTCTGTTGTG	1440

	TGCCTGCTGA ATAACTTCTA TCCCAGAGAG GCCAAAGTAC AGTGGAAAGGT GGATAACGCC	1500
	CTCCAATCGG GTAACCTCCA GGAGAGTGTC ACAGAGCAGG ACAGCAAGGA CAGCACCTAC	1560
5	AGCCTCAGCA GCACCCCTGAC GCTGAGCAAA GCAGACTACG AGAACACCAA AGTCTACGCC	1620
	TGCGAAGTCA CCCATCAGGG CCTGAGCTCG CCCGTACAA AGAGCTTCAA CAGGGGAGAG	1680
10	TGTTGAATTTC AGATCCGTTA ACGGTTACCA ACTACCTAGA CTGGATTCTG GACAACATGC	1740
	GGCCGTGATA TCTACGTATG ATCAGCCTCG ACTGTGCCTT CTAGTTGCCA GCCATCTGTT	1800
	GTTTGCCCCCT CCCCCGTGCC TTCCCTGACC CTGGAAGGTG CCACCTCCAC TGTCCTTTCC	1860
15	TAATAAAATG AGGAAATTGC ATCGCATTGT CTGAGTAGGT GTCATTCTAT TCTGGGGGGT	1920
	GGGGTGGGGC AGGACAGCAA GGGGGAGGAT TGGGAAGACA ATAGCAGGCA TGCTGGGGAT	1980
20	GCGGTGGGCT CTATGGAACC AGCTGGGCT CGACAGCTAT GCCAAGTACG CCCCTATTG	2040
	ACGTCAATGA CGGTAAATGG CCCGCCTGGC ATTATGCCA GTACATGACC TTATGGACT	2100
	TTCCTACTTG GCAGTACATC TACGTATTAG TCATCGCTAT TACCATGGTG ATGCGGTTTT	2160
25	GGCAGTACAT CAATGGCGT GGATAGCGGT TTGACTCACG GGGATTTCCA AGTCTCCACC	2220
	CCATTGACGT CAATGGGAGT TTGTTTTGGC ACCAAAATCA ACGGGACTTT CCAAAATGTC	2280
30	GTAACAACTC CGCCCCATTG ACGCAAATGG GCGGTAGGCG TGTACGGTGG GAGGTCTATA	2340
	TAAGCAGAGC TGGGTACGTC CTCACATTC A GTGATCAGCA CTGAACACAG ACCCGTCGAC	2400
	ATGGGTTGGA GCCTCATCTT GCTCTTCCTT GTCGCTGTTG CTACGCGTGT CCTGTCCCAG	2460
35	GTACAACCTGC AGCAGCCTGG GGCTGAGCTG GTGAAGCCTG GGGCCTCAGT GAAGATGTCC	2520
	TGCAAGGCTT CTGGCTACAC ATTTACCACT TACAATATGC ACTGGGTAAA ACAGACACCT	2580
40	GGTCGGGCC TGGAAATGGAT TGGAGCTATT TATCCCGGAA ATGGTGATAC TTCCTACAAT	2640
	CAGAAGTTCA AAGGCAAGGC CACATTGACT GCAGACAAAT CCTCCAGCAC AGCCTACATG	2700
	CAGCTCAGCA GCCTGACATC TGAGGACTCT GCGGTCTATT ACTGTGCAAG ATCGACTTAC	2760
45	TACGGCGGTG ACTGGTACTT CAATGTCTGG GGCGCAGGGA CCACGGTCAC CGTCTCTGCA	2820
	GCTAGCACCA AGGGCCCATC GGTCTTCCCC CTGGCACCCCT CCTCCAAGAG CACCTCTGG	2880
50	GGCACAGCGG CCCTGGGCTG CCTGGTCAAG GACTACTTCC CCGAACCGGT GACGGTGTGCG	2940
	TGGAACTCAG GCGCCCTGAC CAGCGCGTG CACACCTTCC CGGCTGTCCT ACAGTCCTCA	3000
	GGACTCTACT CCCTCAGCAG CGTGGTGACC GTGCCCTCCA GCAGCTTGGG CACCCAGACC	3060
55	TACATCTGCA ACGTGAATCA CAAGCCCAGC AACACCAAGG TGGACAAGAA AGCAGAGCCC	3120
	AAATCTTGTG ACAAAACTCA CACATGCCA CCGTGCCAG CACCTGAACCT CCTGGGGGGA	3180
60	CCGTCAGTCT TCCTCTTCCC CCCAAAACCC AAGGACACCC TCATGATCTC CGGGACCCCT	3240
	GAGGTACAT GCGTGGTGGT GGACGTGAGC CACGAAGACC CTGAGGTCAA GTTCAACTGG	3300
	TACGTGGACG GCGTGGAGGT GCATAATGCC AAGACAAAGC CGCGGGAGGA GCAGTACAAC	3360

	AGCACGTACC GTGTGGTCAG CGTCCTCACC GTCCTGCACC AGGACTGGCT GAATGGCAAG	3420
5	GAGTACAAGT GCAAGGTCTC CAACAAAGCC CTCCCAGCCC CCATCGAGAA AACCATCTCC	3480
	AAAGCCAAAG GGCAGCCCCG AGAACACAG GTGTACACCC TGCCCCCATC CCGGGATGAG	3540
	CTGACCAAGA ACCAGGTCAAG CCTGACCTGC CTGGTCAAAG GCTTCTATCC CAGCGACATC	3600
10	CCCCTGGAGT CCCAGAGCAA TGGGCAGCCG GAGAACAACT ACAAGACCAC GCCTCCGTG	3660
	CTGGACTCCG ACGGCTCCTT CTTGCTCTAC AGCAAGCTCA CCCGTGGACAA GAGCAGGTGG	3720
15	CAGCAGGGGA ACGTCTTCTC ATGCTCCGTG ATGCATGAGG CTCTGCACAA CCACTACACG	3780
	CAGAAGAGCC TCTCCCTGTC TCCGGCTAAA TGAGGATCCG TTAACGGTTA CCAACTACCT	3840
	AGACTGGATT CGTGACAACA TGCGGGCGTG ATATCTACGT ATGATCAGCC TCGACTGTGC	3900
20	CTTCTAGTTG CCAGCCATCT GTTGTGGGCC CCTCCCCCGT GCCTCCCTTG ACCCTGGAAG	3960
	GTGCCACTCC CACTGTCCTT TCCTAATAAA ATGAGGAART TGCATCGCAT TGTCTGAGTA	4020
25	GGTGTCAATTG TATTCTGGGG GGTGGGTGG GGCAGGACAG CAAGGGGGAG GATTGGGAAG	4080
	ACAATAGCAG GCATGCTGGG GATGCGGTGG GCTCTATGGA ACCAGCTGGG COTCGACAGC	4140
	GCTGGATCTC CCGATCCCCA GCTTTGCTTC TCAATTCTT ATTGATCAA TGAGAAAAAA	4200
30	AGGAARATTA ATTTAACAC CAATTCACTA GTTGATTGAG CAAATCCGTT GCCAAAAAGG	4260
	ATGCTTTAGA GACAGTGTTC TCTGCACAGA TAAAGACAAA CATTATTCAG AGGGAGTACC	4320
35	CAGAGCTGAG ACTCCTAACG CAGTGAGTGG CACAGCATTC TAGGGAGAAA TATGCTGTG	4380
	ATCACCGAAG CCTGATTCCG TAGAGCCACA CCTTGGTAAG GGCCAATCTG CTCACACAGG	4440
	ATAGACAGGG CAGGACCCAG GGCACAGCAT ATAACGTGAG GTAGGATCAG TTGCTCCTCA	4500
40	CATTTGCTTC TGACATAGTT GTGTTGGAG CTTGGATAGC TTGGACAGCT CAGGGCTGCG	4560
	ATTTCGCGCC AAACCTGACG GCAATCCTAG CGTGAAGGCT GGTAGGATT TATCCCCGCT	4620
45	GCCATCATGG TTCGACCATT GAACTGCATC GTCGCCCCGT CCCAAAATAT GGGGATTGGC	4680
	AAGAACGGAG ACCTACCCCTG GCCTCCCGTC AGGAACCGAGT TCAAGTACTT CCAAAGAATG	4740
	ACCACAAACCT CTTCAGTGGA AGCTAAACAG AATCTGGTGA TTATGGGTAG GAAAACCTGG	4800
50	TTCTCCATTC CTGAGAAGAA TCGACCTTTA AAGGACAGAA TTAATATAGT TCTCAGTAGA	4860
	GAACCTCAAAG AACCAACCACG AGGAGCTCAT TTTCTGCCA AAAGTTGGTA TGATGCCCTA	4920
55	AGACTTATTG AACAAACCGGA ATTGGCAAGT AAAGTAGACA TGGTTGGAT AGTCGGAGGC	4980
	AGTTCTGTTT ACCAGGAAGC CATGAATCAA CGAGGCCACC TTAGACTCTT TGTGACAAGG	5040
	ATCATGCAGG AATTTGAAAG TGACACGTT TTCCCGAGAA TTGATTTGGG GAAATATAAA	5100
60	CTTCTCCAG AATACCCAGG CGTCCTCTCT GAGGTCCAGG ACCAAAAAGG CATCAAGTAT	5160
	AAGTTGAAG TCTACGAGAA GAAAGACTAA CAGGAAGATG CTTCAAGTT CTCTGCTCCC	5220

	CTCCTAAAGC TATGCATTT TATAAGACCA TGGGACTTTT GCTGGCTTA GATCAGCCTC	5280
	GACTGTGCC TCTAGTTGCC AGCCATCTGT TGTTGCC CCCCCGTGC CTTCCTTGAC	5340
5	CCTGGAAGGT GCCACTCCC CTGTCTTTC CTAATAAAAT GAGGAAATTG CATCGCATTG	5400
	TCTGAGTAGG TGTCATTCTA TTCTGGGGG TGGGGTGGGG CAGGACAGCA AGGGGGAGGA	5460
10	TTGGGAAGAC AATAGCAUGC ATGCTGGGJA TGCCTGGGC TCTATGGAAC CAGCTGGGC	5520
	TCGAGCTACT AGCTTTGCTT CTCATTCT TATTGCTATA ATGAGAAAAA AAGGAAAATT	5580
	AATTTAACCA CCAATTCAAGT AGTTGATTGA GCAAATGCGT TGCCAAAAG GATGCTTAG	5640
15	AGACAGTGTT CTCTGCACAG ATAAGGACAA ACATTATTCA GAGGGAGTAC CCAGAGCTGA	5700
	GACTCCTAAG CCAGTGAGTG GCACAGCATT CTAGGGAGAA ATATGCTTGT CATCACCGAA	5760
20	GCCTGATTCC GTAGAGCCAC ACCTTGGTAA GGGCCAATCT GTCACACAG GATAGAGAGG	5820
	GCAGGAGCCA GGGCAGAGCA TATAAGGTGA GGTAGGATCA GTTGCTCCTC ACATTGCTT	5880
	CTGACATAGT TGTGTTGGGA GCTTGGATCG ATCCTCTATG GTTGAACAAG ATGGATTGCA	5940
25	CGCAGGTTCT CCGGCCGCTT GGGTGGAGAG GCTATTCGGC TATGACTGGG CACAACAGAC	6000
	AATCGGCTGC TCTGATGCCG CCGTGTCCG GCTGTCAGCG CAGGGCGCC CGGTTCTTT	6060
30	TGTCAAGACC GACCTGTCCG GTGCCCTGAA TGAACATGCAG GACGAGGCAG CGCGGCTATC	6120
	GTGGCTGGCC ACGACGGCGC TTCCTTGCGC AGCTGTGCTC GACGTTGTCA CTGAAGCGGG	6180
	AAGGGACTGG CTGCTATTGG GCGAAGTGCC GGGGCAGGAT CTCCTGTCAT CTCACCTTGC	6240
35	TCCTGCCGAG AAAGTATCCA TCATGGCTGA TGCAATGCGG CGGCTGCATA CGCTTGATCC	6300
	GGCTACCTGC CCATTCGACC ACCAAGCGAA ACATCGCATC GAGCGAGCAC GTACTCGGAT	6360
40	GGAAGCCGGT CTTGTCGATC AGGATGATCT GGACGAAGAG CATCAGGGC TCGCGCCAGC	6420
	CGAACTGTTG GCCAGGCTCA AGGCGCGCAT GCCCACGGC GAGGATCTCG TCGTGACCCA	6480
	TGGCGATGCC TGCTTGCCGA ATATCATGGT GGAAAATGGC CGCTTTCTG GATTCATCGA	6540
45	CTGTGGCCGG CTGGGTGTGG CGGACCGCTA TCAGGACATA GCGTTGGCTA CCCGTGATAT	6600
	TGCTGAAGAG CTTGGCGCG AATGGGCTGA CCGCTTCCTC GTGCTTACG GTATGCCGC	6660
50	TCCCGATTCTG CAGCGCATCG CCTTCTATCG CCTTCTTGAC GAGTTCTTCT GAGCGGGACT	6720
	CTGGGGTTCG AAATGACCGA CCAAGCGACG CCCAACCTGC CATCACGAGA TTTCGATTCC	6780
	ACCGCCGCCT TCTATGAAAG GTTGGCTTC GGAATCGTTT TCCGGACGC CGGCTGGATG	6840
55	ATCCTCCAGC GCGGGGATCT CATGCTGGAG TTCTTCGCC ACCCCAACTT GTTTATTGCA	6900
	GCTTATAATG GTTACAAATA AAGCAATAGC ATCACAAATT TCACAAATAA AGCATTTTT	6960
60	TCACTGCATT CTAGTTGTGG TTTGTCCAAA CTCATCAATC TATCTTATCA TGTCTGGATC	7020
	GCGGCCGCGA TCCCGTCGAG AGCTTGGCGT AATCATGGTC ATAGCTGTT CCTGTGTGAA	7080
	ATTGTTATCC GCTCACAAATT CCACACAACA TACGAGCCGG AAGCATAAAAG TGTAAAGCCT	7140

	GGGGTGCCTA ATGAGTGAGC TAACTCACAT TAATTGCGTT GCGCTCACTG CCCGCTTC	7200
5	AGTCGGAAA CCTGTCGTGC CAGCTGCATT AATGAATCGG CCAACGCGCG GGGAGAGCG	7260
	GTTTCCGTAT TGGCGCGCTCT TCCGCTTCCT CGCTCACTGA CTGGCTGCCTC TCGGTCGTT	7320
	GGCTGCCGGCG AGCGGTATCA GCTCACTCAA AGCGGTTAAT ACGGTTATCC ACAGAACATC	7380
10	GGGATAACGC AGGAAAGAAC ATGTGAGCAA AAGGCCAGCA AAAGGCCAG AACCGTAAA	7440
	AGCCCGCGTT GCTGGCGTTT TTCCATAGGC TCCCCCCCCC TGACCGAGCAT CACAAAAATC	7500
15	GACGCTCAAG TCAGAGGTGG CGAAACCCGA CAGGACTATA AAGATACCAG CGGTTTCCC	7560
	CTGGAAGCTC CCTCGTGCCTC TCTCCTGTT CGACCCCTGCC GCTTACCGGA TACCTGTC	7620
	CCTTCCTCCC TTCGGGAAGC GTGGCGCTTT CTCAATGCTC ACGCTGTAGG TATCTCAGTT	7680
20	CGGTGTAGGT CGTTCGCTCC AAGCTGGGCT GTGTGCACGA ACCCCCCCGTT CAGCCCCGACC	7740
	GCTGCGCCTT ATCCGGTAAC TATCGTCTTG AGTCCAACCC GGTAAGACAC GACTTATCGC	7800
25	CACTGGCAGC AGCCACTGGT AACAGGATTA CCAGAGCGAC GTATGTAGGC GGTGCTACAG	7860
	AGTTCTTGAA GTGGTGGCCT AACTACGGCT AACTACAGAAG GACAGTATTT GGTATCTGG	7920
	CTCTGCTGAA GCCAGTTACC TTCGGAAAAA GAGTTGGTAG CTCTGATCC CCCAAACAAA	7980
30	CCACCGCTGG TAGCGGTGGT TTTTTGTTT GCAAGCAGCA GATTACGCC AGAAAAAAAG	8040
	GATCTCAAGA AGATCCTTG ATCTTTCTA CGGGGTCTGA CGCTCAGTGG AACGAAAACT	8100
35	CACGTTARGG GATTTGGTC ATGAGATTAT CAAAAAGGAT CTTCACCTAG ATCCTTTAA	8160
	ATTAAAAATG AAGTTTAAA TCAATCTAAA GTATATATGA GTAAACTTGG TCTGACAGTT	8220
	ACCAATGCTT AATCAGTGAG GCACCTATCT CAGCGATCTG TCTATTCGT TCATCCATAG	8280
40	TTGCCTGACT CCCCCTCGTG TAGATAACTA CGATAACGGGA GGGCTTACCA TCTGGCCCCA	8340
	GTGCTGCAAT GATAACGGGA GACCCACGCT CACCGGCTCC AGATTTATCA GCAATAAAC	8400
45	AGCCAGCCGG AAGGGCCGAG CGCAGAAGTG GTCCTGCAAC TTTATCCGCC TCCATCCAGT	8460
	CTATTAATTG TTGCCGGGAA GCTAGAGTAA GTAGTTGCC AGTTAATAGT TTGCGCAACG	8520
	TTGTTGCCAT TGCTACAGGC ATCGTGGTGT CACGCTCGTC GTTTGGTATG GCTTCATTCA	8580
50	GCTCCGGTTC CCAACGATCA AGGCGAGTTA CATGATCCCC CATGTTGTGC AAAAAAGCGG	8640
	TTAGCTCCTT CGGTCTCTCCG ATCGTTGTCA GAAGTAAGTT GGCCGCAGTG TTATCACTCA	8700
55	TGGTTATGGC AGCACTGCAT AATTCTCTTA CTGTCACTGCC ATCCGTAAGA TGCTTTCTG	8760
	TGACTGGTCA GTACTCAACC AAGTCATTCT GAGAATAGTG TATGCCGGCGA CCGAGTTGCT	8820
	CTTGCCCGGC GTCAATACGG GATAATACCG CGCCACATAG CAGAACTTTA AAACTGCTCA	8880
60	TCATTGGAAA ACGTTCTTCG GGGCGAAAAC TCTCAAGGAT CTTACCGCTG TTGAGATCCA	8940
	GTTCGATGTA ACCCACTCGT GCACCCAACT GATCTTCAGC ATCTTTACT TTGACCCAGCG	9000

	TTTCTGGGTG AGCAAAAACA GGAAGCCAAA ATGCCGCAA AAAGGGAATA AGGGCGACAC	9060
	GGAAATGTTG AATACTCATA CTCTTCCTTT TTCAATATTA TTGAAGCATT TATCAGGGTT	9120
5	ATTGTCTCAT GAGCGGATAC ATATTGAAAT GTATTTAGAA AAATAAACAA ATAGGGGTTC	9180
	CGCGCACATT TCCCCGAAAA GTGCCACCT	9209

## 10 (4) INFORMATION FOR SEQ ID NO: 3:

## (i) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 54 bases  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: yes

(iv) ANTI-SENSE: no

25 (ix) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

5' ATC ACA GAT CTC TCA CCA TGG ATT TTC AGG TBC AGA TTA TCA GCT  
 TC 3'

52  
2

## 30 (5) INFORMATION FOR SEQ ID NO: 4:

## (i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 30 bases  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: yes

(iv) ANTI-SENSE: yes

45 (ix) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

50 5' TGC AGC ATC CGT ACG TTT GAT TTC CAG CTT 3'

30

## (6) INFORMATION FOR SEQ ID NO: 5:

## 55 (i) SEQUENCE CHARACTERISTICS:

- |    |                                                                     |     |
|----|---------------------------------------------------------------------|-----|
|    | (A) LENGTH: 384 bases                                               |     |
|    | (B) TYPE: nucleic acid                                              |     |
|    | (C) STRANDEDNESS: single                                            |     |
|    | (D) TOPOLOGY: linear                                                |     |
| 5  | (ii) MOLECULE TYPE: DNA (genomic)                                   |     |
|    | (iii) HYPOTHETICAL: yes                                             |     |
| 10 | (iv) ANTI-SENSE: no                                                 |     |
|    | (ix) SEQUENCE DESCRIPTION: SEQ ID NO: 5:                            |     |
| 15 | ATG GAT TTT CAG GTG CAG ATT ATC AGC TTC CTG CTA ATC AGT GCT TCA GTC | 51  |
|    | ATA ATG TCC AGA GGG CAA ATT GTT CTC TCC CAG TCT CCA GCA ATC CTG TCT | 102 |
|    | GCA TCT CCA GGG GAG AAG GTC ACA ATG ACT TGC AGG GCC AGC TCA AGT GTA | 153 |
| 20 | AGT TAC ATC CAC TGG TTC CAG CAG AAG CCA GGA TCC TCC CCC AAA CCC TGG | 204 |
|    | ATT TAT GCC ACA TCC AAC CTG GCT TCT GGA GTC CCT GTT CGC TTC AGT GGC | 255 |
| 25 | AGT GGG TCT GGG ACT TCT TAC TCT CTC ACA ATC AGC AGA GTG GAG GCT GAA | 306 |
|    | GAT GCT GCC ACT TAT TAC TGC CAG CAG TGG ACT AGT AAC CCA CCC ACG TTC | 357 |
| 30 | GGA GGG GGG ACC AAG CTG GAA ATC AAA                                 | 384 |

(7) INFORMATION FOR SEQ ID NO: 6:



5' GCG GCT CCC ACG CGT GTC CTG TCC CAG 3'

## (8) INFORMATION FOR SEQ ID NO: 7:

## (i) SEQUENCE CHARACTERISTICS:

- 5                   (A) LENGTH: 29 bases  
                  (B) TYPE: nucleic acid  
                  (C) STRANDEDNESS: single  
                  (D) TOPOLOGY: linear

10               (ii) MOLECULE TYPE: DNA (genomic)

                 (iii) HYPOTHETICAL: yes

15               (iv) ANTI-SENSE: yes

                 (ix) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

5' GGS TGT TGT GCT AGC TGM RGA GAC RGT GA 3'      29

20               (9) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

- 25                   (A) LENGTH: 420 bases  
                  (B) TYPE: nucleic acid  
                  (C) STRANDEDNESS: single  
                  (D) TOPOLOGY: linear

30               (ii) MOLECULE TYPE: DNA (genomic)

                 (iii) HYPOTHETICAL: yes

35               (iv) ANTI-SENSE: no

                 (ix) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

40	ATG GGT TGG AGC CTC ATC TTG CTC TTC CTT GTC GCT GTC GTT GCT ACG CGT GTC	51
	CTG TCC CAG GTA CAA CTG CAG CAG CCT GGG GCT GAG CTG GTG AAG CCT GGG	102
	GCC TCA GTG AAG ATG TCC TGC AAG GCT TCT GGC TAC ACA TTT ACC AGT TAC	153
45	AAT ATG CAC TGG GTA AAA CAG ACA CCT GGT CGG GGC CTG GAA TGG ATT GGA	204
	GCT ATT TAT CCC GGA AAT GGT GAT ACT TCC TAC AAT CAG AAG TTC AAA GGC	255
50	AAG GCC ACA TTG ACT GCA GAC AAA TCC TCC AGC ACA GCC TAC ATG CAG CTC	306
	AGC AGC CTG ACA TCT GAG GAC TCT GCG GTC TAT TAC TGT GCA AGA TCG ACT	357
	TAC TAC GGC GGT GAC TGG TAC TTC AAT GTC TGG GGC GCA GGG ACC ACG GTC	408
	ACC GTC TCT GCA	420

H. CLAIMS

What is claimed is:

- 5     1. A method for the treatment of B cell lymphoma comprising the step of administering a therapeutically effective amount of at least one immunologically active, chimeric anti-CD20 antibody to a human.
- 10    2. The method of claim 1 wherein the amount of said antibody administered to said human is between about 0.001 to about 30 milligrams of antibody per kilogram body weight of said human ("mg/kg").
- 15    3. The method of claim 1 wherein said antibody is derived from a transfectoma comprising anti-CD20 in TCAE 8 as deposited with the American Type Culture Collection as part of ATCC deposit number 69119.
- 20    4. The method of claim 1 further comprising the step of administering a second therapeutically effective amount of at least one immunologically active, chimeric anti-CD20 antibody.
- 25    5. The method of claim 4 wherein said additional administration of said antibody to said human occurs within about seven days of said first administration of said antibody to said human.
6. A method for the treatment of B cell lymphoma comprising the steps of:
  - 1) administering, at a first administration period, a first therapeutically effective amount of immunologically active, chimeric anti-CD20 antibody to a human;

- 2) administering at a second subsequent administration period, a second therapeutically effective amount of said antibody;
- 3) administering, at a third subsequent administration period, a third therapeutically effective amount of said antibody.

5

7. The method of claim 6 wherein said first, second and third therapeutically effective amount of said antibody is between about 0.001 mg/kg to about 30 mg/kg.

10 8. The method of claim 6 wherein said second administration period is within about seven days of said first administration period.

9. The method of claim 6 wherein said third administration period is within about fourteen days of said first administration period.

15

10. The method of claim 6 wherein said antibody is derived from a transfectoma comprising anti-CD20 in TCAE 8 (within ATCC deposit number 69119).

20 11. Immunologically active, chimeric anti-CD20 produced from a transfectoma comprising anti-CD20 in TCAE 8 (within ATCC deposit number 69119).


12. A hybridoma which secretes anti-CD20 antibody, said hybridoma being identified by American Type Culture Collection deposit number HB 11388.

25

13. A monoclonal antibody secreted from the hybridoma of claim 12.

14. A radiolabeled antibody according to claim 12.

15. The radiolabeled antibody of claim 14 where the radiolabel is selected from the group consisting of yttrium [90]; indium [111], and iodine [131].
16. A method for the treatment of B cell lymphoma comprising of steps of  
5 administering a therapeutically effective amount of the antibody of claim 14 to a human.
17. The method of claim 16 when the radiolabel of said antibody is yttrium [90].  
10
18. A method for the treatment of B cell lymphoma comprising the steps of:
  - 1) administering, at a first administration period, an immunology active chimeric anti-CD20 antibody to human; and  
15
  - 2) administering, at a second administration period, a radiolabeled anti-CD20 antibody to said human.
19. The method of claim 18 when said chimeric anti-CD20 is derived from a  
20 transfectoma comprising anti-CD20 in TCAE 8 as deposited with the American Type Culture Collection as part of ATCC deposit number 69119.
20. The method of claim 8 when said radiolabeled antibody comprises a  
monoclonal antibody secreted from a hybridoma identified by American Type  
25 Culture Collection deposit number HB 11388.



LINKER #1 15bp | SV40 ORIGIN=332bp  
 GACGTCGCGG CCGCTCTAGG CCTCCAAAAA AGCCTCCTCA CTACTTCTGG AATAGCTCAG 60  
 AGGCCGAGGC GGCCCTCGGCC TCTGCATAAA TAAAAAAAAT TAGTCAGCCA TGCACTGGGGC 120  
 GGAGAATGGG CGGAACCTGGG CGGAGTTAGG GGCGGGATGG GCGGAGTTAG GGGCGGGACT 180  
 ATGGTTGCTG ACTAATTGAG ATGCATGCTT TGCACTACTTC TGCCCTGCTGG GGAGCCTGGG 240  
 GACTTCCAC ACCTGGTTGC TGACTAATTG AGATGCATGC TTTGCATACT TCTGCCTGCT 300  
 GGGGAGCCTG GGGACTTCC ACACCCTAAC TGACACACAT TCCACAGAAAT TAATTCCCCT |  
 347 8 360 1 LINKER #2=13bp  
 AGTTATTAAT AGTAATCAAT TACGGGGTCA TTAGTTCAT A CCCATATAT GGAGTTCCGC 420  
 GTTACATAAC TTACGGTAAA TGGCCCGCCT GGCTGACCGC CCAACGACCC CCGCCATTG 480  
 CMV PROMOTER-ENHANCER=567bp  
 ACGTCAATAA TGACGTATGT TCCCATAGTA ACGCCAATAG GGACTTCCA TTGACGTCAA 540  
 TGGGTGGACT ATTTACGGTA AACTGCCAC TTGGCAGTAC ATCAAGTGT A TCATATGCCA 600  
 AGTACGCCAC CTATTGACGT CAATGACGGT AAATGGCCCG CCTGGCATT TGCCCAGTAC 660  
 ATGACCTTAT GGGACTTCC TACTTGGCAG TACATCTACG TATTAGTCAT CGCTATTAC 720  
 ATGGTGATGC GGTTTGGCA GTACATCAAT GGGCGTGGAT AGCGGTTGA CTCACGGGA 780  
 TTTCCAAGTC TCCACCCAT TGACGTCAAT GGGAGTTGT TTTGGCACCA AAATCAACGG 840  
 GACTTCCAA AATGTCGTA CAACTCCGCC CCATTGACGC AAATGGCGG TAGGCCTGTA 900  
 CGGTGGGAGG TCTATATAAG CAGAGCTGGG TACGTGAACC GTCAGATCGC CTGGAGACGC 960  
 Bgl II | LEADER=60bp  
 CATCACAGAT CTCTCACCAT 727 8 978 9 GAGGGTCCCC GCTCAGCTCC TGGGGCTCCT GCTGCTCTGG 1020  
 +1 101 102 107 108  
 CTCCCAGGTG CACGATGTGA TGGTACCAAG GTGGAAATCA AACGTACGGT GGCTGCACCA 1080  
 1038 9 1062 3 Bsi WI  
 TCTGTCTTCA TCTTCCCGCC ATCTGATGAG CAGTTGAAAT CTGGAACTGC CTCTGTTGTG 1140  
 TGCCTGCTGA ATAACCTCTA TCCCAGAGAG GCCAAAGTAC AGTGGAAAGGT GGATAACGCC 1200  
 HUMAN KAPPA CONSTANT 324bp 107 AMINO ACID & STOP CODON  
 CTCCAATCGG GTAACCTCCA GGAGAGTGTG ACAGAGCAGG ACAGCAAGGA CAGCACCTAC 1260  
 AGCCTCAGCA GCACCCCTGAC GCTGAGCAAA GCAGACTACG AGAAACACAA AGTCTACGCC 1320  
 TGCGAAGTCA CCCATCAGGG CCTGAGCTCG CCCGTCACAA AGAGCTTCAA CAGGGGAGAG 1380  
 STOP  
 LIGHT  
 CHAIN | Eco RI LINKER #4=85bp  
 TGTTGAATTG AGATCCGTTA ACGGTTACCA ACTACCTAGA CTGGATTCTG GACAACATGC 1440  
 1386 7  
 GGCGTGATA TCTACGTATG ATCAGCCTCG ACTGTGCCTT CTAGTTGCCA GCCATCTGTT 1500  
 1471 2

*FIG. 2A*

GTTTGCCCTT CCCCCGTGCC TTCCCTTGACC CTGGAAGGTG CCACTCCCAC TGTCCCTTCC 1560  
 BGH poly A=231bp  
 TAATAAAATG AGGAAATTGC ATCGCATTGT CTGAGTAGGT GTCATTCTAT TCTGGGGGGT 1620  
 GGGGTGGGGC AGGACAGCAA GGGGGAGGAT TGGGAAGACA ATAGCAGGCA TGCTGGGGAT 1680  
 | LINKER #5=15bp |  
 GCGGTGGGCT CTATGGAACC AGCTGGGCT CGACAGCTAT GCCAAGTACG CCCCCTATTG 1740  
 1702 3 1717 8  
 ACGTCAATGA CGGTAAATGG CCCGCCTGGC ATTATGCCA GTACATGACC TTATGGGACT 1800  
 TTCCTACTTG GCAGTACATC TACGTATTAG TCATCGCTAT TACCATGGTG ATGCGGTTTT 1860  
 CMV PROMOTER-ENHANCER=334bp  
 GGCAAGTACAT CAATGGGCGT GGATAGCGGT TTGACTCACG GGGATTTCCA AGTCTCCACC 1920  
 CCATTGACGT CAATGGGAGT TTGTTTGGC ACCAAAATCA ACGGGACTTT CCAAAATGTC 1980  
 GTAACAACTC CGCCCCATTG ACGCAAATGG GCGGTAGGCG TGTACGGTGG GAGGTCTATA 2040  
 | LINKER #6=7bp | Sal I  
 TAAGCAGAGC TGGGTACGTC CTCACATTCA GTGATCAGCA CTGAACACAG ACCCGTCGAC 2100  
 2051 2 2058 9 LEADER=51bp Mu I 2151 2 Nhe I  
 ATGGGTTGGA GCCTCATCTT GCTCTTCCTT GTCGCTGTTG CTACCGTGT CGCTAGCACC 2160  
 START HEAVY CHAIN -5 -4 -3 114 115  
 AAGGGCCCAT CGGTCTTCCC CCTGGCACCC TCCTCCAAGA GCACCTCTGG GGGCACAGCG 2220  
 GCCCTGGGCT GCCTGGTCAA GGACTACTTC CCCGAACCGG TGACGGTGTC GTGGAACTCA 2280  
 GGCGCCCTGA CCAGCGGCGT GCACACCTTC CCGGCTGTCC TACAGTCCYC AGGACTCTAC 2340  
 HUMAN GAMMA 1 CONSTANT  
 TCCCTCAGCA GCGTGGTGAC CGTGCCTCC AGCAGCTTGG GCACCCAGAC CTACATCTGC 2400  
 993bp=330 AMINO ACID & STOP CODON  
 AACGTGAATC ACAAGCCCAG CAACACCAAG GTGGACAAGA AAGCAGAGCC CAAATCTTGT 2460  
 GACAAAATC ACACATGCC ACCGTGCCA GCACCTGAAC TCCTGGGGGG ACCGTCACTC 2520  
 TTCCTCTTCC CCCCCAAACC CAAGGACACC CTCATGATCT CCCGGACCCC TGAGGTACCA 2580  
 TGGCGTGGTGG TGGACGTGAG CCACGAAGAC CCTGAGGTCA AGTTCAACTG GTACGTGGAC 2640  
 GGCCTGGAGG TGCATAATGC CAAGACAAAG CCGCGGGAGG AGCAGTACAA CAGCACGTAC 2700  
 CGTGTGGTCA GCGTCCTCAC CGTCCTGCAC CAGGACTGGC TGAATGGCAA GGACTACAAG 2760  
 TGCAAGGTCT CCAACAAAGC CCTCCCAGCC CCCATCGAGA AAACCACCTC CAAAGCCAAA 2820  
 GGGCAGCCCC GAGAACACCA GGTGTACACC CTGCCCCCAT CCCGGGATGA GCTGACCAGG 2880  
 AACCCAGGTCA GCCTGACCTG CCTGGTCAA GGCTTCTATC CCAGCGACAT CGCCGTGGAG 2940  
 TGGGAGAGCA ATGGGCAGCC GGAGAACAAAC TACAAGACCA CGCCTCCCGT GCTGGACTCC 3000

*FIG. 2B*

GACGGCTCCT TCTTCCTCTA CAGCAAGCTC ACCGTGGACA AGAGCAGGTG GCAGCAGGGG 3060  
 AACGTCTTCT CATGCTCCGT GATGCATGAG GCTCTGCACA ACCACTACAC GCAGAAGAGC 3120  
 STOP HEAVY CHAIN Bam HI LINKER #7=81bp  
 CTCTCCCTGT CTCCGGGTAA ATGAGGATCC GTTAACGGTT ACCAACTACC TAGACTGGAT 3180  
 3144 5  
 TCGTGACAAAC ATGCGGCCGT GATATCTACG TATGATCAGC CTCGACTGTG CCTTCTAGTT 3240  
 3225 6  
 GCCAGCCATC TGTTGTTTC GC CCCTCCCCG TGCTTCCTT GACCCTGGAA GGTGCCACTC 3300  
 BOVINE GROWTH HORMONE POLYADENYLATION REGION=231bp  
 CCACTGTCCT TTCTTAATAA AATGAGGAAA TTGCATCGCA TTGTCTGAGT AGGTGTCATT 3360  
 CTATTCTGGG GGGTGGGGTG GGGCAGGACA GCAAGGGGGA GGATTGGGAA GACAATAGCA 3420  
 GGCATGCTGG GGATGCGGTG GGCTCTATGG AACCAAGCTGG GGCTCGACAG CGCTGGATCT 3480  
 3456 7  
 CCCGATCCCC | AGCTTGCTT CTCAATTCT TATTGCTA ATGAGAAAAA AAGGAAATT 3540  
 3490 1  
 AATTTAACCA CCAATTCACT AGTTGATTGA GCAAATGCGT TGCCAAAAAG GATGCTTTAG 3600  
 MOUSE BETA GLOBIN MAJOR PROMOTER=366bp  
 AGACAGTGTT CTCTGCACAG ATAAGGACAA ACATTATTCA GAGGGAGTAC CCAGAGCTGA 3660  
 GACTCCTAAG CCAGTGAGTG GCACAGCATT CTAGGGAGAA ATATGCTTGT CATCACCGAA 3720  
 GCCTGATTCC GTAGAGCCAC ACCTTGGTAA GGGCCAATCT GCTCACACAG GATAGAGAGG 3780  
 GCAGGAGCCA GGGCAGAGCA TATAAGGTGA GGTAGGATCA GTTGCTCCTC ACATTTGCTT 3840  
 CTGACATAGT TGTGTTGGGA GCTTGGATAG 3856 7 LINKER #9=19bp 5' UNTRANSLATED DHFR=82bp  
 CTTGGACAGC 3875 6 TCAGGGCTGC GATTCGCGC 3900 START DHFR  
 CAAACTTGAC GGCAATCCTA GCGTGAAGGC TGGTAGGATT TTATCCCCGC TGCCATGATG 3960  
 3957 8  
 GTTCGACCAT TGAACTGCAT CGTCGCCGTG TCCCAAAATA TGGGGATTGG CAAGAACCGGA 4020  
 GACCTACCT GGCCTCCGCT CAGGAACGAG TTCAAGTACT TCCAAAGAAT GACCACAAAC 4080  
 TCTTCAGTGG AAGGTAAACA GAATCTGGTG ATTATGGGTAA GGAAAACCTG GTTCTCCATT 4140  
 MOUSE DHFR=564bp=187 AMINO ACID & STOP CODON  
 CCTGAGAAGA ATCGACCTTT AAAGGACAGA ATTAATATAG TTCTCAGTAG AGAACTCAA 4200  
 GAACCACCAAC GAGGAGCTCA TTTCTTGCC AAAAGTTGG ATGATGCCTT AAGACTTATT 4260  
 GAACAACCGG AATTGGCAAG TAAAGTAGAC ATGGTTTGGG TAGTCGGAGG CAGTTCTGTT 4320  
 TACCAAGGAAG CCATGAATCA ACCAGGCCAC CTTAGACTCT TTGTGACAAG GATCATGCAG 4380  
 GAATTTGAAA GTGACACGTT TTTCCAGAA ATTGATTGAGG GGAAATATAA ACTTCTCCCA 4440  
 GAATACCCAG GCGTCCTCTC TGAGGTCCAG GAGGAAAAAG GCATCAAGTA TAAGTTGAA 4500

*FIG. 2C*

STOP DHFR|  
 GTCTACGAGA AGAAAGAC|TA ACAGGAAGAT GCTTCAAGT TCTCTGCTCC CCTCCTAAAG 4560  
 4521 2

3' UNTRANSLATED DHFR=82bp |LINKER #10=10bp|  
 TCATGCATT TTATAAGACC ATGGGACTTT TGCTGGCTTT AGATCAGGCT CGA|CTGTGCC 4620  
 4603 4 4613 4

TTCTAGTTGC CAGCCATCTG TTGTTTGCCTC CTCCCCCGTG CCTTCCTTGA CCCTGGAAGG 4680  
 BOVINE GROWTH HORMONE POLYADENYLATION REGION=231bp  
 TGCCACTCCC ACTGTCCTTT CCTAATAAAA TGAGGAAATT GCATCGCATT GTCTGAGTAG 4740  
 GTGTCATTCT ATTCTGGGGG GTGGGGTGGG GCAGGACAGC AAGGGGGAGG ATTGGGAAGA 4800  
 CAATAGCAGG CATGCTGGGG ATGCGGTGGG CTCTATGGAA CCAGCTGGGG CTCGAGCTAC 4860  
 4844 5

|TAGCTTTGCT TCTCAATTTC TTATTTGCAT AATGAGAAAA AAAGGAAAAT TAATTTAAC 4920  
 ACCAATTCAAG TAGTTGATTG AGCAAATGCG TTGCCAAAAAA GGATGCTTTA GAGACAGTGT 4980  
 MOUSE BETA GLOBIN MAJOR PROMOTER=366bp  
 TCTCTGCACA GATAAGGACA AACATTATTC AGAGGGAGTA CCCAGAGCTG AGACTCCTAA 5040  
 GCCAGTGAGT GGCACAGCAT TCTAGGGAGA AATATGCTTG TCATCACCGA AGCCTGATTG 5100  
 CGTAGAGCCA CACCTTGGTA AGGGCCAATC TGCTCACACA GGATAGAGAG GGCAGGAGCC 5160  
 AGGGCAGAGC ATATAAGGTG AGGTAGGATC AGTTGCTCCT CACATTGCT TCTGACATAG 5220  
 |LINKER #12=21bp |START NEO  
 TTGTGTTGGG AGCTTGGATC GATCCTCTAT|GGTTGAACAA GATGGATTGC ACGCAGGGTC 5280  
 5227 8 5248 9

TCCGGCCGCT TGGGTGGAGA GGCTATTGG CTATGACTGG GCACAAACAGA CAATGGCTG 5340  
 CTCTGATGCC GCCGTGTTCC GGCTGTCAGC GCAGGGGCGC CCGGTTCTTT TTGTCAAGAC 5400  
 NEOMYCIN PHOSPHOTRANSFERASE  
 CGACCTGTCC GGTGCCCTGA ATGAACTGCA GGACGAGGCA GCGCGGCTAT CGTGGCTGGC 5460  
 795bp=264 AMINO ACIDS & STOP CODON  
 CACGACGGGC GTTCCCTGCG CAGCTGTGCT CGACGTTGTC ACTGAAGCGG GAAGGGACTG 5520  
 GCTGCTATTG GGCGAAGTGC CGGGGCAGGA TCTCCTGTCA TCTCACCTTG CTCTGCCGA 5580  
 GAAAGTATCC ATCATGGCTG ATGCAATGCG GCGGCTGCAT ACGCTTGATC CGGCTACCTG 5640  
 CCCATTGAC CACCAAGCGA AACATCGCAT CGAGCGAGCA CGTACTCGGA TGGAAAGCCGG 5700  
 TCTTGTGAT CAGGATGATC TGGACGAAGA GCATCAGGGG CTCGCGCCAG CCGAACTGTT 5760  
 CGCCAGGCTC AAGGCGCGCA TGCCCGACGG CGAGGGATCTC GTCGTGACCC ATGGCGATGC 5820  
 CTGCTTGCCTG AATATCATGG TGGAAAATGG CCGCTTTCT GGATTGATCG ACTGTGGCCG 5880  
 GCTGGGTGTG GCGGACCGCT ATCAGGACAT AGCGTTGGCT ACCCGTGATA TTGCTGAAGA 5940  
 GCTTGGCGGC GAATGGGCTG ACCGCTTCCCT CGTGCTTTAC GGTATCGCCG CTTCCCGATTG 6000

*FIG. 2D*

STOP NEO|  
GCAGCGCATC GCCTTCTATC GCCTTCTTGA CGAGTTCTTC ~~TGAGCGGGAC~~ TCTGGGGTTC 6060  
6043 4

GAAATGACCG ACCAAGCGAC GCCCAACCTG CCATCACGAG ATTCGATTC CACCGCCGCC 6120  
3' UNTRANSLATED NEO=173bp  
TTCTATGAAA GGTTGGGCTT CGGAATCGTT TTCCGGGACG CGGGCTGGAT GATCCTCCAG 6180  
CGCGGGGATC TCATGCTGGA GTTCTTCGCC CACCCCGACT TGTTTATTGC AGCTTATAAT 6240  
6216 7

GGTTACAAAT AAAGCAATAG CATCACAAAT TTCACAAATA AAGCATTTC TTCACTGCAT 6300  
SV40 POLY A EARLY=133bp LINKER #13=19bp  
TCTAGTTGTG GTTTGTCAA ACTCATCAAT CTATCTTATC ATGTC~~TGGAT~~ CGCGGCCGCG 6360  
6349 50

ATCCC~~GTC~~GA GAGCTTGGCG TAATCATGGT CATAGCTGTT TCCTGTGTGA AATTGTTATC 6420  
6368 9

CGCTCACAAT TCCACACAAAC ATACGAGCCG GAAGCATAAA GTGTAAAGCC TGGGGTGCCT 6480  
AATGAGTGAG CTAACTCACA TTAATTGCGT TGCCTCACT GCGCCTTTC CAGTCGGGAA 6540  
ACCTGTCGTG CCAGCTGCAT TAATGAATCG GCCAACGCGC GGGGAGAGGC GGTTTGCATA 6600  
PVC 19  
TTGGGCGCTC TTCCGCTTCC TCGCTCACTG ACTCGCTGCG CTCGGTCGTT CGGCTGCGGC 6660  
GAGCGGTATC AGCTCACTCA AAGGCGGTAA TACGGTTATC CACAGAATCA GGGGATAACG 6720  
CAGGAAAGAA CATGTGAGCA AAAGGCCAGC AAAAGGCCAG GAACCGTAAA AAGGCCGCGT 6780  
6792=BACTERIAL ORIGIN OF REPLICATION  
TGCTGGCGTT T~~T~~TCCATAGG CTCGGCCCC CGACGAGCA TCACAAAAAT CGACGCTCAA 6840  
GTCAGAGGTG GCGAAACCCG ACAGGACTAT AAAGATAACCA GGCCTTCCC CCTGGAAGCT 6900  
CCCTCGTGCCT CTCTCCTGTT CCGACCCCTGC CGCTTACCGG ATACCTGTCC GCCTTCTCC 6960  
CTTCGGGAAG CGTGGCGCTT TCTCAATGCT CACGCTGTAG GTATCTCAGT TCGGTGTAGG 7020  
TCGTTCGCTC CAAGCTGGC TGTGTGCACG AACCCCCCGT TCAGCCGAC CGCTGCGCCT 7080  
TATCCGGTAA CTATCGTCTT GAGTCCAACC CGGTAAGACA CGACTTATCG CCACTGGCAG 7140  
CAGCCACTGG TAACAGGATT AGCAGAGCGA GGTATGTAGG CGGTGCTACA GAGTTCTTGA 7200  
AGTGGTGGCC TAACTACGGC TACACTAGAA GGACAGTATT TGGTATCTGC GCTCTGCTGA 7260  
AGCCAGTTAC CTTGGAAAA AGAGTTGGTA GCTTTGATC CGGCAAACAA ACCACCGCTG 7320  
GTAGCGGTGG TTTTTTGTT TGCAAGCAGC AGATTACGCG CAGAAAAAAA GGATCTCAAG 7380  
AAGATCCTTT GATCTTTCT ACGGGGTCTG ACGCTCAGTG GAACGAAAAC TCACGTTAAG 7440  
GGATTTGGT CATGAGATTA TCAAAAGGA TCTTCACCTA GATCCTTTA AATTAAAAAT 7500

*FIG. 2E*

STOP BETA LACTAMASE

GAAGTTTAA ATCAATCTAA AGTATATATG AGTAAACTTG GTCTGACAGT TACCAATGCT 7560  
7550

TAATCAGTGA GGCACCTATC TCAGCGATCT GTCTATTCG TTCATCCATA GTGCCCTGAC 7620

TCCCCGTCGT GTAGATAACT ACGATACGGG AGGGCTTACC ATCTGGCCCC AGTGCTGCAA 7680

TGATACCGCG AGACCCACGC TCACCGGCTC CAGATTATC AGCAATAAAC CAGCCAGCCG 7740

**BETA LACTAMASE=861bp**  
 GAAGGGCCGA GCGCAGAAGT GGTCCCTGCAA CTTTATCCGC CTCCATCCAG TCTATTAAATT 7800

286 AMINO ACID & STOP CODON

GTTGCCGGGA AGCTAGAGTA AGTAGTTCGC CAGTTAATAG TTTGCGCAAC GTTGTGCA 7860

TTGCTACAGG CATCGTGGTG TCACGCTCGT CGTTTGGTAT GGCTTCATTG AGCTCCGGTT 7920

CCCAACGATC AAGGCGAGTT ACATGATCCC CCATGTTGTG CAAAAAAAGCG GTTAGCTCCT 7980

TCGGTCCTCC GATCGTTGTC AGAAGTAAGT TGGCCGCAGT GTTATCACTC ATGGTTATGG 8040

CAGCACTGCA TAATTCTCTT ACTGTCATGC CATCCGTAAG ATGCTTTCT GTGACTGGTG 8100

AGTACTCAAC CAAGTCATTG TGAGAATAGT GTATGCGGCG ACCGAGTTGC TCTTGCCCGG 8160

CGTCAATACG GGATAATACC GCGCCACATA GCAGAACCTT AAAAGTGCTC ATCATTGGAA 8220

AACGTTCTTC GGGGCGAAAAA CTCTCAAGGA TCTTACCGCT GTTGAGATCC AGTCGATGT 8280

AACCCACTCG TGCACCCAAC TGATCTTCAG CATCTTTAC TTTCACCCAGC GTTCTGGGT 8340

GAGCAAAAAC AGGAAGGCAA AATGCCGCAA AAAAGGGAAT AAGGGCGACA CGGAAATGTT 8400

**START BETA LACTAMASE**

GAATACTCAT ACTCTTCCTT TTTCATATT ATTGAAGCAT TTATCAGGGT TATTGTCTCA 8460  
8410

TGAGCGGATA CATATTTGAA TGTATTTAGA AAAATAAACAA AATAGGGGTT CCGCGCACAT 8520

TTCCCCGAAA AGTGCCACCT

*FIG. 2F*

LINKER #1=15bp  
 GACGTCGGCGG CGCGCTAGG CCTCCAAAAA AGCCTCCTCA CTACTTCTGG AATAGCTCAG 60  
 15 6

AGGCCGAGGC GGCTCGGCC TCTGCATAAA TAAAAAAAAT TAGTCACCCA TGCA~~TGGGGU~~ 120  
 SV40 ORIGIN=332bp  
 GGAGAATGGG CGGA~~ACT~~GGG CGGAGTTAGG GCGGGATGG GCGGAGTTAG GGGCGGGACT 180  
 ATGGTTGCTG ACTAATTGAG ATGCATGCTT TGCA~~TACTTC~~ TGCTGCTGG GGAGCCTGG 240  
 GACTTTCCAC ACCTGGTTGC TGACTAATTG AGATGCATGC TTTGCATACT TCTGCCTGCT 300  
 GGGGAGCCTG GGGACTTTCC ACACC~~TAAC~~ TGACACACAT TCCACAGAA~~T~~ TAATTCCCCCT 360  
 347 8

AGTTATTAAT AGTAATCAAT TACGGGGTCA TTAGTTCAT~~A~~ G~~CCC~~ATATAT GGAGTTCCGC 420  
 GTTACATAAC TTACGGTAAA TGGCCCGCCT GGCTGACCGC CCAACGACCC CCGCCCATTG 480  
 ACGTCAATAA TGACGTATGT TCCC~~CATAGTA~~ ACGCCAATAG GGACTTTCCA TTGACGTCAA 540

CVM PROMOTER-ENHANCER=567bp  
 TGGGTGGACT ATTTACGGTA AACTGCCAC TTGGCAGTAC ATCAAGTGTA TCATATGCCA 600  
 AGTACGCC~~CC~~ CTATTGACGT CAATGACGGT AAATGGCCCG CCTGGCATT~~A~~ TGCCCAGTAC 660  
 ATGACCTTAT GGGACTTTCC TACTTGGCAG TACATCTACG TATTAGTCAT CGCTATTACC 720  
 ATGGTGATGC GGTTTGGCA GTACATCAAT GGGCGTGGAT AGCGGTTTGA CTCACGGGGA 780  
 TTTCCAAGTC TCCACCCAT TGACGTCAAT GGGAGTTTGT TTTGGCACCA AAATCAACGG 840  
 GACTTTCCAA AATGTCGTA~~A~~ CAACTCCGCC CCATTGACGC AAATGGGCGG TAGGC~~G~~TGTA 900

CGGTGGGAGG TCTATATAAG CAGAGCTGGG TACGTGAACC GTCAGATGCC CTGGAGACGC 960  
 927 8 934 5

Bgl 2 START LIGHT CHAIN NATURAL LEADER=66bp  
 CATCACAGAT CTCTCACTAT GGATTTCA~~G~~ GTGCAGATT~~A~~ TCAGCTTC~~C~~ GCTAATCAGT 1020  
 978 9

GCTTCAGTCA TAATGTCCAG AGGACAAATT GTTCTCTCCC AGTCTCCAGC AATCCTGTCT 1080  
 1044 5+1

GCATCTCCAG GGGAGAAGGT CACAATGACT TGCA~~GGGCCA~~ GCTGAAGTGT AAGTTACATC 1140  
 CACTGGTTCC AGCAGAAGCC AGGATCCTCC CCCAAACCC~~T~~ GGATT~~T~~ATGC CACATCCAAC 1200

LIGHT CHAIN VARIABLE REGION 318bp 106 AMINO ACID  
 CTGGCTTCTG GAGTCCCTGT TCGCTTCAGT GGCAGTGGGT CTGGGACTTC TTACTCTCTC 1260

ACCATCAGCA GAGTGGAGGC TGAAGATGCT GCCACTTATT ACTGCCAGCA GTGGACTAGT 1320

BsiWI  
 AACCCACCCA CGTTCGGAGG GGGGACCAAG CTGGAAATCA AACGTACGGT GGCTGCACCA 1380  
 1362 3

TCTGTCTTCA TCTTCCCGCC ATCTGATGAG CAGTTGAAAT CTGGAAC~~T~~GC CTCTGTTGTG 1440  
 TGCC~~T~~GCTGA ATAAC~~TT~~CTA TCCCAGAGAG GCCAAAGTAC AGTGGAGGT GGATAACGCC 1500

*FIG. 3A.*

HUMAN KAPPA CONSTANT=324bp=107 AMINO ACID & STOP CODON  
 CTCCAATCGG GTAACCCCCA GGAGAGTGT ACAGAGCAGG ACAGCAAGGA CAGCACCTAC 1560  
 AGCCTCAGCA GCACCCTGAC GCTGAGCAAA GCAGACTACG AGAAACACAA AGTCTACGCC 1620  
 TGCAGAGTCA CCCATCAGGG CCTGAGCTCG CCCGTACCAA AGAGCTTCAA CAGGGGAGAG 1680  
 STOP  
 LIGHT  
CHAIN Eco RI LINKER #4=81bp  
 TGT~~TGA~~ATTC AGATCCGTTA ACGGTTACCA ACTACCTAGA CTGGATTCTG GACAACATGC 1740  
 1646<sup>17</sup>  
 GCCCGTGATA TCTACGTATG ATCAGCCTCG ACTGTGCCTT CTAGTTGCCA GCCATCTGTT 1800  
 1771<sup>2</sup>  
 GTTTGCCCTT CCCCCGTGCC TTCCCTGACC CTGGAAGGTG CCACTCCCAC TGTCCTTCC 1860  
 TAATAAAATG AGGAAATTGC ATCGCATTGT CTGAGTAGGT GTCATTCTAT TCTGGGGGGT 1920  
 BOVINE GROWTH HORMONE POLYADENYLATION REGION=231bp  
 GGGGTGGGGC AGGACAGCAA GGGGGAGGAT TGGGAAGACA ATAGCAGGCA TGCTGGGGAT 1980  
 GCGGTGGGCT CTATGGAACC AGCTGGGCT CGACAGCTAT GCCAAGTACG CCCCCTATTG 2040  
 2002<sup>3</sup> 2017<sup>8</sup>  
 ACGTCAATGA CGGTAAATGG CCCGCCTGGC ATTATGCCCA GTACATGACC TTATGGGACT 2100  
 TTCCTACTTG GCAGTACATC TACGTATTAG TCATCGCTAT TACCATGGTG ATGCGGTTT 2160  
 CMV PROMOTER-ENHANCER=334bp  
 GGCAGTACAT CAATGGCGT GGATAGCGGT TTGACTCAGG GGGATTTCCA AGTCTCCACC 2220  
 CCATTGACGT CAATGGGAGT TTGTTTGGC ACCAAAATCA ACGGGACTTT CCAAAATGTC 2280  
 GTAACAACTC CGCCCCATTG ACGCAAATGG GCGGTAGGCG TGTACGGTGG GAGGTCTATA 2340  
 LINKER #6=7bp Sal I  
 TAAGCAGAGC TGGGTACGTC CTCACATTCA GTGATCAGCA CTGAACACAG ACCCGTGCAG 2400  
 START 2351<sup>2</sup> 2358<sup>9</sup>  
HEAVY CHAIN SYNTHETIC & NATURAL LEADER Mlu I 2457<sup>18</sup>  
ATGGGTTGGA GCCTCATCTT GCTCTTCCCT GTCGCTGTT CTACGGTGT CCTGTCCAG 2460  
 2401 -5 -4 -3 -2 -1 +1  
 GTACAACACTGC AGCAGCCTGG GGCTGAGCTG GTGAAGCCTG GGGCCTCAGT GAAGATGTCC 2520  
 TGCAAGGCTT CTGGCTACAC ATTTACCACT TACAATATGC ACTGGGTAAA ACAGACACCT 2580  
 HEAVY CHAIN VARIABLE=363bp=121 AMINO ACID  
 GGTCGGGGCC TGGAATGGAT TGGAGCTATT TATCCCGGAA ATGGTGATAC TTCCCTACAAT 2640  
 CAGAAAGTTCA AAGGCAAGGC CACATTGACT GCAGACAAAT CCTCCAGCAC AGCCTACATG 2700  
 CAGCTCAGCA GCCTGACATC TGAGGACTCT GCGGTCTATT ACTGTGCAAG ATCGACTTAC 2760  
 TACGGCGGTG ACTGGTACTT CAATGTCTGG GGCGCAGGGGA CCACGGTCAC CGTCTCTGCA 2820  
Nhe I  
 GCTAGCACCA AGGGCCCACATC GGTCTTCCCC CTGGCACCCCT CCTCCAAAGAG CACCTCTGGG 2880  
 GGCACAGCGG CCCTGGGCTG CCTGGTCAAG GACTACTTCC CCGAACCGGT GACGGTGTGG 2940  
 HUMAN GAMMA 1 CONSTANT=993bp  
 TGGAACCTCAG GCGCCCTGAC CAGCGGCGTG CACACCTTCC CGGCTGTCCT ACAGTCCTCA 3000

FIG. 3B

330 AMINO ACID & STOP CODON

GGACTCTACT CCCTCAGCAG CGTGGTGACC GTGCCCTCCA GCAGCTTGGG CACCCAGACC 3060  
 TACATCTGCA ACGTGAATCA CAAGCCCAGC AACACCAAGG TGGACAAGAA AGCAGAGCCC 3120  
 AAATCTTGTG ACAAAACTCA CACATGCCA CCGTGCCCAG CACCTGAACCT CCTGGGGGGA 3:80  
 CCGTCAGTCT TCCTCTTCCC CCCAAAACCC AAGGACACCC TCATGATCTC CCGGACCCCT 3240  
 GAGGTCACAT GCGTGGTGGT GGACGTGAGC CACGAAGACC CTGAGGTCAA GTTCAACTGG 3300  
 TACGTGGACG GCGTGGAGGT GCATAATGCC AAGACAAAGC CGCGGGAGGA GCAGTACAAC 3360  
 AGCACGTACC GTGTGGTCAG CGTCCTCACC GTCCCTGCACC AGGACTGGCT GAATGGCAAG 3420  
 GAGTACAAGT GCAAGGTCTC CAACAAAGCC CTCCCAGCCC CCATCGAGAA AACCATCTCC 3480  
 AAAGCCAAAG GGCAGCCCCG AGAACACACAG GTGTACACCC TGCCCCCATC CCGGGATGAG 3540  
 CTGACCAAGA ACCAGGTCAG CCTGACCTGC CTGGTCAAAG GCTTCTATCC CAGCGACATC 3600  
 GCCGTGGAGT GGGAGAGCAA TGGGCAGCCG GAGAACAACT ACAAGACCAC GCCTCCCGTG 3660  
 CTGGACTCCG ACGGCTCCTT CTTCCCTCTAC AGCAAGCTCA CCGTGGACAA GAGCAGGTGG 3720  
 CAGCAGGGGA ACGTCTTCTC ATGCTCCGTG ATGCATGAGG CTCTGCACAA CCAACTACACG 3780  

STOP HEAVY CHAIN Bam HI LINKER #7=81bp

CAGAAGAGCC TCTCCCTGTC TCCGGGTAAA TGAGGATCCG TTAACGGTTA CCAACTACCT 3840  
 3813 4

AGACTGGATT CGTGACAACA TGCGGCCGTG ATATCTACGT ATGATCAGCC TCGACTGTGC 3900  
 3894 5

CTTCTAGTTG CCAGCCATCT GTTGTGGCC CCTCCCCCGT GCCTCCCTG ACCCTGGAAAG 3960  
 GTGCCACTCC CACTGTCCCTT TCCTAATAAA ATGAGGAAAT TGCATCGCAT TGTCTGAGTA 4020  

BOVINE GROWTH HORMONE POLYADENYLATION REGION=231bp

GGTGTCAATT TATTCTGGGG GGTGGGGTGG GGCAGGACAG CAAGGGGGAG GATTGGGAAG 4080  
 ACAATAGCAG GCATGCTGGG GATGCGGTGG GCTCTATGGA ACCAGCTGGG GCTCGACAGC 4140  
 4125 6

GCTGGATCTC CCGATCCCCA GCTTGCTTC TCAATTCTT ATTTGCATAA TGAGAAAAAA 4200  
 AGGAAAATTA ATTTAACAC CAATTAGTA GTTGATTGAG CAAATGCGTT GCCAAAAAAGG 4260  

MOUSE BETA GLOBIN MAJOR PROMOTER=366bp

ATGCTTACA GACAGTGGTC TCTGCACAGA TAAGGACAAA CATTATTCAAG AGGGAGTACC 4320  
 CAGAGCTGAG ACTCCTAACGC CAGTGAGTGG CACAGCATTC TAGGGAGAAA TATGCTTGTC 4380  
 ATCACCGAAG CCTGATTCCG TAGAGCCACA CCTTGGTAAG GGCCAATCTG CTCACACAGG 4440  
 ATAGAGAGGG CAGGAGCCAG GGCAGAGCAT ATAAGGTGAG GTAGGATCAG TTGCTCCTCA 4500

*FIG. 3C*

CATTGCTTC TGACATAGTT **LINKER #9=19bp** 5' UNTRANSLATED DHFR=82bp  
 4525 6 4544 5 4560  
 ATTCGCGCC AAACTTGACG GCAATCCTAG CGTGAAGGCT GGTAGGATT TATCCCCGCT 4620  
 START DHFR  
 4626 7  
 GCCATCATGG TTGACCATT GAACTGCATC GTCGCCGTGT CCCAAAATAT GGGGATTGGC 4680  
 AAGAACGGAG ACCTACCCCTG GCCTCCGCTC AGGAACGAGT TCAAGTACTT CCAAAGAATG 4740  
 ACCACAAACCT CTTAGTGGA AGGTAACAG AATCTGGTGA TTATGGGTAG GAAAACCTGG 4800  
 DHFR=564bp=187 AMINO ACID & STOP CODON  
 TTCTCCATTCTGAGAAGAA TCGACCTTTA AAGGACAGAA TTAATATAGT TCTCAGTAGA 4860  
 GAACTCAAAG AACCAACCACG AGGAGCTCAT TTTCTTGCCA AAAGTTGGA TGATGCCCTA 4920  
 AGACTTATTG AACAAACCGGA ATTGGCAAGT AAAGTAGACA TGGTTGGAT AGTCGGAGGC 4980  
 AGTTCTGTTT ACCAGGAAGC CATGAATCAA CCAGGCCACC TTAGACTCTT TGTGACAAGG 5040  
 ATCATGCAGG AATTGAAAG TGACACGTTT TTCCCAGAAA TTGATTTGGG GAAATATAAA 5100  
 CTTCTCCAG AATAACCCAGG CGTCCTCTCT GAGGTCCAGG AGGAAAAAGG CATCAAGTAT 5160  
 AAGTTTGAAG TCTACGAGAA **STOP DHFR** 3' UNTRANSLATED DHFR=82bp  
 5140 1 GAAAGACTAA CAGGAAGATG CTTCAAGTT CTCTGCTCCC 5220  
 CTCCTAAAGC TATGCATTT TATAAGACCA TGGGACTTTT GCTGGCTTTA GATCAGCCTC 5280  
 =10bp 5272 3  
 GACTGTGCCT TCTAGTTGCC AGCCATCTGT TGTTTGCCCC TCCCCCGTGC CTTCTTGAC 5340  
 BOVINE GROWTH HORMONE POLYADENYLATION=231bp  
 CCTGGAAAGGT GCCACTCCCCA CTGTCCTTTC CTAATAAAAT GAGGAAATTG CATCGCATTG 5400  
 TCTGAGTAGG TGTCAATTCTA TTCTGGGGGG TGGGGTGGGG CAGGACAGCA AGGGGGAGGA 5460  
 TTGGGAAGAC AATAGCAGGC ATGCTGGGGA TGCGGTGGGC TCTATGGAAC **LINKER #11**  
 5513 4 CAGCTGGGGC 5520  
 TCGAGCTACT AGCTTTGCTT CTCATTCT TATTGCTATA ATGAGAAAAA AAGGAAAATT 5580  
 5530 1  
 AATTAAACA CCAATTCACT AGTTGATTGA GCAAATGCGT TGCCAAAAAG GATGCTTTAG 5640  
 MOUSE BETA GLOBIN MAJOR PROMOTER=366bp  
 AGACAGTGTT CTCTGCACAG ATAAGGACAA CTAGGGAGAA ATATGCTTGT CATCACCGAA 5700  
 GACTCCTAAG CCAGTGAGTG GCACAGCATT CTAGGGAGAA ATATGCTTGT CATCACCGAA 5760  
 GCCTGATTCC GTAGAGCCAC ACCTTGGTAA GGGCCAATCT GCTCACACAG GATAGAGAGG 5820  
 GCAGGAGCCA GGGCAGAGCA TATAAGGTGA GGTAGGATCA GTTGCTCCTC ACATTTGCTT 5880  
 CTGACATAGT TGTGTTGGGA **LINKER #12=21bp** START NEO  
 5896 7 GCTTGGATCG ATCCTCTATG 5917 8 GTTGAACAAAG ATGGATTGCA 5940  
 CGCAGGTTCT CGGGCCGCTT GGGTGGAGAG GCTATTGGC TATGACTGGG CACAACAGAC 6000

FIG. 3D

AATCGGCTGC TCTGATGCCG CCGTGTCCG GCTGTCAGCG CAGGGGCGCC CGGTTCTTT 6060  
 NEOMYCIN PHOSPHOTRANSFERASE=795bp=264 AMINO ACID & STOP CODON  
 TGTCAAGACC GACCTGTCCG GTGCCCTGAA TGAACGTGAG GACGAGGCAG CGCGGCTATC 6120  
 GTGGCTGGCC ACGACGGGCG TTCCTTGCAG AGCTGTGCTC GACGTTGTCA CTGAAGCGCG 6180  
 AAGGGACTGG CTGCTATTGG GCGAAGTGCC GGGGCAGGAT CTCCTGTATC CTCACCTTGC 6240  
 TCCTGCCGAG AAAGTATCCA TCATGGCTGA TGCAATGCGG CGGCTGCATA CGCTTGATCC 6300  
 GGCTACCTGC CCATTCGACC ACCAAGCGAA ACATCGCATC GAGCGAGCAC GTACTCGGAT 6360  
 GGAAGCCGGT CTTGTGATC AGGATGATCT GGACGAAGAG CATCAGGGGC TCGCGCCAGC 6420  
 CGAACTGTTG GCCAGGCTCA AGGCGCGCAT GCCCGACGGC GAGGATCTCG TCGTGACCCA 6480  
 TGGCGATGCC TGCTTGCCGA ATATCATGGT GGAAAATGGC CGCTTTCTG GATTGATCGA 6540  
 CTGTGGCCGG CTGGGTGTGG CGGACCGCTA TCAGGACATA GCGTTGGCTA CCCGTGATAT 6600  
 TGCTGAAGAG CTTGGCGGCG AATGGGCTGA CCGCTTCCTC GTGCTTTACG GTATCGCCGC 6660  
 STOP NEO  
 TCCCGATTG CAGCGCATCG CCTTCTATCG CCTTCTTGAC GAGTTCTTCTGAGCGGGACT 6720  
 6712 3  
 CTGGGGTTCG AAATGACCGA CCAAGCGACG CCCAACCTGC CATCACGAGA TTTCGATTCC 6780  
 3' UNTRANSLATED NEO=173bp  
 ACCGCCGCCT TCTATGAAAG GTTGGGCTTC GGAATCGTTT TCCGGGACGC CGGCTGGATG 6840  
 ATCCTCCAGC GCGGGGATCT CATGCTGGAG TTCTTCGCCA ACCCCAACTT GTTATTGCA 6900  
 6885 6  
 GCTTATAATG GTTACAAATA AAGCAATAGC ATCACAAATT TCACAAATAA AGCATTTC 6960  
 SV40 EARLY POLYADENYLATION REGION=133bp  
 TCACTGCATT CTAGTTGTGG TTTGTCCAAA CTCATCAATC TATCTTATCA TGTCTGGATC 7020  
 7018 9  
 LINKER #13=19bp  
 GCGGCCGCAGA TCCCCTGAG AGCTTGGCGT AATCATGGTC ATAGCTGTTT CCTGTGTGAA 7080  
 7037 8  
 PUC 19  
 ATTGTTATCC GCTCACAAATT CCACACAAACA TACGAGCCGG AAGCATAAAG TGTAAAGCCT 7140  
 GGGGTGCCTA ATGAGTGAGC TAACTCACAT TAATTGCGTT GCGCTCACTG CCCGCTTCC 7200  
 AGTCGGGAAA CCTGTCGTGC CAGCTGCATT AATGAATCGG CCAACGCGCG GGGAGAGCG 7260  
 GTTTGCGTAT TGGGGCGCTCT TCCGCTTCCT CGCTCACTGA CTCGCTGCAG TCGGTGTTG 7320  
 GGCTGCGGCG AGCGGTATCA GCTCACTCAA AGGCGGTAAAT ACGGTTATCC ACAGAATCAG 7380  
 GGGATAACGC AGGAAAGAAC ATGTGAGCAA AAGGCCAGCA AAAGGCCAGG AACCGTAAAA 7440  
 7461=BACTERIAL ORIGIN OF REPLICATION  
 AGGCCGCGTT GCTGGCGTT TCCATAGGC TCCGCCCCC TGACGAGCAT CACAAAAATC 7500

*FIG. 3E*

GACGCTCAAG TCAGAGGTGG CGAAACCGA CAGGACTATA AAGATACCAAG GCGTTCCCC 7560  
 CTGGAAAGCTC CCTCGTGCAC TCTCCTGTTC CGACCCCTGCC GCTTACCGGA TACCTGTCCG 7620  
 CCTTTCTCCC TTCGGGAAGC GTGGCGCTTT CTCATGCTC ACGCTGTAGS TATCTCAGTT 7680  
 CGGTGTAGGT CGTTCGCTCC AAGCTGGGCT GTGTGCACGA ACCCCCCGTT CAGCCCGACC 7740  
 GCTGCGCCTT ATCCGGTAAC TATCGTCTTG AGTCCAACCC GGTAAGACAC GACTTATCGC 7800  
 CACTGGCAGC AGCCACTGGT AACAGGATTA GCAGAGCGAG GTATGTAGGC GGTGCTACAG 7860  
 AGTTCTTGAA GTGGTGGCCT AACTACGGCT ACACTAGAAG GACAGTATTG GGTATCTCCG 7920  
 CTCTGCTGAA GCCAGTTACC TTCGGAAAAA GAGTTGGTAG CTCTTGATCC GGCAAACAAA 7980  
 CCACCGCTGG TAGCGGTGGT TTTTTGTTT GCAAGCAGCA GATTACGCGC AGAAAAAAAG 8040  
 GATCTCAAGA AGATCCTTG ATCTTTCTA CGGGGTCTGA CGCTCAGTGG AACGAAAAC 8100  
 CACGTTAAGG GATTTGGTC ATGAGATTAT CAAAAAGGAT CTTCACCTAG ATCCTTTAA 8160  
 STOP  
ATTAAAATG AAGTTTAAA TCAATCTAAA GTATATATGA GTAAACTTGG TCTGACAGT 8220  
**BETA LACTAMASE**  
ACCAATGCT AATCAGTGAG GCACCTATCT CAGCGATCTG TCTATTCGT TCATCCATAG 8280  
 TTGCGCTGACT CCCCGTCGTG TAGATAACTA CGATAACGGGA GGGCTTACCA TCTGGCCCCA 8340  
 GTGCTGCAAT GATACCGCGA GACCCACGCT CACCGGCTCC AGATTATCA GCAATAAAC 8400  
 BETA LACTAMASE=861bp=286 AMINO ACID & STOP CODON  
 AGCCAGCCGG AAGGGCCGAG CGCAGAAGTG GTCCTGCAAC TTTATCCGCC TCCATCCAGT 8460  
 CTATTAATTG TTGCCGGGAA GCTAGAGTAA GTAGTTCGCC AGTTAATAGT TTGCGCAACG 8520  
 TTGTTGCCAT TGCTACAGGC ATCGTGGTGT CACGCTCGTC GTTTGGTATG GCTTCATTCA 8580  
 GCTCCGGTTC CCAACGATCA AGGCGAGTTA CATGATCCCC CATGTTGTGC AAAAAAGCGG 8640  
 TTAGCTCCTT CGGTCCCTCCG ATCGTTGTCA GAAGTAAGTT GGCCGCAGTG TTATCACTCA 8700  
 TGTTTATGGC AGCACTGCAT AATTCTCTTA CTGTCATGCC ATCCGTAAGA TGCTTTCTG 8760  
 TGACTGGTGA GTACTCAACC AAGTCATTCT GAGAATAGTG TATGCGGCGA CCGAGTTGCT 8820  
 CTTGCCCGGC GTCAATAACGG GATAATAACCG CGCCACATAG CAGAACTTTA AAAGTGCTCA 8880  
 TCATTGGAAA ACGTTCTTCG GGGCGAAAAC TCTCAAGGAT CTTACCGCTG TTGAGATCCA 8940  
 GGTGATGTA ACCCACTCGT GCACCCAACT GATCTTCAGC ATCTTTACT TTCACCAGCG 9000  
 TTTCTGGGTG AGCAAAAACA GGAAGGCCAA ATGCCGCAAA AAAGGGAATA AGGGCGACAC 9060  
 START BETA LACTAMASE  
GGAAATGTTG AATACTCATA CTCTTCCTT TTCAATATTAA TTGAAGCATT TATCAGGGTT 9120  
 ATTGTCTCAT GAGCGGATAC ATATTTGAAT GTATTTAGAA AAATAAACAA ATAGGGGTTC 9180  
 CGCGCACATT TCCCCGAAAA GTGCCACCT

FIG. 3F

## LEADER

	-20		-15		-10				
FRAME 1	Met Asp Phe Gln Val Gln Ile Ile Ser Phe Leu Leu Ile Ser Ala Ser Val								
	ATG GAT TTT CAG GTG CAG ATT ATC AGC TTC CTG CTA ATC AGT GCT TCA GTC								
	987	996	1005	1014	1023				
	<b>FR1</b>								
	-5	-1	+1		10				
Ile Met Ser Arg Gly	Gln	Ile Val	Leu Ser Gln Ser Pro Ala	Ile Leu Ser Ala Ser					
ATA ATG TCC AGA GGA	CAA	ATT GTT CTC TCC CAG TCT CCA GCA ATC CTG TCT GCA TCT							
1038	1047	1056	1065	1074	1083				
	20	23	24	<b>CDR1</b>	27/ 29	30	34		
Pro Gly Glu Lys Val Thr Met Thr	Cys	Arg Ala Ser Ser Val Ser Tyr	Ile His						
CCA GGG GAG AAG GTC ACA ATG ACT	TGC	AGG GCC AGC TCA AGT GTA AGT TAC ATC CAC							
1095	1104	1113	1122	1131	1140				
	<b>FR2</b>	40	45	49	50	<b>CDR2</b>			
Trp Phe Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr									
TGG TTC CAG CAG AAG CCA GGA TCC TCC CCC AAA CCC TGG ATT TAT									
1152	1161	1170	1179	1188	1197				
	55	56	57	60	65	70			
Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser Gly Thr Ser Tyr Ser									
CTG GCT TCT GGA GTC CCT GTT CGC TTC AGT GGC AGT GGG TCT GGG ACT TCT TAC TCT									
1209	1218	1227	1236	1245	1254				
	75	80	85	88	89	90			
Leu Thr Ile Ser Arg Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys									
CTC ACC ATC AGC AGA GTG GAG GCT GAA GAT GCT GCC ACT TAT TAC TGC									
1266	1275	1284	1293	1302	1311				
	<b>CDR3</b>	95	97	98	100	<b>FR4</b>	105	107	
Thr Ser Asn Pro Pro Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys									
ACT AGT AAC CCA CCC ACG TTC GGA GGG GGG ACC AAG CTG GAA ATC AAA									
1323	1332	1341	1350	1359					

FIG. 4

## LEADER

-19		-15		-10		-5												
FRAME 1 Met Gly Trp Ser Leu Ile Leu Leu Phe Leu Val Ala Val Ala Thr Arg Val																		
ATG GGT TGG AGC CTC ATC TTG CTC TTC CTT GTC GCT GTT GCT ACG CGT GTC																		
2409		2418		2427		2445												
-1	+1	FR1		10		15												
Leu Ser	Gln	Val	Gln	Leu	Gln	Pro	Gly	Ala	Glu	Leu	Val	Lys	Ala	Gly	Ala	Ser		
CTG	TCC	CAG	GTA	CAA	CTG	CAG	CAG	CCT	GGG	GCT	GAG	CTG	GTG	AAG	CCT	GGG	GCC	TCA
2460		2469		2478		2487		2496		2505								
20		25		30		31	CDR1		35	136								
Val	Lys	Met	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Ser	Tyr	Asn	Met	His	Trp
GTG	AAG	ATG	TCC	TGC	AAG	GCT	TCT	GGC	TAC	ACA	TTT	ACC	AGT	TAC	AAT	ATG	CAC	TGG
2517		2526		2536		2544		2553		2562								
40	FR2		45		49		50	52	52A	53	54							
Val	Lys	Gln	Thr	Pro	Gly	Arg	Gly	Leu	Glu	Trp	Ile	Gly	Ala	Ile	Tyr	Pro	Gly	Asn
GTA	AAA	CAG	ACA	CCT	GGT	CGG	GGC	CTG	GAA	TGG	ATT	GGA	GCT	ATT	TAT	CCC	ÜGA	AAT
2574		2583		2592		2601		2610		2619								
55	CDR2	60		65		66	FR3		70									
Gly	Asp	Thr	Ser	Tyr	Asn	Gln	Lys	Phe	Lys	Gly	Lys	Ala	Thr	Leu	Thr	Ala	Asp	Lys
GGT	GAT	ACT	TCC	TAC	AAT	CAG	AAG	TTC	AAA	GGC	AAG	GCC	ACA	TTG	ACT	GCA	GAC	AAA
2631		2640		2649		2658		2667		2676								
75		80		82	82A	82B	82C	83		85								
Ser	Ser	Ser	Thr	Ala	Tyr	Met	Gln	Leu	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val
TCC	TCC	AGC	ACA	GCC	TAC	ATG	CAG	CTC	AGC	AGC	CTG	ACA	TCT	GAG	GAC	TCT	GCG	GTC
2688		2697		2706		2715		2724		2733								
90		94	95	CDR3		100	100A	100B	100C	100D	101	102	103					
Tyr	Tyr	Cys	Ala	Arg	Ser	Thr	Tyr	Tyr	Gly	Gly	Asp	Trp	Tyr	Phe	Asn	Val	Trp	Gly
TAT	TAC	TGT	GCA	AGA	TCG	ACT	TAC	TAC	GGC	GGT	GAC	TGG	TAC	TTC	AAT	GTC	TGG	GGC
2745		2754		2763		2772		2781		2790								
105	FR4		110		113													
Ala	Gly	Thr	Thr	Val	Thr	Val	Ser	Ala										
GCA	GGG	ACC	ACG	GTC	ACC	GTC	TCT	GCA										
2802		2811		2820														

FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14A




FIG. 14B



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : <b>A61K 39/395, 43/00, C12N 15/02 C12P 21/08</b>		A3	(11) International Publication Number: <b>WO 94/11026</b> (43) International Publication Date: <b>26 May 1994 (26.05.94)</b>		
(21) International Application Number: <b>PCT/US93/10953</b>		(74) Agents: WEISS, Steven, M. et al.; Lyon & Lyon, 611 West Sixth Street, 34th Floor, Los Angeles, CA 90017 (US).			
(22) International Filing Date: <b>12 November 1993 (12.11.93)</b>		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).			
(30) Priority data: 07/978.891 13 November 1992 (13.11.92) US 08/149,099 03 November 1993 (03.11.93) US		(71) Applicant: IDEC PHARMACEUTICALS CORPORATION [US/US]; 11011 Torreyana Road, San Diego, CA 92121-1104 (US).			
(72) Inventors: ANDERSON, Darrell, R. ; 1851 Navato Place, Escondido, CA 92029 (US). RASTETTER, William, H. ; 16067 Puerta Del Sol, Rancho Santa Fe, CA 92067 (US). HANNA, Nabil ; 3255 Fortuna Ranch Road, Olivenhain, CA 92024 (US). LEONARD, John, E. ; 1960 Avenida Joaquin, Encinitas, CA 92024 (US). NEWMAN, Roland, A. ; 43111 Robbins Street, San Diego, CA 92122 (US). REFF, Mitchell, E. ; 4166 Combe Way, San Diego, CA 92122 (US).		<p>Published  <i>With international search report.</i></p> <p>(88) Date of publication of the international search report:  <b>18 August 1994 (18.08.94)</b></p>			
(54) Title: <b>THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELED ANTIBODIES TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR TREATMENT OF B CELL LYMPHO-MA</b>					
<b>(57) Abstract</b>					
<p>Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.</p>					

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 93/10953

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 5 A61K39/395 A61K43/00 C12N15/02 C12P21/08

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 5 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 274 394 (INTERNATIONAL GENETIC ENGINEERING, INC (INGENE)) 13 July 1988 cited in the application see page 9, line 22 - line 37 see page 13, line 8 - line 44 -----	1
X	JOURNAL OF IMMUNOLOGY vol. 139, no. 10 , 15 November 1987 , BALTIMORE US pages 3521 - 3526 ALVIN Y. LIU ET AL. 'PRODUCTION OF A MOUSE-HUMAN CHIMERIC MONOCLONAL ANTIBODY TO CD20 WITH POTENT FC-DEPENDENT BIOLOGIC ACTIVITY.' cited in the application see the whole document -----	1

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

3

Date of the actual completion of the international search

19 April 1994

Date of mailing of the international search report

20. 05. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 cpo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Rempp, G

# INTERNATIONAL SEARCH REPORT

:national application No.

PCT/US 93/ 10953

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
Remark : Although claims 1 to 10, 16 to 20 are directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 93/10953

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0274394	13-07-88	AU-B-	606653	14-02-91

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**